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Professor Tammie L.S. Benzinger, Chair 
 
Age-related cognitive decline and pathological brain changes are a widespread and growing 
public health issue. Several environmental factors, including engagement in physical activity and 
personality, have been shown to have potential protective effects in slowing cognitive decline 
and preserving healthy brain aging. However, the underlying mechanisms providing exercise- or 
personality-induced resilience to aging and disease remains largely unknown. Importantly, there 
has been an emergence of several novel biomarkers to study healthy brain aging and age-related 
neurodegenerative diseases including in vivo assessments of tau burden and brain metabolism via 
positron emission tomography (PET) imaging and neurofilament light chain (NfL), a marker of 
neurodegeneration, via blood-based biomarkers. During the first part of my thesis research, I 
examined these emerging biomarkers within healthy aging and AD cohorts at Washington 
University, in the Australian Imaging, Biomarkers, and Lifestyle (AIBL) cohort, and in the 
Dominantly Inherited Alzheimer Network (DIAN) observational study (Chapters 2 – 5). For the 
second part of my thesis research, I first used my new knowledge and experience with these 
biomarkers to characterize and determine the influence of physical activity on cerebral glucose 
metabolism (Chapter 6). Next, to better translate these findings to an exercise intervention in the 
 xiii 
future, I further completed a pilot study to determine feasibility and validity of performing a 
submaximal exercise protocol in a diverse US population (Chapter 7). For the third part of my 
thesis research, I discovered a cross-sectional association between personality traits and 
neurofibrillary tangle pathology (Chapter 8). Taken together, the results from my thesis suggest 
utility in all three emerging biomarkers examined (tau-PET, blood-based NfL, and multi-tracer 
brain metabolism PET) for monitoring and understanding complex changes associated with brain 
aging and disease. Additionally, this thesis research adds to the current understanding of the 
potential role of increased physical activity in preservation of glycolytic metabolism in the aging 
brain and increased risk of AD-related tau pathophysiology in neurotic personality traits. Further 
research extending these findings to longitudinal studies are needed to help determine 




















 Pathophysiological brain changes that occur during normal aging and in 
neurodegenerative diseases, such as AD, can begin several decades prior to overt cognitive 
symptoms or the diagnosis of clinical dementia (J. C. Morris, 2005). The vast majority of adults 
will experience age- and disease-related alterations in cognition driven by pathological changes 
in the brain. Importantly, the advent of neuroimaging and fluid biomarkers to study structural, 
protein, and metabolic brain changes now permits in vivo identification and monitoring of these 
of complex process throughout adulthood. Investigating biomarkers throughout adulthood 
uniquely allows us to understand how proteins in specific pathways are temporally and spatially 
related to one another, and to the eventual manifestation of cognitive decline and disease 
symptoms. To this end, there has been an emergence of several novel biomarkers to study healthy 
aging and age-related neurodegenerative diseases including in vivo assessments of 
tau/neurofibrillary tangle burden and brain metabolism via positron emission tomography (PET) 
imaging and neurofilament light chain (NfL), a marker of neurodegeneration, via fluid biomarkers.  
Additionally, there is a need to develop interventions that delay or prevent age- and 
disease-related cognitive decline and pathological brain changes. Unfortunately, currently 
available drugs for AD only treat AD symptoms and do not alter the course of further 
pathophysiological changes. Furthermore, findings from clinical trials testing disease-modifying 
therapeutics have been unsuccessful. Several modifiable lifestyle factors, including engagement 
in physical activity, have been shown to have potential beneficial effects in slowing cognitive 
decline and preserving healthy brain aging. However, the underlying mechanisms providing 
exercise-induced resilience to aging and disease remains largely unknown. Physical activity is 
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important physiological and behavioral measures that predict health outcomes throughout the 
lifespan. In adulthood, a sedentary lifestyle increases an individual’s risk for cardiovascular 
disease. There is now growing interest to consider the predictive value and effects of improved 
fitness on brain aging and dementia. 
 
1.2 Alzheimer disease 
AD is the most common cause of dementia, accounting for 60–80% of cases in the 
United States and approximately 1 in 9 seniors in the United States have AD (Alzheimer's, 
2016). As AD is primarily a disease of old age, its prevalence and associated costs for care are 
projected to dramatically increase given the unprecedented expansion in the elderly segment of 
the United States’ population (He et al., 2017). Given this looming epidemic posed by AD, 
delaying the onset of AD symptoms and curbing the progression of the underlying disease 
process has become a global public health imperative (Rosow et al., 2011). Faced by this 
pressing need, there has been an increased focus on developing AD treatments. Unfortunately, 
currently available drugs treat only AD symptoms. Furthermore, findings from clinical trials 
testing disease-modifying therapeutics have been largely unsuccessful. The urgency of 
alternative approaches for halting the global crisis posed by AD cannot be overstated.  
1.3 Physical activity and brain health 
An accumulation of findings from animal studies now show that physical exercise 
represents an efficacious means for favorably altering not only cognitive trajectories but also the 
underlying AD pathophysiological processes, including beta-amyloid burden, tau 
phosphorylation, hypometabolism, and neuronal loss (Adlard, Perreau, & Cotman, 2005; Adlard, 
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Perreau, Pop, & Cotman, 2005; Fuss et al., 2014; Marlatt, Potter, Lucassen, & van Praag, 2012; 
K. M. Moore et al., 2016). Whereas the beneficial effects of exercise on cognition in elderly 
persons have been well-studied (Angevaren, Aufdemkampe, Verhaar, Aleman, & Vanhees, 
2008; Brown et al., 2016; Muller et al., 2018), investigations of the influence of exercise on 
biomarkers of aging and AD pathology in humans are ongoing. The emerging evidence suggests 
that physical exercise is associated with preserved brain volume in AD-vulnerable structures 
such as the hippocampus (Dougherty, Schultz, Boots, et al., 2017; Erickson et al., 2009; Erickson 
et al., 2011; Hamer, Sharma, & Batty, 2018; Okonkwo et al., 2014), reduced cerebral 
hypometabolism (Deeny et al., 2012; Dougherty, Schultz, Kirby, et al., 2017; Okonkwo et al., 
2014), and reduced beta-amyloid burden (Head et al., 2012; Law et al., 2018; Liang et al., 2010; 
Okonkwo et al., 2014; Rabin et al., 2019). Importantly, a review found that, of 7 key modifiable 
risk factors for AD, physical activity had the highest impact on reducing the national prevalence 
of AD (Barnes & Yaffe, 2011). Taken together, these reports raise the exciting possibility that 
physical exercise might play a pivotal role in the prevention of age-and AD-related cognitive 
impairment.  
Even so, there remain some critical gaps in our knowledge about the relationship between 
a physically active lifestyle and maintaining healthy brain function and resilience against AD. 
First, because most of this research has been done in elderly persons, very little is known about 
the potential influence of exercise on AD risk in early- and late-midlife, which is the life stage 
within which most age and AD-related changes begin. The current thesis aims to address this 
knowledge gap by studying the association of exercise on brain health across adulthood in 
individuals between 25 and 85 years old.  
1.4 Biomarkers for studying brain health 
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The broad neurobiological mechanisms that underlie the beneficial effects of exercise on 
brain health remain largely unknown. To this end, there has been an emergence of several novel 
biomarkers to study healthy aging and age-related neurodegenerative diseases including in vivo 
assessments of tau burden and brain metabolism via positron emission tomography (PET) imaging 
and neurofilament light chain (NfL), a marker of neurodegeneration, via blood-based biomarkers. 
This thesis aims to first examine these emerging biomarkers within healthy aging and AD cohorts 
at Washington University, in the Australian Imaging, Biomarkers, and Lifestyle (AIBL) cohort, 
and in the Dominantly Inherited Alzheimer Network (DIAN) observational study. Next, I will 
apply this knowledge and experience with these biomarkers to characterize and determine the 
influence of lifestyle factors on healthy aging and AD.  
Multiple clinicopathologic studies demonstrate that AD pathology is present in 
individuals before clinical symptoms develop; such individuals are at elevated risk for 
progression to AD dementia (Fagan et al., 2007; J. C. Morris et al., 2009; Vos et al., 2013). The 
accumulation of beta-amyloid plaques and NFTs in CN individuals has been suggested to 
represent preclinical AD. The 2011 National Institute of Aging (NIA) criteria, and recently 
updated criteria (Jack, Bennett, et al., 2018), further propose that preclinical AD be divided into 
separate stages: stage 1 with beta-amyloidosis only (A+); stage 2 with beta-amyloidosis and 
indicators of pathologic tau (T+) and neurodegenerative pathology (N+); and stage 3 with beta-
amyloidosis, pathologic tau, neurodegeneration, and subtle cognitive decline (Jack et al., 2012; 
R. A. Sperling et al., 2011). These three proposed stages of preclinical AD can be described by 
surrogate markers in CSF; low CSF beta-amyloid-42 is generally accepted as a marker of beta-
amyloidosis, high CSF phosphorylated tau as a marker of pathologic tau, and high CSF total tau 
or low hippocampal volume is generally accepted as a marker of neurodegeneration. However, 
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there are several limitations of CSF markers, including lack of direct information about 
distributions or densities of beta-amyloid or of the NFTs. Additionally, increased CSF total tau 
levels, commonly observed in AD, are similarly observed with other dementing diseases such as 
frontotemporal lobar degeneration and traumatic brain injury, as well as normal aging (Franz et 
al., 2003; Riemenschneider et al., 2002), making it non-specific for AD.  In contrast, PET tracers 
thought to bind to NFTs (Lowe et al., 2016; Marquie et al., 2017) reflects both total tauopathy 
burden and topography, although off target binding has been noted (Lemoine, Leuzy, Chiotis, 
Rodriguez-Vieitez, & Nordberg, 2018). Additionally, spatial information from tau-PET will be 
critical for monitoring potential tau aggregate accumulation over time and for linking the 
regional spread of pathologic tau to other key mechanisms involved in AD progression. 
Furthermore, by providing this spatial information, tau-PET may help to distinguish preclinical 
AD and symptomatic AD from other tauopathy-related diseases that exhibit different anatomical 
patterns of tau aggregates. For this reason, PET measures of tau may be more suitable than CSF 
measures for applying NIA-AA criteria for preclinical AD classification. 
1.4.1 Tau-PET 
While there is an established literature describing tau-PET findings in the setting of AD 
dementia, the investigation of regional distribution of tauopathy in CN individuals with or 
without preclinical AD (A+ or A-) remains relatively unexplored. Initial studies investigating 
tau-PET ligand binding in small cohorts of CN adults have identified several brain regions that 
show evidence of tauopathy in older individuals (Hanseeuw et al., 2017; Jack, Wiste, et al., 
2018; Jacobs et al., 2018; LaPoint et al., 2017; Lowe, Bruinsma, et al., 2018; Scholl et al., 2016; 
Vemuri et al., 2017), and report that increased tau-PET binding inversely correlates with beta-
amyloid-42 levels in the cerebrospinal fluid (Chhatwal et al., 2016; B. A. Gordon et al., 2016). 
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This early work suggests tau-PET binding is elevated in preclinical AD, but further work is 
needed to define the topography of tau-PET binding early in the disease course. The 
characterization of regional tau accumulation in CN adults in vivo using tau-PET could be 
important for identifying CN individuals most at risk of cognitive decline and might encourage 
the evaluation of tau-related pharmacological interventions early in the disease course.  
1.4.2 CSF and serum NfL 
Secondly, there have been advancements in markers of neurodegeneration, including CSF 
and blood-based markers of NfL. NfL is a component of the axonal cytoskeleton and is primarily 
expressed in large caliber myelinated axons (A. Petzold, 2005; W. W. Schlaepfer & R. G. Lynch, 
1977). Changes of NfL in bodily fluids have been linked to brain damage and brain atrophy in 
mouse models and multiple neurological disorders including proteopathic neurodegenerative 
diseases (M. Bacioglu et al., 2016; C. Barro et al., 2018; A. Brureau et al., 2017; J. Kuhle et al., 
2016; A. Petzold, 2005). Importantly, CSF collection and imaging modalities are invasive and 
expensive, respectively, and therefore not well suited to routine clinical practice, making blood 
biomarkers would ideal.  
Recent progress in the analysis of Aβ, tau, and NfL in blood has been reported (N. 
Fandos et al., 2017; N. Mattsson, U. Andreasson, H. Zetterberg, & K. Blennow, 2017; A. 
Nakamura et al., 2018; V. Ovod et al., 2017; P. S. J. Weston et al., 2017), sparking interest in an 
NfL blood-based biomarker that monitors neurodegeneration and disease progression. However, 
longitudinal analyses are largely missing and the importance of NfL as a molecular biomarker 
for the presymptomatic phase of neurodegenerative diseases remains unclear (N. Mattsson et al., 
2017; P. S. J. Weston et al., 2017; W. Zhou et al., 2017). 
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1.4.2 Multitracer PET for Brain Metabolism 
Lastly, aerobic glycolysis (AG) is an emerging biomarker of a group of metabolic 
functions, which includes biosynthesis of glycogen, proteins, lipids, and nucleic acids; and 
neuroprotection. Metabolic dysfunction appears to be a prominent feature of AD and is known to 
occur early in the disease process. Recent studies suggest that a specific component of brain 
glucose metabolism, that which is outside of oxidative phosphorylation (referred to as AG), not 
only plays an important role in brain function, but also carries with it a risk for AD (Vlassenko et 
al., 2011; Vlassenko et al., 2010). 
Interestingly, similar to the known effects of exercise on the brain, it has been shown, 
recently, that AG also supports developmental processes, particularly those required for synapse 
formation and replacement, and has a prominent role in the regulation of neuronal activity. 
Importantly, there remains a need to evaluate AG across adulthood and as a potential biomarker 
of brain function.  
After investigating the ability of these emerging biomarkers to detect change in 
cognitively normal and cognitively impaired individuals we will apply our knowledge to better 
understand the role of potential risk and resilience factors in brain aging and disease. 
1.5 Physical activity and cerebral brain metabolism 
Converging evidence suggests that both increased exercise and increased AG may be 
beneficial for maintaining blood flow and impact Learning and Memory through similar 
biological mechanisms. Importantly, preliminary data suggest that whereas the regional 
topographies for cerebral blood flow (CBF) and total brain glucose (CMRGlc) and oxygen 
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(CMRO2) metabolism remain relatively stable throughout the lifespan, the topography of brain 
AG changes significantly with age. Overall, these findings raise the possibility that AG might 
represent a key marker of ‘brain reserve’. Therefore, one proposed mechanism is that increased 
physical activity promotes “youthful” brain glucose metabolism, which may impact cognition, 
neurodegeneration, and healthy brain aging.  
Initial findings from the Wisconsin Registry for Alzheimer’s Prevention cohort suggests 
that engagement in ≥ 150 minutes of physical activity per week, assessed via self-reported physical 
activity measurements, can modify age-associated changes in AD-related biomarkers, including 
cerebral glucose metabolism in the posterior cingulate and Immediate Memory performance 
(Okonkwo et al., 2014). These initial results suggest that physical activity can provide resilience to 
deleterious brain changes, including hypometabolism, in an age-dependent manner.  
1.6 Objective measurement of free-living physical activity 
While studies of physical activity in cognitive neuroscience are dominated by assessment 
with questionnaire-based physical activity measurements, including the above example, such 
methods may be subject to recall and social desirability biases (Dyrstad, Hansen, Holme, & 
Anderssen, 2014). The recent advent of the accelerometer, a device that continuously records 
physical activity, has made possible the objective measurement of free-living physical activity. 
Another advantage of accelerometer-measured physical activity is its ability to capture the 
intensity and duration of activity. Recently, this method was used to study the relationship between 
intensity-specific engagement in physical activity and cerebral glucose metabolism in older adults. 
Results suggest that individuals who engage in higher levels of moderate-intensity physical activity 
have correspondingly higher cerebral glucose metabolism in the rostral middle frontal gyrus 
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(Dougherty, Schultz, Kirby, et al., 2017). Taken together, these prior studies support the notion that 
physical activity may be beneficial for maintaining cerebral glucose metabolism and cognitive 
functioning in older adults.   
1.7 Exercise interventions and monitoring cardiorespiratory 
fitness 
While observational studies have reported positive associations between engagement in 
physical activity and cognitive and brain health, limited interpretations regarding directionality 
or causality can be made. Interventions aimed at improving or maintaining cognitive functioning 
and brain health report mixed results on the effectiveness of improving cardiorespiratory fitness 
(CRF) on brain health outcomes, with one reporting detrimental effects (Wagner et al., 2015), 
many reporting null or mixed effects (Colcombe et al., 2006; J. K. Morris et al., 2017; Niemann, 
Godde, & Voelcker-Rehage, 2014; Sanders et al., 2020; Steen Jensen et al., 2016), and a few 
positive trials (Erickson et al., 2011; Ngandu et al., 2015; Pentikainen et al., 2019; Tamura et al., 
2015). However, such exercise interventions aimed at improving or maintaining cognition and 
brain health vary drastically in their exercise intervention protocol and population involved, 
ranging from 6-week to 24-week resistance or aerobic activities. Additionally, the populations 
studied include both cognitively normal and cognitively impaired, as well as those who have no 
cardiovascular risk factors and those who are at risk. 
Lastly, while observational studies predominately use self-report or objectively-measure 
physical activity levels to characterize physical activity habits intervention studies primarily 
focus on measures of CRF, which is thought to reflect habitual physical activity. Assessment of 
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maximal oxygen consumption (VO2max) during a graded exercise test is considered the gold 
standard measure for evaluating CRF (Lea & Febiger, 1995). Obtaining a true measure of 
VO2max, where a plateau in oxygen consumption is observed despite further increases in 
intensity of exercise, is often challenging in certain populations, including older adults, 
individuals with physical limitations, and with cognitive impairment. Submaximal exercise 
testing is therefore commonly used to predict VO2max, as a proxy measure of CRF, particularly 
when laboratory equipment or physician supervision is unavailable or when the target population 
is unlikely to go to volitional exhaustion. A recently developed Ekblom-Bak (EB) cycle 
ergometer test (Bjorkman, Ekblom-Bak, Ekblom, & Ekblom, 2016; Ekblom-Bak, Bjorkman, 
Hellenius, & Ekblom, 2014) for prediction of VO2max is low-risk, easy to administer, and shown 
to be valid for a wide range of aerobic capacities and ages (Vaisanen et al., 2020). Validation of 
the Ekblom-Bak test in a diverse US population will improve future ability to collect accurate 
CRF data in a wide range of individuals undergoing exercise interventions. 
1.8 Conclusions 
The overall aim of the current thesis is to rigorously characterize the relationship between 
risk and resilience factors (i.e., objective measures of physical activity and personality traits) and 
brain health (brain metabolism, neurodegeneration, tau). We additionally propose a pilot study 
(n=15) to test the feasibility of collecting maximal CRF data, via graded exercise testing (GXT), 
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 The objective of this study was to examine the distribution and severity of tau-PET 
binding in cognitively normal adults with preclinical Alzheimer's disease as determined by 
positive beta-amyloid PET. 18F-AV-1451 tau-PET data from 109 cognitively normal older 
adults were processed with 34 cortical and 9 subcortical FreeSurfer regions and averaged across 
both hemispheres. Individuals were classified as being beta-amyloid positive (N = 25, A+) or 
negative (N = 84, A−) based on a 18F-AV-45 beta-amyloid-PET standardize uptake value ratio 
of 1.22. We compared the tau-PET binding in the 2 groups using covariate-adjusted linear 
regressions. The A+ cohort had higher tau-PET binding within 8 regions: Precuneus, amygdala, 
banks of the superior temporal sulcus, entorhinal cortex, fusiform gyrus, inferior parietal cortex, 
inferior temporal cortex, and middle temporal cortex. These findings, consistent with preclinical 
involvement of the medial temporal lobe and parietal lobe and association regions by tauopathy, 
emphasize that therapies targeting tauopathy in Alzheimer's disease could be considered before 
the onset of symptoms to prevent or ameliorate cognitive decline. 
 
2.2 Introduction 
 Alzheimer’s disease (AD), the most common cause of dementia, is characterized by 
extracellular beta-amyloid plaques and intra- neuronal neurofibrillary tangles (NFTs); the latter 
contain abnormal filaments of pathologic tau protein (Braak, Alafuzoff, Arzberger, Kretzschmar, 
& Del Tredici, 2006; Braak & Braak, 1991).  In vivo neuroimaging and cerebrospinal fluid 
(CSF) quantification of both beta-amyloid and tau protein can now detect pathological 
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aggregates and abnormal fluid concentrations of these proteins as early as 2 decades before the 
onset of clinical symptoms (R. J. Bateman et al., 2012; R. A. Sperling et al., 2011). 
 Multiple clinicopathologic studies demonstrate that AD pathology is present in 
individuals before clinical symptoms develop; such individuals are at elevated risk for 
progression to AD dementia (Fagan et al., 2007; J. C. Morris et al., 2009; Vos et al., 2013). The 
accumulation of beta-amyloid plaques and NFTs in cognitively normal (CN) individuals has 
been suggested to represent preclinical AD. The 2011 National Institute of Aging (NIA) criteria, 
and recently updated criteria(Jack, Bennett, et al., 2018), further propose that preclinical AD be 
divided into separate stages: stage 1 with beta-amyloidosis only (A+); stage 2 with beta-
amyloidosis and indicators of neurodegenerative pathology (N+); and stage 3 with beta-
amyloidosis, neurodegeneration, and subtle cognitive decline (Jack et al., 2012; R. A. Sperling et 
al., 2011). These 3 proposed stages of preclinical AD can be described by surrogate markers in 
CSF; low CSF beta- amyloid-42 is generally accepted as a marker of beta-amyloidosis, and high 
CSF tau is generally accepted as a marker of neurodegeneration. However, there are several 
limitations of CSF markers, including lack of direct information about distributions or densities 
of beta-amyloid or of the NFTs. In addition, increased CSF total tau levels, commonly observed 
in AD, are similarly observed with other dementing diseases such as frontotemporal lobar 
degeneration and traumatic brain injury, as well as normal aging (Franz et al., 2003; 
Riemenschneider et al., 2002), making it nonspecific for AD. By contrast, PET tracers thought to 
bind to NFTs (Lowe et al., 2016; Marquie et al., 2017) reflect both total tauopathy burden and 
topography, although off target binding has been noted (Lemoine et al., 2018). In addition, 
spatial information from tau-PET will be critical for monitoring potential tau aggregate 
accumulation over time and for linking the regional spread of pathologic tau to other key 
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mechanisms involved in AD progression. Furthermore, by providing this spatial information, 
tau-PET may help to distinguish preclinical AD and symptomatic AD from other tauopathy-
related diseases that exhibit different anatomical patterns of tau aggregates. Therefore, PET 
measures of tau may be more suitable than CSF measures for applying NIA-AA criteria for 
preclinical AD or ATN classification. 
 While the regional deposition of beta-amyloid plaques in vivo, as detected by beta-
amyloid-PET tracers, has been well established (Klunk et al., 2004; V. L. Villemagne et al., 
2011), experience with tau- PET to describe the distribution of tauopathy in vivo is more limited. 
Nevertheless, findings with tau-PET to date appear to be fairly consistent with the spatial 
distributions of tauopathy that have been as described in neuropathologic studies (Braak et al., 
2006; Braak & Braak, 1991). Initial ex vivo autoradiographic studies suggest tau-PET correlates 
with postmortem tauopathy (Lowe et al., 2016; Marquie et al., 2015). Furthermore, in vivo 
studies examining individuals with symptomatic AD compared with controls have found tau-
PET ligand binding in temporal as well as neocortical areas in a spatial pattern that is generally 
consistent with, but not identical to, advanced Braak stages V and VI (Chien et al., 2013; Cho et 
al., 2016; B. A. Gordon et al., 2016; Johnson et al., 2016; Schwarz et al., 2016). The spatial 
pattern of binding also colocalizes with changes in hypometabolism (Bischof et al., 2016; 
Ossenkoppele et al., 2016), and atrophy (L. Wang et al., 2016), observed in atypical forms of AD 
(Day et al., 2017; Ossenkoppele et al., 2016), and mirrors the degree of selective cognitive 
impairment in those cases. 
 While there is an established literature describing tau-PET findings in the setting of AD 
dementia, the investigation of regional distribution of tauopathy in CN individuals with or 
without preclinical AD (A+ or A-) remains relatively unexplored. Initial studies investigating 
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tau-PET ligand binding in small cohorts of CN adults have identified several brain regions that 
show evidence of tauopathy in older individuals (Hanseeuw et al., 2017; Jack, Wiste, et al., 
2018; Jacobs et al., 2018; LaPoint et al., 2017; Lowe, Bruinsma, et al., 2018; Lowe, Wiste, et al., 
2018; Scholl et al., 2016; Vemuri et al., 2017) and report that increased tau-PET binding 
inversely correlates with beta-amyloid- 42 levels in the cerebrospinal fluid (Chhatwal et al., 
2016; B. A. Gordon et al., 2016). This early work suggests tau-PET binding is elevated in 
preclinical AD, but further work is needed to define the topography of tau-PET binding early in 
the disease course. The characterization of regional tau accumulation in CN adults in vivo using 
tau-PET could be important for identifying CN individuals most at risk of cognitive decline and 
might encourage the evaluation of tau- related pharmacological interventions early in the disease 
course. 
2.3 Methods 
2.3.1 Participants  
 Data from 109 participants from studies at the Knight Alzheimer’s Disease Research 
Center, Washington University in St. Louis (including the Adult Children Study and the Healthy 
Aging and Senile Dementia Study) were used. Inclusion criteria included cognitive normality 
[Clinical Dementia Rating score equals 0 (J. C. Morris, 1997)] and completion of both beta-
amyloid and tau-PET scans. The Washington University in St. Louis Institutional Review Board 






 Data were acquired on a Siemens Biograph mMR (n=83) or Trio3T scanner (n=26). T1-
weighted images were acquired using a magnetization-prepared rapid acquisition gradient echo 
(MPRAGE) sequence with the following: repetition time=2300 ms, echotime=2.95 ms, flip 
angle=9,176 slices, in plane resolution 240-256, slice thickness=1.2 mm acquired in sagittal 
orientation. Images underwent volumetric segmentation using FreeSurfer 5.3 
[http://freesurfer.net (Fischl et al., 2004) to identify regions of interest (ROIs) used in the PET 
analyses. 
2.3.3 PET imaging 
Beta-amyloid-PET  
 Participants underwent beta-amyloid-PET imaging with18F-AV-45 (florbetapir). 
Participants received a single intravenous bolus of370 MBq (10 mCi) of florbetapir infused over 
60 seconds. Scans were acquired on a Siemens Biograph mMR PET/MR scanner and attenuation 
corrected with a corresponding CT. Data were processed using an ROI approach using 
FreeSurfer software. As described previously (B. A. Gordon et al., 2016), data between the 50- 
to70-minute post injection window were examined. In each ROI, data were converted to 
standardized uptake value ratios (SUVRs) using the cerebellar gray as the reference region and 
partial volume corrected using a regional spread function approach (Rousset, Ma, & Evans, 




 Tau-PET imaging was performed within 13 months (mean: 44.0 days, range: 1-373 days) 
of the beta-amyloid-PET imaging session using18F-AV-1451 (flortaucipir). Participants received 
a single 6.5-10 mCi intravenous bolus of flortaucipir infused over 20seconds. Data were 
processed using an ROI approach using Free-Surfer and, as done in prior work using 18F-AV-
1451 (M. R. Brier et al., 2016; Chien et al., 2013), and data from the 80- to100-minute post 
injection window were examined. Scans were acquired on a Siemens Biograph 40 PET/CT 
scanner. As described previously, in each ROI, data were converted to SUVRs using the 
cerebellar gray as the reference region and partial volume corrected using a regional spread 
function approach (Rousset et al., 1998; Su et al., 2015). This partial volume correction method, 
including nonbrain region sampling, may additionally help minimize off-target binding. Tau-
PET SUVRs for each cortical and subcortical ROI were extracted and averaged together from the 
left and right hemispheres to form 1 bilateral measure. The average amount of time between 
clinical assessment and tau-PET imaging session was 103-57 days, and the average time between 
beta-amyloid-PET and tau-PET imaging sessions was 82-84 days. 
2.3.4 Amyloid positivity classification  
 As previously described, a composite beta-amyloid deposition measure was created using 
the average across the left and right lateral orbitofrontal, medial orbitofrontal, rostral middle 
frontal, superior frontal, superior temporal, middle temporal, and precuneus regions(Su et al., 
2013). To identify individuals who were beta-amyloid positive, we split our sample based on a 
partial volume corrected florbetapir SUVR cutoff of 1.22 (Mishra et al., 2017). To generate a 
cutoff value for 18F-AV-45, a previously established cutoff using 11C-Pittsburgh compound B 
(B. A. Gordon et al., 2015) was translated using a linear regression from a separate cohort of 100 
individuals who had both 18F-AV-45 and11C-Pittsburgh compound B imaging as part of a 
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crossover study. Based on this cutoff, our current sample included 25 beta-amyloid-positive (A+) 
individuals and 84 beta-amyloid-negative (A-) participants. 
2.3.5 Neuropsychological assessment 
 Each cohort at the Knight ADRC receives slightly different cognitive batteries, and in the 
interest of maximizing the available sample size, only tests that were common across all cohorts 
were considered for the present analyses. This resulted in a sample size of 108 individuals. Tests 
included a measure of episodic memory: the free recall score from the Free and Cued Selective 
Reminding Test (Grober, Buschke, Crystal, Bang, & Dresner, 1988); a measure of working 
memory: Letter Number Sequencing (Wechsler, 1997); a measure of semantic memory retrieval: 
category fluency for Animal Naming (Goodglass & Kaplan, 1983); a test of processing speed: 
Trail Making part A and a test of executive function: Trail Making part B (Armitage, 1946). 
Tests were standardized using the sample mean and standard deviation of the cognitive 
assessment that was nearest to the tau-PET scan and then averaged to form a cognitive composite 
score (A. Aschenbrenner, B. Gordon, T. Benzinger, J. Morris, & J. Hassenstab, 2018). 
2.3.6 Statistics 
 To test for group differences between A+ and A-cohorts on demographics, t-tests were 
performed for age, years of education, and Mini-Mental State Examination score; chi-squared 
tests were per-formed for sex and apolipoprotein E ε4 (APOE4) genotype. To visualize the 
collective anatomic distribution of tau-PET SUVR in each of the groups, we created 
representative group mean images. For each participant, their non partial volume corrected 
SUVR images were aligned to their individual MPRAGE using a rigid body transformation, 
subsequently transformed to MNI atlas space using a nonlinear warp, and resampled into a 2-mm 
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isotropic resolution. Voxels across all participants in either the A+ or A- groups were then 
averaged together (Figure 2.1A and 2.1B). Higher SUVRs indicate higher binding of the tracer 
relative to the cerebellar reference region, which reflects more tau pathology or greater 
nonspecific binding, in one group compared to the other.  
 Next, to statistically compare regional tau-PET SUVRs in the A+ and A- groups, we ran 
linear regressions for each of the 34 cortical and 9 subcortical regions examined (see Table 2.2 
for list of regions), including age and sex as covariates in the model. Covariates were selected 
based on their established association with AD and brain measures. To correct for multiple 
comparisons, we implemented a Benjamini-Hochberg procedure with a false discovery rate of 
5%. 
 Next, because APOE4 status was significantly different between the A- and A+ groups, 
we repeated these multivariable linear regressions, comparing regional tau-PET SUVRs in the 
A+ and A- groups, for each cortical and subcortical region found to be significant in the primary 
analyses, but added APOE4 status as a covariate, along with age and sex. To correct for multiple 
comparisons, we implemented a Benjamini-Hochberg procedure with a false discovery rate of 
5%.  
 Since the A+ classification was derived from a composite beta-amyloid-PET SUVR, we 
wanted to explore further the relationship between regional tau-PET and this composite beta-
amyloid-PETSUVR value. We ran a multivariate model for each of the 8 regions identified as 
having significantly higher tau-PET SUVRs in the A+ cohort compared to controls, controlled 
for age and sex. We additionally report the within-group Pearson’s correlation of regional tau-
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PET and beta-amyloid-PET for these 8 regions. To correct for multiple comparisons, we 
implemented a Benjamini-Hochberg procedure with a false discovery rate of 5%. 
 Finally, to determine whether the regional tau deposition is related to cognition, we ran 
linear regression models between18F-AV-1451 and the global cognition score, adjusting for age 
and sex. To correct for multiple comparisons, we implemented a Benjamini-Hochberg procedure 
with a false discovery rate of 5%. 
 
2.4 Results 
2.4.1 Participant characteristics 
 As shown in Table 2.1, participants in the A+ cohort were older (mean age = 71.9 years) 
compared to A- individuals (mean age = 66.8 years, Fdf  = 1.2591,107, p = 0.008) and had a higher 
percentage of APOE4 carriers (56.0%) than the A- group (23.2%, X2 = 9.681, p = 0.002). 
 
2.4.2 Tau distribution in A+ cohort 
 Linear regressions evaluating group differences between the A+ and A- groups show that 
the A+ cohort had significantly higher tau- PET SUVR in 9 regions (Table 2.2), including within 
the amygdala (B = 0.136, p = 0.004), banks of the superior temporal sulcus (B = 0.094, p = 
0.006), entorhinal cortex (B = 0.168, p = 0.004), fusiform gyrus (B = 0.095, p = 0.001), inferior 
parietal cortex (B = 0.100, p = 0.006), inferior temporal cortex (B = 0.111, p = 0.002), 
parahippocampal gyrus (B = 0.086, p = 0.019), middle temporal cortex (B = 0.098, p = 0.001), 
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precuneus (B = 0.110, p = 0.005). Effect size maps of regression coefficients (B values) from 
significant linear regressions are presented in Figure 2.2. Violin plots show the distribution of 
AV1451 in 9 significant regions of interest (Figure 2.3). Furthermore, 18F-AV-1451 signal in 
these regions is highly correlated across all regions (Table 2.3). 
 
 When APOE4 status was included as a covariate, regional tau- PET SUVRs for the A+ 
cohort remained significantly higher compared to the A- group in 8 of the 9 regions including the 
amygdala (B = 0.141, p = 0.005), banks of the superior temporal sulcus (B = 0.091, p = 0.013), 
entorhinal cortex (B = 0.152, p = 0.014), fusiform gyrus (B = 0.084, p = 0.005), inferior parietal 
cortex (B = 0.101, p = 0.009), inferior temporal cortex (B = 0.103, p = 0.008), middle temporal 
cortex (B = 0.098, p = 0.003), and precuneus (B = 0.109, p = 0.010), with the exception being the 
parahippocampal gyrus (p = 0.110). Furthermore, in these models, APOE4 status is not 
significantly associated with tau-PET SUVRs in any regions examined. Full models are 
presented in Table 2.4. 
2.4.3 Relationship between beta-amyloid- and tau-PET 
 There were significant associations between regional tau-PET SUVR and composite beta-
amyloid SUVR levels in all 8 regions examined (Figure 2.4), including the amygdala (B 
[standard error [SE] = 0.153 [0.04], p <0.001, η2 =0.121), banks of the superior temporal sulcus 
(B [SE] =0.090[0.03], p =0.003, η2 =0.080), entorhinal cortex (B[SE]=0.168[0.05], p =0.001, η2 
=0.098), fusiform gyrus (B [SE] =0.087[0.03], p =0.001, η2 =0.106), inferior parietal (B[SE] 
=0.102[0.03], p =0.002, η2 =0.092), inferior temporal (B[SE] =0.106 [0.03], p =0.001, η2 
=0.098), middle temporal (B[SE] =0.093[0.03], p =0.001, η2 =0.104), and precuneus (B[SE] 
=0.135[0.03], p =<0.001, η2 =0.136). In addition, there were within-group correlations between 
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tau-PET and beta-amyloid-PET in A+ individuals in the inferior parietal (r =0.498, p =0.011), 
inferior temporal (r =0.453, p =0.023), and middle temporal (r =0.531, p =0.006). There was no 
correlation in A- individuals between tau-PET and beta- amyloid-PET in any region examined. 
2.4.4 Relationship between cognition and tau-PET 
 There was no relationship between tau-PET and the cognitive composite score in any of 
the 8 regions examined (p > 0.101, Table 2.5). 
 
2.5 Discussion 
 Clinicopathologic studies of AD propose a stereotypical spread of tauopathy based on 
postmortem pathological studies. The Braak and Braak staging scheme envisions spread of NFTs 
from the brainstem and transentorhinal cortex to entorhinal cortex, then into neocortical regions, 
including the fusiform gyrus, medialtemporal gyrus, and insular cortex, and, later, into frontal, 
parietal, and occipital cortices (Braak & Braak, 1991). Recent studies (Lowe et al., 2016; 
Marquie et al., 2017) comparing 18F-AV-1451 autoradiography with tau immunohistochemistry 
have found high colocalization of 18F-AV-1451 with tauopathy in AD compared to other non-
AD tauopathies, particularly in the brains with advanced Braak NFT stages, supporting the use of 
this tracer to map AD-associated tauopathy.  
 Other studies have investigated the spatial pattern of 18F-AV-1451 binding tauopathy in 
vivo, using 18F-AV-1451 and PET, comparing CN individuals to older adults with symptomatic 
AD. Johnson and colleagues (2016) found that participants with mild cognitive impairment and 
AD had significantly higher tau-PETSUVRs in regions including the inferior temporal lobe, 
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fusiform gyrus, posterior cingulate cortex, occipital cortex, parahippocampal gyrus, and 
entorhinal cortex compared with CN peers. Similarly, our group (M. R. Brier et al., 2016) and 
others (Cho et al., 2016; Johnson et al., 2016) have shown patterns of increased tau-PET SUVRs 
in cognitively impaired individuals compared to controls in temporal and occipital neocortical 
areas. This homogeneity across multiple centers suggests a consistent spatial pattern of tau-PET 
binding in symptomatic AD cohorts relative to cognitively normal controls. This spatial pattern 
of tau-PET binding in symptomatic AD has been stereotyped into an estimated tau-PET Braak 
staging scheme (Maass et al., 2017; Scholl et al., 2016) in which the regional tau burden in 
symptomatic AD participants appears consistent with higher Braak stages (V and VI). 
 This study adds to converging literature examining tau-PET in A+ and A- CN individuals 
(Hanseeuw et al., 2017; Jack, Wiste, et al., 2018; Mishra et al., 2017; Sepulcre et al., 2016; V. 
Villemagne et al., 2017). For example, Schöl land colleagues (2016) examined18F-AV-1451 tau-
PET, mapped on to the Braak NFT staging scheme, being distributed across all Braak stages, in a 
cohort of 5 CN young adults, 33 CN older adults, and 15symptomatic AD patients. Among them, 
CN older adults ranged across stages 0, I/II, and III/IV. Other studies also described regional 
associations with other core AD biomarkers including beta-amyloid-PET (M. R. Brier et al., 
2016; Lockhart et al., 2017), CSF tau levels (Chhatwal et al., 2016; L. Wang et al., 2016), gray 
matter volumes and cortical thinning (LaPoint et al., 2017; Sepulcre et al., 2016), and functional 
connectivity MRI in CN individuals (A. P. Schultz et al., 2017). Specifically, a study 
investigating difference in inherent tau-PET signal across the brain in younger adults proposed 
implementation of region-specific z-score values to assess severity of NFT burden (Vemuri et 
al., 2017). Results focus on the entorhinal cortex as an AD-specific tau-PET signature. Similarly, 
we find an increase in tau-PET signal in the entorhinal cortex in A+ individuals compared to A-. 
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However, we importantly show that there are a number of other regions also significantly 
elevated in this A+ cohort, which extend outside the medial temporal lobe. Recent studies 
investigating the cross-sectional and longitudinal tau-PET signal in CN and cognitively impaired 
individuals additionally support our results. Using a meta-region of interest approach to assess 
longitudinal change in tau, results were in alignment with the current findings, suggesting 
increase in the rates of tau accumulation in regions other than the entorhinal cortex, including 
midtemporal, retrosplenial, and posterior cingulate (Jack, Wiste, et al., 2018). However, the 
regions characterized as an “early-AD” meta-region for longitudinal analyses included the 
fusiform and posterior cingulate gyrus, therefore not completely consistent with our results. 
  The present study extends the work of those studies in several critical ways. First, it 
focuses on the generation of a topographical map of 18F-AV-1451 signal in A+ CN individuals. 
Such work aids in our interpretation of tau accumulation in preclinical AD. 
 Second, with its restriction specifically on a large A+ cohort, characterized clinically by 
CDR and for AD pathology by beta-amyloid-PET, this study provides strong evidence that 
regions of tauopathy detected by tau-PET in A+ are comparable to those identified in recent 
studies of AD dementia and are comparable, but not identical to, Braak NFT staging. It is 
possible that the discrepancy in our results compared to Braak NFT staging is due to differences 
in specificity of 18F-AV-1451 binding of certain tau isoforms compared to classical 
histochemical staining or signal contamination in 18F-AV-1451 from nonspecific binding in 
nearby regions. Alternatively, this discordance could be related to subtle difference in the cohorts 
studied and comparisons examined. While Braak NFT staging is primarily a classification of 
presence or absence of regional NFT, our analyses more specifically examined not only the 
distribution of NFT in A+ CN individuals but also the density of NFTs in these regions, as 
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compared to an A- cohort. We therefore provide evidence for significant regional differences in 
18F-AV-1451 signal in A+ CN individuals, compared to A- individuals.  
 We additionally report that APOE e4 may not be associated with tau-PET signal above 
and beyond that of A- and A+ classification. This is in contrast to recent studies in animal 
models suggesting a role of APOE e4 exacerbating NFT accumulation (Shi et al., 2017). It is 
possible, however, that the present study may be underpowered to detect a modulating effect of 
APOE e4 status within A- and A+ groups. Larger studies with a sufficient sample of APOE e4 
A- individuals are needed to determine whether there are interactions between APOE e4 status 
and beta-amyloid load on regional tau-PET signal. Furthermore, we report no associations 
between regional 18F-AV-1451 and global cognition in our cohort. These results support 
findings by Schöll and colleagues (2016) who similarly reported a lack of association between 
cross-sectional global cognition and 18F-AV-1451.  
 Overall, results from prior studies, in addition to the present study, provide evidence that 
there are associations with tau-PET and established biomarkers of AD in preclinical stage, 
further strengthening the utility of tau-PET in AD research and clinical trials. 
 Overall, by emphasizing the presence of widespread tauopathy early in the disease 
course, these findings should inform treatment strategies for preclinical AD. Having learned 
from previous clinical trials that unsuccessfully targeted mild-to-moderate AD dementia (Y. 
Wang et al., 2017), ongoing clinical trials are now administering anti-beta-amyloid therapies in 
asymptomatic individuals who are determined to be positive by beta-amyloid-PET. The results 
of those trials will provide insight into the potential benefit of targeting beta-amyloid pathology 
early in the disease course. However, the results of this present study demonstrate that many 
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clinical trial participants who are beta-amyloid-PET positive are also likely to have a significant 
tauopathy burden. Given that both tauopathy and beta-amyloid deposits are present in 
presymptomatic stages, it maybe worthwhile to consider anti-tau therapies at this early staged 
either alone, or in combination with anti-beta-amyloid therapy. Indeed, combined therapy might 
be more effective than either single therapy alone.  
 A particular strength of the present study is its large, well-characterized sample compared 
with prior studies (Johnson et al., 2016; Ossenkoppele et al., 2016). However, its sample size re-
mains relatively modest for evaluating effects at a whole-brain level, underscoring the future 
need for an increasingly larger sample. 
 There remain several limitations of the present study. First, the current interpretation of 
NFT pathophysiology through utilization of 18F-AV-1451-PET in CN individuals is a potential 
limitation. It has been reported that 18F-AV-1451 may bind nonspecifically to neuromelanin, 
MAO, and iron deposits, in regions including putamen and thalamus. Furthermore, most 
investigations on off-target binding of 18F-AV-1451 have been conducted primarily in 
individuals with impairment or dementia, and little is known about the contribution of off-target 
binding in studies of CN individuals. However, the largest factor so far tied to this nonspecific 
binding has been age; thus, we included age as a covariate. Even so, there is evidence, as seen in 
Figure 2.2, of off-target binding, including parts of the basal ganglia and brainstem. Strong 
correlations of 18F-AV-1451between brain regions suggest that associations of primary interest 
are not due to off-target binding of the basal ganglia and brainstem, yet we acknowledge there 
may be minimal bleeding effect of off-target binding on some regions examined, but largely 
controlled by partial volume correction methods including nonbrain region sampling. 
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 Another potential limitation of our study is that the tau-PET imaging sessions were more 
likely to occur after the collection of beta-amyloid-PET data and clinical examination; however, 
we limited this interval to 12 months, so any overestimation of tauopathy in relation to beta-
amyloid and clinical data should be very modest. In addition, similar to many other studies in 
preclinical AD and AD dementia, our A+ group was older than A- group. We accounted for this 
difference by including age as a covariate in the model; however, future studies would be 
improved by age-matching A- and A+ groups. 
 Finally, because we classified our participants categorically as A+ or A- based on beta-
amyloid status, it is possible that some of our beta-amyloid-negative participants are actually 
subtly beta-amyloid-positive, but below threshold (Palmqvist, Mattsson, Hansson, & Alzheimer's 
Disease Neuroimaging, 2016; Vlassenko et al., 2016). Furthermore, as depicted in Figure 2.3, 
there are a few participants who may have elevated 18F-AV-1451 levels in contrast to their low 
beta-amyloid-PET levels, representing a potential primary age-related tauopathy subset in our A- 
group or generally noisy binding properties of the tracer in the absence of AD pathology. In 
addition, it is possible that accumulation of tau pathology might be happening in parallel, and A- 
individuals who present with high AV1451 might convert to A+ in the future. Longitudinal beta-
amyloid- and tau-PET studies would support more confident identification of participants with 
preclinical AD.  
 In summary, our findings contribute to the understanding of tau pathology and illustrate 
in vivo that tauopathy is widespread in preclinical AD, encompassing both the temporal and 
parietal lobes. This and future studies of pathologic tau-PET in preclinical AD will be useful in 
designing clinical trials for AD dementia, especially when tauopathy-related therapies are 
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administered. These results suggest that it may be worthwhile to consider anti tauopathy 
therapies early in the disease course to prevent cognitive decline due to Alzheimer’s disease. 
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Table 2.1. Participant characteristics. 
 
Characteristic A− (N = 84) A+ (N = 25) p-value 
Age, y 66.8 (8.6) [46–91] 71.9 (7.4) [58–90] 0.006 
Female, % (n) 50.0 (42) 60.0 (15) 0.495 
APOE4 positive, % (n) 23.2 (19) 56.0 (14) 0.003 
Education, y 16.1 (2.2) [12–20] 16.6 (1.6) [12–18] 0.425 
GDS 1.16 (1.8) [0–10] 0.68 (1.1) [0–3] 0.104 
MMSE 29.3 (1.1) [25–30] 29.5 (1.0) [27–30] 0.228 
Clinical assessment and tau-
PET time interval, d 
105.0 (54.8) [0–240] 94.9 (65.7) [0–328] 0.548 
Beta-amyloid-PET and tau-
PET time interval, d 
76.4 (80.9) [1–353] 102.8 (94.4) [1–373] 0.212 
Values are mean (SD) [range] unless otherwise indicated. 
Key: GDS, Geriatric Depression Scale, APOE4, apolipoprotein E ε4; MMSE, Mini–Mental State 












































0.044 (0.06) −0.069 
to 0.157 
0.006 0.441 




0.063 (0.17) −0.274 
to 0.400 
0.001 0.712 































−0.009 (0.04) −0.080 
to 0.061 
0.001 0.792 




0.168 (0.06) 0.055 to 
0.281 
0.077 0.004 




























0.095 (0.03) 0.04 to 
0.150 
0.100 0.001 




0.100 (0.04) 0.030 to 
0.170 
0.070 0.006 






































0.053 (0.04) −0.016 
to 0.122 
0.021 0.134 






















0.098 (0.03) 0.039 to 
0.158 
0.092 0.001 






























0.086 (0.04) 0.014 to 
0.159 
0.051 0.019 




0.019 (0.04) −0.055 
to 0.092 
0.002 0.617 




−0.004 (0.05) −0.096 
to 0.089 
0.000 0.928 













0.001 (0.03) −0.066 
to 0.067 
0.000 0.985 













0.075 (0.04) 0.004 to 
0.146 
0.040 0.038 


















































































0.053 (0.03) 0.006 to 
0.112 
0.029 0.079 























































Key: SUVR, standardized uptake value ratio; SE, standard error; CI, confidence interval, A+, 































































































































































































































































































































































































































































Values depict Pearson correlations of AV-1451 SUVRs between the regions. 
* p<0.05, ** p<0.005, *** p<0.001 


















Table 2.4. Full models of association between regional tau-PET SUVR in A+ and A− cohorts. 
Dependent Variable B 
Std. 









Accumbens Intercept 0.793 0.255 3.107 0.002 0.287 1.299 0.086 
Age 0.008 0.004 2.333 0.022 0.001 0.016 0.051 
Sex 0.004 0.058 0.066 0.948 -0.111 0.118 0.000 
APOE e4 
Status 




0.004 0.072 0.054 0.957 -0.139 0.147 0.000 
Amygdala Intercept 0.707 0.175 4.038 0.000 0.360 1.054 0.138 
Age 0.006 0.002 2.318 0.022 0.001 0.011 0.050 
Sex -0.025 0.040 -0.636 0.526 -0.104 0.053 0.004 
APOE e4 
Status 




0.141 0.049 2.853 0.005 0.043 0.239 0.074 
Caudate Intercept 0.754 0.216 3.487 0.001 0.325 1.182 0.107 
Age 0.009 0.003 2.980 0.004 0.003 0.015 0.080 
Sex -0.054 0.049 -1.108 0.271 -0.151 0.043 0.012 
APOE e4 
Status 




0.049 0.061 0.797 0.427 -0.073 0.170 0.006 
Choroid Plexus Intercept 1.139 0.636 1.790 0.076 -0.123 2.401 0.030 
Age 0.011 0.009 1.186 0.238 -0.007 0.029 0.014 
Sex -0.174 0.144 -1.212 0.228 -0.460 0.111 0.014 
APOE e4 
Status 




-0.022 0.180 -0.123 0.902 -0.379 0.335 0.000 




Intercept 1.056 0.127 8.300 0.000 0.803 1.308 0.403 
Age 0.003 0.002 1.508 0.135 -0.001 0.006 0.022 
Sex -0.016 0.029 -0.543 0.588 -0.073 0.041 0.003 
APOE e4 
Status 










Intercept 1.145 0.158 7.256 0.000 0.832 1.457 0.340 
Age -0.001 0.002 -0.400 0.690 -0.005 0.004 0.002 
Sex 0.037 0.036 1.043 0.300 -0.034 0.108 0.011 
APOE e4 
Status 




-0.014 0.045 -0.322 0.748 -0.103 0.074 0.001 
Caudal middle 
frontal 
Intercept 1.065 0.151 7.056 0.000 0.765 1.364 0.328 
Age -0.001 0.002 -0.564 0.574 -0.005 0.003 0.003 
Sex 0.003 0.034 0.080 0.937 -0.065 0.070 0.000 
APOE e4 
Status 




0.092 0.043 2.163 0.033 0.008 0.177 0.044 
Cuneus Intercept 1.003 0.130 7.694 0.000 0.744 1.262 0.367 
Age 0.003 0.002 1.362 0.176 -0.001 0.006 0.018 
Sex 0.053 0.029 1.807 0.074 -0.005 0.112 0.031 
APOE e4 
Status 




-0.032 0.037 -0.875 0.383 -0.105 0.041 0.007 
Frontal pole Intercept 0.665 0.214 3.104 0.002 0.240 1.090 0.086 
Age 0.005 0.003 1.495 0.138 -0.001 0.011 0.021 
Sex 0.091 0.048 1.887 0.062 -0.005 0.188 0.034 
APOE e4 
Status 




0.152 0.061 2.499 0.014 0.031 0.272 0.058 
Entorhinal 
cortex 
Intercept 1.268 0.238 5.326 0.000 0.796 1.741 0.218 
Age -0.008 0.003 -2.338 0.021 -0.015 -0.001 0.051 
Sex 0.297 0.054 5.516 0.000 0.190 0.404 0.230 
APOE e4 
Status 




-0.030 0.067 -0.448 0.655 -0.164 0.103 0.002 
Fusiform Intercept 0.931 0.104 8.913 0.000 0.724 1.138 0.438 
Age 0.004 0.001 2.518 0.013 0.001 0.007 0.059 
Sex 0.055 0.024 2.338 0.021 0.008 0.102 0.051 
APOE e4 
Status 






0.084 0.030 2.843 0.005 0.025 0.143 0.073 
Inferior 
parietal 
Intercept 1.065 0.134 7.936 0.000 0.799 1.331 0.382 
Age 0.002 0.002 0.990 0.325 -0.002 0.006 0.010 
Sex 0.079 0.030 2.592 0.011 0.018 0.139 0.062 
APOE e4 
Status 




0.101 0.038 2.649 0.009 0.025 0.176 0.064 
Inferior 
temporal 
Intercept 0.869 0.134 6.483 0.000 0.603 1.134 0.292 
Age 0.005 0.002 2.756 0.007 0.001 0.009 0.069 
Sex 0.063 0.030 2.079 0.040 0.003 0.123 0.041 
APOE e4 
Status 




0.103 0.038 2.717 0.008 0.028 0.178 0.067 
Insula Intercept 0.959 0.116 8.281 0.000 0.729 1.188 0.402 
Age 0.000 0.002 0.113 0.910 -0.003 0.003 0.000 
Sex -0.008 0.026 -0.297 0.767 -0.060 0.044 0.001 
APOE e4 
Status 




-0.004 0.033 -0.136 0.892 -0.069 0.060 0.000 
Isthmus 
cingulate 
Intercept 1.031 0.152 6.773 0.000 0.729 1.333 0.310 
Age 0.003 0.002 1.392 0.167 -0.001 0.007 0.019 
Sex -0.053 0.034 -1.534 0.128 -0.121 0.015 0.023 
APOE e4 
Status 




0.103 0.043 2.393 0.019 0.018 0.188 0.053 
Lateral 
occipital cortex 
Intercept 0.867 0.186 4.653 0.000 0.498 1.237 0.175 
Age 0.004 0.003 1.598 0.113 -0.001 0.009 0.024 
Sex 0.141 0.042 3.352 0.001 0.058 0.225 0.099 
APOE e4 
Status 




0.007 0.053 0.128 0.899 -0.098 0.111 0.000 
Lateral orbital 
frontal cortex 
Intercept 0.994 0.128 7.744 0.000 0.740 1.249 0.370 
Age 0.002 0.002 1.327 0.187 -0.001 0.006 0.017 









0.030 0.036 0.828 0.409 -0.042 0.102 0.007 
Lingual cortex Intercept 1.003 0.117 8.544 0.000 0.770 1.236 0.417 
Age 0.002 0.002 1.282 0.203 -0.001 0.005 0.016 
Sex -0.013 0.027 -0.495 0.622 -0.066 0.040 0.002 
APOE e4 
Status 




-0.019 0.033 -0.585 0.560 -0.085 0.046 0.003 
Medial orbital 
frontal cortex 
Intercept 0.919 0.146 6.297 0.000 0.629 1.208 0.280 
Age 0.001 0.002 0.569 0.571 -0.003 0.005 0.003 
Sex 0.015 0.033 0.452 0.652 -0.051 0.080 0.002 
APOE e4 
Status 








Intercept 1.098 0.114 9.632 0.000 0.872 1.324 0.476 
Age 0.001 0.002 0.564 0.574 -0.002 0.004 0.003 
Sex 0.100 0.026 3.865 0.000 0.049 0.151 0.128 
APOE e4 
Status 




0.098 0.032 3.049 0.003 0.034 0.162 0.084 
Paracentral 
cortex 
Intercept 1.130 0.160 7.061 0.000 0.812 1.447 0.328 
Age -0.001 0.002 -0.227 0.821 -0.005 0.004 0.001 
Sex -0.086 0.036 -2.379 0.019 -0.158 -0.014 0.053 
APOE e4 
Status 




-0.022 0.045 -0.490 0.625 -0.112 0.068 0.002 
Para-
hippocampal 
Intercept 0.798 0.134 5.937 0.000 0.531 1.064 0.257 
Age 0.002 0.002 1.299 0.197 -0.001 0.006 0.016 
Sex 0.054 0.030 1.762 0.081 -0.007 0.114 0.030 
APOE e4 
Status 




0.061 0.038 1.614 0.110 -0.014 0.137 0.025 
Pars Intercept 1.052 0.140 7.494 0.000 0.774 1.331 0.355 
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opercularis Age -0.001 0.002 -0.331 0.742 -0.005 0.003 0.001 
Sex 0.042 0.032 1.333 0.185 -0.021 0.105 0.017 
APOE e4 
Status 




0.014 0.040 0.340 0.734 -0.065 0.092 0.001 
Pars orbitalis Intercept 1.220 0.174 7.001 0.000 0.875 1.566 0.325 
Age -0.002 0.002 -0.691 0.491 -0.007 0.003 0.005 
Sex 0.161 0.039 4.074 0.000 0.082 0.239 0.140 
APOE e4 
Status 




-0.037 0.049 -0.757 0.451 -0.135 0.060 0.006 
Pars 
triangularis 
Intercept 1.104 0.161 6.844 0.000 0.784 1.424 0.315 
Age -0.001 0.002 -0.305 0.761 -0.005 0.004 0.001 
Sex 0.145 0.036 3.967 0.000 0.072 0.217 0.134 
APOE e4 
Status 




-0.005 0.046 -0.110 0.913 -0.096 0.085 0.000 
Peri calcarine Intercept 0.840 0.126 6.681 0.000 0.591 1.090 0.304 
Age 0.005 0.002 2.662 0.009 0.001 0.008 0.065 
Sex 0.049 0.028 1.732 0.086 -0.007 0.106 0.029 
APOE e4 
Status 




-0.014 0.036 -0.392 0.696 -0.085 0.057 0.002 
Post central Intercept 1.048 0.116 9.026 0.000 0.818 1.279 0.444 
Age -0.001 0.002 -0.851 0.397 -0.005 0.002 0.007 
Sex 0.059 0.026 2.255 0.026 0.007 0.111 0.047 
APOE e4 
Status 












0.002 -0.007 0.995 -0.004 0.004 0.000 
Sex -0.021 0.030 -0.686 0.494 -0.081 0.040 0.005 
APOE e4 
Status 






0.067 0.038 1.762 0.081 -0.008 0.143 0.030 
Precentral 
cortex 
Intercept 0.997 0.120 8.332 0.000 0.759 1.234 0.405 
Age -0.001 0.002 -0.416 0.678 -0.004 0.003 0.002 
Sex 0.029 0.027 1.063 0.290 -0.025 0.082 0.011 
APOE e4 
Status 




0.016 0.034 0.487 0.627 -0.051 0.084 0.002 
Precuneus Intercept 1.135 0.146 7.769 0.000 0.845 1.425 0.372 
Age 0.001 0.002 0.594 0.554 -0.003 0.005 0.003 
Sex -0.039 0.033 -1.170 0.245 -0.104 0.027 0.013 
APOE e4 
Status 








Intercept 0.934 0.151 6.175 0.000 0.634 1.234 0.272 
Age 0.002 0.002 0.723 0.471 -0.003 0.006 0.005 
Sex 0.042 0.034 1.232 0.221 -0.026 0.110 0.015 
APOE e4 
Status 




-0.017 0.043 -0.401 0.689 -0.102 0.068 0.002 
Rostral middle 
frontal 
Intercept 0.883 0.134 6.586 0.000 0.617 1.149 0.298 
Age -0.001 0.002 -0.338 0.736 -0.004 0.003 0.001 
Sex 0.184 0.030 6.086 0.000 0.124 0.245 0.266 
APOE e4 
Status 




0.013 0.038 0.347 0.729 -0.062 0.088 0.001 
Superior 
frontal cortex 
Intercept 0.929 0.140 6.635 0.000 0.652 1.207 0.301 
Age -0.001 0.002 -0.460 0.646 -0.005 0.003 0.002 
Sex 0.023 0.032 0.724 0.471 -0.040 0.086 0.005 
APOE e4 
Status 




0.021 0.040 0.540 0.590 -0.057 0.100 0.003 
Superior 
parietal cortex 
Intercept 1.042 0.167 6.226 0.000 0.710 1.373 0.275 
Age 0.000 0.002 0.073 0.942 -0.005 0.005 0.000 













Intercept 1.099 0.102 10.729 0.000 0.896 1.302 0.530 
Age -0.002 0.001 -1.427 0.157 -0.005 0.001 0.020 
Sex 0.082 0.023 3.560 0.001 0.036 0.128 0.110 
APOE e4 
Status 




0.023 0.029 0.808 0.421 -0.034 0.081 0.006 
Supramarginal  Intercept 0.988 0.113 8.765 0.000 0.764 1.211 0.430 
Age 0.002 0.002 1.224 0.224 -0.001 0.005 0.014 
Sex 0.068 0.025 2.688 0.008 0.018 0.119 0.066 
APOE e4 
Status 




0.051 0.032 1.593 0.114 -0.012 0.114 0.024 
Temporal pole Intercept 1.039 0.151 6.875 0.000 0.739 1.339 0.317 
Age -0.002 0.002 -0.799 0.426 -0.006 0.003 0.006 
Sex 0.117 0.034 3.415 0.001 0.049 0.184 0.103 
APOE e4 
Status 








Intercept 1.142 0.159 7.178 0.000 0.827 1.458 0.336 
Age -0.002 0.002 -0.977 0.331 -0.007 0.002 0.009 
Sex -0.049 0.036 -1.362 0.176 -0.120 0.022 0.018 
APOE e4 
Status 




0.018 0.045 0.410 0.683 -0.071 0.108 0.002 
Hippocampus Intercept 0.897 0.157 5.699 0.000 0.585 1.210 0.242 
Age 0.005 0.002 2.078 0.040 0.000 0.009 0.041 
Sex 0.001 0.036 0.018 0.986 -0.070 0.071 0.000 
APOE e4 
Status 




-0.008 0.045 -0.180 0.857 -0.096 0.080 0.000 










Age 0.016 0.004 4.327 0.000 0.009 0.024 0.155 
Sex -0.129 0.060 -2.153 0.034 -0.248 -0.010 0.043 
APOE e4 
Status 




-0.045 0.075 -0.597 0.552 -0.194 0.104 0.003 
Putamen Intercept 0.603 0.179 3.366 0.001 0.248 0.958 0.100 
Age 0.014 0.003 5.596 0.000 0.009 0.019 0.235 
Sex -0.066 0.040 -1.638 0.105 -0.147 0.014 0.026 
APOE e4 
Status 




0.016 0.051 0.311 0.756 -0.085 0.116 0.001 
Thalmus Intercept 1.224 0.128 9.534 0.000 0.969 1.479 0.471 
Age 0.001 0.002 0.345 0.731 -0.003 0.004 0.001 
Sex -0.043 0.029 -1.470 0.145 -0.100 0.015 0.021 
APOE e4 
Status 




0.013 0.036 0.353 0.725 -0.059 0.085 0.001 
Ventral 
diencephalon 
Intercept 1.414 0.183 7.746 0.000 1.052 1.777 0.370 
Age 0.001 0.003 0.531 0.596 -0.004 0.007 0.003 
Sex -0.045 0.041 -1.098 0.275 -0.127 0.037 0.012 
APOE e4 
Status 




-0.043 0.052 -0.827 0.410 -0.145 0.060 0.007 
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Table 2.5. Associations between regional tau-PET SUVR and cognition. 
 




95% CI Partial eta 
squared 
Amygdala 0.049 (0.03) 0.101 −0.010 to 
0.108 
0.026 
Banks of superior 
temporal sulcus 
0.035 (0.02) 0.102 −0.007 to 
0.078 
0.026 
Entorhinal 0.010 (0.04) 0.789 −0.064 to 
0.083 
0.001 
Fusiform −0.012 (0.02) 0.529 −0.048 to 
0.025 
0.004 
Inferior parietal −0.007 (0.02) 0.755 −0.053 to 
0.039 
0.001 
Inferior temporal −0.008 (0.02) 0.735 −0.054 to 
0.038 
0.001 
Middle temporal −0.001 (0.02) 0.943 −0.041 to 
0.038 
0.000 











Figure 2.1. Mean tau distribution in A+ and A− cohorts. Mean tau deposition represented as 
SUVRs for (A) A+ and (B) A− participants. Higher SUVRs indicate higher mean binding and 
more tau pathology. Abbreviations: SUVR, standardized uptake value ratio; A+, beta-amyloid-















Figure 2.2. Difference in tauopathy in A+ cohort compared to A-. Effect size maps, 
depicting regression coefficients (B values), from significant linear regressions, 
adjusting for age and sex, comparing A- and A+ participants. Abbreviations: AD, 






Figure 2.3. Violin plots depicting the regional tau-PET SUVRs in A+ and A− cohorts. 
 






Figure 2.4. Association between regional tau-PET and beta-amyloid-PET. Relationship between 
composite beta-amyloid-PET measure and regional tau-PET SUVR from (A) amygdala, (B) 
banks of superior temporal sulcus, (C) entorhinal cortex, (D) fusiform, (E) inferior parietal, (F) 
inferior temporal, (G) middle temporal, and (H) precuneus. Abbreviations: Red, beta-amyloid-
PET positive; A+ and blue, beta-amyloid-PET negative; A− PET, positron emission tomography; 






Visually identified 18F-MK-6240-PET 
neurofibrillary tangle pattern subtypes 
are associated with distinct memory and 
cognitive performance. 
 









3.1 Summary  
Neuropathologically-defined subtypes of Alzheimer disease (AD), based on neurofibrillary 
tangle (NFT) distribution, have been linked to distinct clinical phenotypes. In this study we 
examined 204 participants who completed 18F-MK-6240 tau-PET imaging and 
neuropsychological testing. Tau-PET scans were visually rated on a 4-point scale as Negative, 
Limbic Predominant, Hippocampal Sparing or Typical. The Limbic Predominant pattern was 
seen in 5% of Aß-ve cognitively normal (CN), 35% Aß+ve CN, and 25% of Aß+ve MCI and 
AD. The Limbic Predominant group was older than other subgroups and had worse performance 
on MMSE and Memory tasks, but preserved Non-Memory function, compared to the Negative 
group. The Hippocampal Sparing (10% of MCI/AD group) and Typical groups had decrements 
in all cognitive domains. NFT patterns, identified with tau-PET, are detectable and consistent 
with neuropathological subtypes of AD and their associated cognitive profiles. Identification of 
in vivo NFT subtypes may have implications for tau therapy trials and patient prognosis.  
 
3.2 Introduction 
Alzheimer's disease (AD) is characterized by extracellular beta-amyloid plaques and 
intraneuronal neurofibrillary tangles (NFTs); the latter contain abnormal filaments of pathologic 
tau protein (Braak et al., 2006; Braak & Braak, 1991). The ability to detect NFT pathology in 
vivo is important for differential diagnosis of dementias, disease staging, and in monitoring 
treatment response in tauopathy-related therapies. The advent of first-generation tau-PET tracers, 
including AV-1451, has provided strong evidence of concordance between the spatial 
distribution of NFT accumulation in vivo and earlier established NFT staging criteria through 
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neuropathologic studies (Braak et al., 2006; Braak & Braak, 1991) in AD (M. R. Brier et al., 
2016; Scholl et al., 2016; S. A. Schultz et al., 2018; Schwarz et al., 2016). However, more recent 
neuropathological studies (Janocko et al., 2012; Murray et al., 2014; Murray et al., 2011) have 
proposed variant subtypes of AD based on the relative number of NFT counts in medial 
temporal lobe (MTL) compared to cortical regions. Importantly, these subtypes have been linked 
to distinct clinical phenotypes, age, and apolipoproteinE (APOE) allele differences compared to a 
typical AD NFT distribution. 
To date, in vivo evaluation of regional heterogeneity of NFT distribution in AD has 
largely focused on small cohorts with atypical AD diagnosis including posterior cortical atrophy 
(PCA), logopenic variant primary progressive aphasia (lvPPA), and corticobasal syndrome 
(CBS). Such studies (Dickerson et al., 2017; Dronse et al., 2017; Ossenkoppele et al., 2016; Xia 
et al., 2017) have provided initial information on the utility of tau-PET imaging in these 
populations and evidence of a strong relationship between localization of NFT pathology and 
clinical presentation. In addition, studies in larger cohorts of older adults with and without late-
onset sporadic AD (Bejanin et al., 2017) and autosomal-dominant AD (A. Aschenbrenner et al., 
2018), further strengthen our knowledge on this relationship, demonstrating an association 
between neuroanatomic NFT distribution and performance within specific cognitive domains. It 
remains unknown whether in vivo tau-PET methods can be used to identify variant subtypes of 
AD based on the relative distribution of NFT in MTL compared to cortical regions with visual 
and quantitative methods and whether these identified groups have distinct memory and 
cognitive phenotypes. 
Furthermore, tau-PET ligands, including AV-1451 and THK series, have limitations such 
as off-target binding that affects quantification and monitoring of NFT deposition in regions of 
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interest such as the hippocampus, which may impact the identification of subtype variants of AD. 
Advances in tau-PET tracers, including generation of 18F-MK-6240, have led to tracers with no 
in vivo off-target binding in the basal ganglia in nonhuman primates (Hostetler et al., 2016) and, 
importantly, lack off-target binding near the hippocampus (e.g., choroid plexus) in human studies 
(Betthauser et al., 2019), making it an ideal tracer for investigations of NFT binding in MTL 
regions. 
Therefore, the objectives of this study were to determine (1) whether neuropathologically 
defined subtypes of AD (i.e., hippocampal sparing, limbic predominant, and typical) are present 
and detectable with 18F-MK-6240 in a well-characterized cohort, (2) whether neurofibrillary 
pattern subtype classification is associated with decrements on distinct cognitive and memory 
domains, and (3) whether subtype classifications are associated with demographic, clinical, 




215 participants enrolled in the AIBL flagship study of aging, details which have been 
described elsewhere (Ellis et al., 2009), were considered for inclusion in the current study based 
on successful completion of an 18F-MK-6240  tau-PET scan before July 1, 2019. Eleven 
individuals were excluded due to incomplete clinical data at the time of data analyses (n=4) or a 
diagnosis other than Cognitively Normal (CN), Mild Cognitive Impairment (MCI), or AD (n=7). 
Of the seven individuals excluded due other diagnoses, one had a diagnosis of Dementia Not 
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Otherwise Specified, one had a diagnosis of mixed AD, and five had a Frontal Temporal 
Dementia diagnosis. Of the resultant 204 participants, 126 were CN, 44 were MCI, and 34 were 
AD. 
3.3.2 Clinical Evaluation 
An expert clinical panel reviewed all available neuropsychological and psychiatric 
information for participants obtained at the visit closest in time to their tau-PET imaging (mean 
time between neuropsychological testing and tau-PET scan was 3.0 ± 3.2 months). They were 
blinded to information about beta-amyloid burden, NFT accumulation, and APOE ε4 status, and 
consensus classifications were made using standard clinical criteria for MCI and AD.  
3.3.3 Neuropsychological Testing 
Participants were administered the Mini Mental State Examination (MMSE) (Folstein, 
Folstein, & McHugh, 1975), 30-item Boston Naming Test (BNT) (Saxton et al., 2000), Digit 
Span forwards [DSp(f)] and backwards [DSp(b)] and Digit Symbol-Coding (DS-C) from the 
Wechsler Adult Intelligence Scale – Third edition (WAIS-III) (Wechsler, 1997), California 
Verbal Learning Test – Second edition (CVLT-II) (Delis, 2000), Rey Complex Figure Test 
(RCFT) (Meyers & Meyers, 1995), letter fluency (Benton, 1968) and category fluency tasks. As 
described elsewhere (Pike et al., 2007), a composite episodic memory score was calculated by 
taking the average of the z scores (generated using an AIBL healthy aging group as the 
reference) for RCFT (30 min) long delay and CVLT-II long delay. A composite Non-Memory 
cognition score was designed to examine participants’ average performance on tasks not 
involving episodic memory. This was calculated by taking the average of the z scores for the 




APOE genotype was determined from whole blood extracted DNA as per previously 
described methodology (Porter et al., 2018) and was available for 128 of the study participants 
3.3.5 Image acquisition 
For tau, participants were injected with 185 MBq (+/- 10%) of 18F-MK-6240. 9/204 
participants were recruited for a pilot dynamic 18F-MK-6240 scan performed on Phillips Gemini 
TF TF64 PET/CT scanner, for the remaining 195 participants acquisition was from 90 to 110 
minutes after injection (on either a Phillips Gemini TF TF64 PET/CT, Phillips Ingenuity TF 
PET/CT, or Siemens Biograph mCT scanner). Similarly, for beta-amyloid, participants were 
injected with 200 (+/- 10%) MBq of 18F-NAV4694 and acquisition was from 50 to 70 min after 
injection.  
3.3.6 Tau-PET  
Visual Classification 
Visual inspection for subtype scoring was first established on a set of 30 scans by two 
readers (SAS and CCR); a single rater (SAS), blind to participant characteristics, then rates the 
entire set of scans. 18F-MK-6240 tau-PET scans were visually inspected and rated on a 4-point 
scale for classification of NFT pattern, where 0 represented no MTL or cortical NFT uptake 
(Negative); 1 represented MTL uptake with no or minimal cortical uptake (Limbic Predominant); 
2 represented cortical uptake with no or minimal MTL uptake (Hippocampal Sparing); and 3 





Specifically, 18F-MK-6240 images, depicting raw counts, were normalized to MNI space. 
Images, overlaid with AAL atlas [34], were viewed by raters with Mango software in an inverted 
greyscale with scale set from 0-4500. The raters evaluated the scan by first setting the axial plane 
to the top of orbital sockets at the level of the entorhinal cortex and parahippocampal gyrus and 
assessing, in ascending direction through each slice, the presence or absence of tracer uptake 
within the medial temporal lobe. The raters then viewed the sagittal plane starting at midline, 
moving 1-2 slices laterally, and examining for tracer uptake in MTL regions including 
entorhinal, hippocampal and parahippocampal regions. The raters additionally viewed MR co-
registered 18F-MK-6240 scans, when available (n=169), to verify anatomical tracer binding 
location. The scan was then further evaluated for cortical binding, in Mango, starting in the axial 
pane. The raters moved superiorly examining the scan for presence or absence of tracer binding, 
more laterally, in the inferior temporal and middle temporal, and throughout the remainder of the 
cortex, including parietal, posterior cingulate, precuneus, supramarginal, and frontal regions. 
Cortical tracer binding was further verified on the sagittal and coronal planes. The primary rater 
additionally visually rated the 18F-MK-6240 SUVR images, viewed in spectrum colorscale with 
SUVR range restricted from 0.5 to 5.5.  
Quantitative classification 
Tau scans were spatially normalized in the MNI space using CapAIBL, using a specific 
tau atlas. A quantitative subtype classification was generated based on regional tau-PET SUVR 
values from averaged left and right hemisphere uptake in MTL and remaining cortical areas. The 
MTL composite included hippocampus, entorhinal, parahippocampus and amygdala, while the 
Cortical composite included fusiform, inferior and middle temporal gyri, supra marginal and 
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angular gyri, lateral occipital, parietal and posterior cingulate/precuneus, dorsolateral, 
ventrolateral and orbitofrontal, anterior cingulate and superior temporal gyrus (V. Villemagne et 
al., 2017). A positive and negative NFT classification for MTL and Cortical summary regions, 
separately, were developed using a positivity cut-off value of 2 standard deviations above the 
mean of a beta-amyloid negative CN cohort (n=90). For MTL ROI, an SUVR ≥ 1.30 was 
considered positive and for Cortical ROI an SUVR ≥ 1.17 was considered positive. The 
cerebellar grey matter was used as the reference region. 
 Participants were classified as Negative (MTL negative and Cortical negative), Limbic 
Predominant (MTL positive and Cortical negative), Hippocampal Sparing (MTL negative and 
Cortical positive), and Typical (MTL positive and Cortical positive).  
3.3.7 Beta-Amyloid Image Processing 
Beta-amyloid imaging was completed on 202 of the individuals. All scans were spatially 
normalized in the MNI space using CapAIBL (Bourgeat et al., 2015),  an adaptive MRI-Less 
approach. We used the Centiloid cortical and whole cerebellum masks to compute the SUVR for 
each subject and we used the CapAIBL calibration equation (Bourgeat et al., 2018) to convert all 
SUVR into Centiloid units (CL). The threshold for a positive amyloid scan was set at greater 
than 25 CL. The mean time between beta-amyloid-PET scan and tau-PET scan was 2.24 ± 5.0 
months. 




 To compare background characteristics between CN and MCI/AD groups, we performed 
t-tests and chi-square tests, as appropriate. 
Visual Rating and Quantitative Rating  
 Cohen’s kappa coefficient was assessed for agreement between visual rating and 
quantitative rating classification. The relationship between visual assessment and continuous 
measurements of MTL and Cortical ROI SUVRs, and a ratio of MTL-to-Cortical SUVRs were 
evaluated with linear regression analyses. 
NFT Subtypes and Memory and Cognitive Functioning 
 To determine the relationship between our visual NFT rating classification and memory 
and cognitive functioning, we performed analyses of covariance (ANCOVA) where the 
independent variable of intertest was the visual rating classification, fit as a fixed factor, and the 
dependent variable was a cognitive test; adjusting for age, gender and years of education. 
Analyses were run, for each cognitive test (i.e., MMSE, memory composite, or Non-Memory 
composite), within the CN Group (n=126) and MCI/AD Group (n=77).  
 Next, to determine whether MMSE, Memory or Non-Memory Function was 
preferentially affected within a certain NFT subtype (i.e., Limbic Predominant, Hippocampal 
Sparing, or Typical), we fit a series of linear regression models, releveling the reference group as 
Negative, Limbic Predominant, or Hippocampal Sparing, as appropriate. Models were adjusted 
for age, gender, and years of education.  
NFT Subtypes and Clinical, pathophysiological, and genetic characteristics 
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 To determine whether our NFT subtypes differed by diagnosis, age, APOE ε4 status, and 
Centiloid levels we fit covariate-adjusted linear or logistic regression models.  
 
3.4 Results 
3.4.1 Participant characteristics 
Participants’ relevant characteristics are listed in Table 3.1. The MCI/AD group was on 
average older, more likely to be APOE ε4 positive and beta-amyloid positive, compared to the 
CN group. They also had higher clinical dementia rating (CDR) scores and lower MMSE, 
Memory and Non-Memory Function scores. 
 
3.4.2 Visual assessment 
Distinct NFT patterns were clearly identified in our cohort. Interestingly, Thirteen 
percent of the CN group showed tau tracer binding, mostly limited to MTL. See Figure 3.2 for 
comparison of visual rating to MTL SUVR, Cortical SUVR, and MTL SUVR/Cortical SUVR 
ratio. The largest classification discordance between visual and quantitative assessment was in 
the Limbic Predominant category. Specifically, within the 28 individuals visually classified as 
Limbic Predominant, 8 were quantitatively classified as Negative and 9 as Typical. Furthermore, 
within the 8 individuals visually classified as Hippocampal Sparing, 5 were quantitatively 
classified as Typical.  
3.4.3 Visual Rating and Memory and Cognitive Functioning 
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Within the MCI/AD group there were relationships between the visual rating 
classification and MMSE, Memory Function, and Non-Memory Function (p= 0.004, <0.001, and 
<0.001, respectively; Table 3.2). However, within the CN group, the visual rating classification 
was associated with MMSE (p = 0.017), but not associated with Memory or Non-Memory 
Function (p = 0.472 and 0.390, respectively). 
Between-group analyses revealed there was, on average, a one-point decrement on 
MMSE between CN individuals with a Negative NFT pattern and those with a Limbic 
Predominant NFT pattern (B [SE] = -1.08 [0.4], p = 0.006; Figure 3.3A). There were no 
differences in the CN group between individuals with Negative, Limbic Predominant, 
Hippocampal Sparing, or Typical NFT patterns on Memory or Non-Memory Function (Figure 
3.3B-C).  
Within the MCI/AD group, those who were classified as Limbic Predominant tauopathy 
performed worse on tests of Memory Function (B [SE] = -0.72 [0.3], p = 0.022), but similar on 
MMSE (B [SE] = -1.48 [1.0], p = 0.126) and Non-Memory Function (B [SE] = -0.51 [0.4], p = 
0.196), compared to individuals with a Negative NFT pattern (Figure 3.3D-F).  
Those classified as Hippocampal Sparing performed worse on MMSE (B [SE] = -2.5 
[1.2], p = 0.036), Memory Function (B [SE] = -1.28 [0.4], p = 0.001), and Non-Memory 
Function (B [SE] = -1.44 [0.5], p = 0.004) compared to NFT Negative individuals, and a trend 
for worse on Non-Memory Function (B [SE] = -0.92 [0.6], p=0.083), but not MMSE (B [SE] = -
1.02 [1.3], p = 0.427) or Memory Function B [SE] = -0.57 [0.4], (p = 0.171), compared to 
Limbic Predominant group.  
63 
 
Lastly, the Typical group performed worse on MMSE (B [SE] = -3.54 [0.8], p < 0.001), 
Memory Function (B [SE] = -1.44 [0.3], p < 0.001), and Non-Memory Function (B [SE] = -1.12 
[0.3], p = 0.001), compared to the Negative group. The Typical group performed worse on 
MMSE (B [SE] = -2.07 [1.0], p = 0.040), Memory Function (B [SE] = -0.72 [0.3], p = 0.024), 
and Non-Memory Function (B [SE] = -1.11 [1.0], p = 0.040), compared to the Limbic 
Predominant group. 
3.4.4 Visual Rating and Age, Centiloid, and APOE4 status 
Within the CN group, the Limbic Predominant group was older (B [SE] = 3.80 [1.7], p = 
0.023; Figure 3.4A) and had higher Centiloid values (B [SE] = 35.05 [11.2], p = 0.002; Figure 
3.4C), but had similar frequency of APOE ε4 positivity (20%) compared to the Negative group 
(30.9%). The Typical group also had higher Centiloid values compared to the Negative group (B 
[SE]= 95.8 [21.6], p < 0.001) and the Limbic Predominant group (B [SE] = 60.70 [23.7], p = 
0.012) and larger proportion of APOE ε4 positive individuals (100%) compared to the Negative 
(30.9%) and Limbic Predominant groups (20.0%). There were no differences between the 
Typical group and Limbic Predominant or Negative groups on age (p = 0.764 and p = 0.407, 
respectively). 
Within the MCI/AD group, there were no differences on age between any of the groups 
(p’s < 0.139; Figure 3.4B) and no significant difference between frequencies of APOE ε4 
positivity in the Negative group (57.0%) and Limbic Predominant (60.0%), Hippocampal 
Sparing (33.0%), or Typical groups (83.0%). 
The Negative group had lower Centiloid levels compared to the Limbic Predominant (B 
[SE] = -77.89 [16.6], p < 0.001), Hippocampal Sparing (B [SE] = -69.16 [20.5], p = 0.001), and 
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Typical (B [SE] = -91.63 [13.9], p < 0.001) groups (Figure 3.4D). There were no between-group 
differences on Centiloid levels between Limbic Predominant, Hippocampal Sparing, or Typical 
groups (p’s > 0.280). 
3.5 Discussion 
Our results demonstrate that in a well-characterized cohort of CN and cognitively 
impaired older adults, distinct regional NFT patterns are detectable, both visually and 
quantitatively, and that the predominant location of tau corresponds with the predominant 
cognitive decrement when defined as memory vs other cognitive impairment. Furthermore, we 
identified demographic, pathophysiological, and genetic differences among these subtypes. 
Specifically, we found that 30 percent of our MCI/AD group were identified as Limbic 
Predominant or Hippocampal Sparing. This is consistent with prior pathological and 
neuroimaging studies investigating atypical variants of AD (Murray et al., 2011; Risacher et al., 
2017; Whitwell et al., 2012). We found that limbic predominant tau was more common in older 
persons, whether CN or MCI/AD and with higher amyloid burden.  
This is the first study to apply visual assessment methods for identification of NFT 
subtypes with 18F-MK-6240.  We identified MTL binding as the predominant pattern in CN 
individuals, suggesting that 18F-MK-6240 visual assessment is sensitive to early-stage NFT 
accumulation though detection in beta-amyloid negative CN was rare at 5% compared to 35% in 
those with a positive amyloid scan. Our visual assessment was overall in agreement with a 
quantitative ratio of MTL, particularly in the Negative and Typical groups. The discordant cases 
in classification were mostly due to detection of more MTL binding by visual assessment and 
may be because our quantitative assessment is based on composite ROIs. The earliest 
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accumulation of NFT pathology in AD is restricted to the entorhinal and parahippocampal area 
(Braak & Braak, 1991), and therefore using a composite ROI may dilute the effect of earliest 
accumulation.  
With visual assessment, within the CN sample, we found decrements between Negative 
and Limbic Predominant NFT groups on MMSE, suggesting that early MTL NFT accumulation, 
detected visually, in CN individuals may be detrimental to global cognition. The small effect and 
lack of findings on memory-specific domains may be due to our relatively small sample sizes in 
MTL and typical groups. However, these findings are consistent with previous studies (Scholl et 
al., 2016; S. A. Schultz et al., 2018) finding no robust association between tau and cognition in 
CN individuals. In contrast, Maas and Colleagues (Maass et al., 2018) recently report unadjusted 
associations between in vivo entorhinal tau and episodic memory in a CN cohort. This 
discrepancy highlights the need for further investigation in CN individuals, with a comparison of 
tau-PET tracers and cognitive tests used across studies. 
Within the MCI/AD group we found those who had Limbic Predominant NFT performed 
worse on Memory Function tests compared to Negative NFT individuals but had preserved Non-
Memory performance. This finding is in agreement with prior pathological and in vivo studies 
(Risacher et al., 2017).  
To this end, the Hippocampal Sparing group performed worse on both memory and Non-
Memory performance compared to Negative group. Previous reports on comparable 
hippocampal-spared individuals (Risacher et al., 2017) suggest preserved memory performance 
in this subtype. However, in our sample those visually classified as Hippocampal Sparing MTL 
NFT pathology had some MTL NFT pathology, when inspected with quantitative values, in 
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addition to substantial cortical NFT involvement. This relatively minor MTL involvement likely 
contributes to the poor memory scores in this group. Alternatively, tau deposition in other parts 
of the limbic memory circuit, such as the posterior cingulate gyrus might explain the memory 
deficit when MTL tau appears relatively low. Further investigation in Cortical NFT only 
individuals would contribute to our understanding on the impact of cortical NFT on memory 
performance, in the absence of MTL NFT. 
Additionally, we show that there are distinct clinical, pathological, and genetic 
characteristics of the NFT subtypes. Individuals who have Limbic Predominant NFT pathology 
are on average older compared to other subtypes of AD, consistent with prior studies on limbic 
predominant subtypes of AD (Murray et al., 2011; Risacher et al., 2017), and suggests that we 
accurately characterized a Limbic Predominant AD subtype and not early-stage typical AD. 
Furthermore, Hippocampal Sparing individuals had a lower proportion of APOE4 positivity 
compared to other AD subtypes, however small sample size limited the power to detect statistical 
differences. Similarly, Risacher and colleagues (Risacher et al., 2017) evaluated the prevalence 
of APOE4 in AD subtypes, using MRI volumetric as a proxy for NFT pathology, and found that 
individuals visually classified as hippocampal sparing had a lower proportion of APOE4-positive 
individuals (53%) compared to those with limbic predominant or typical AD (82% and 77%, 
respectively). Another study (Mattsson et al., 2018) found that APOE4-negative AD individuals 
were more likely to have a Hippocampal Sparing NFT pattern, compared to APOE4-positive AD 
individuals.  
While we attempted to identify NFT heterogeneity in preclinical stages of AD, our sample 
was relatively small. Future studies with 18F-MK-6240 tau-PET with larger sample sizes may be 
useful in identifying additional associations between preclinical NFT subtypes and subtle 
67 
 
cognitive decline on domain-specific tests. Lastly, longitudinal neuroimaging and cognitive 
testing in this cohort and comparison cohorts will elucidate whether the Limbic Predominant 
group progresses to a typical AD distribution and whether these subtypes have distinct memory 
and Non-Memory trajectories. 
In summary, our findings highlight the utility for visual assessment with 18F-MK-6240 tau-
PET in identifying distinct NFT patterns. We further provide evidence that regional 
heterogeneity in NFT pathology is associated with certain memory and Non-Memory profiles, 
genetic, and pathophysiological characteristics. The ability to distinguish these subtypes with in 
vivo imaging methods may prove useful for prognosis and in subject selection and monitoring of 
tau-related treatments. 
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Table 3.1. Participant characteristics. 
Variable Cognitively Normal 
(n=126) 
MCI or AD diagnosis 
(n=77) 
P-value 
Age, yrs 75.8 (5.6) 72.8 (8.1) 0.006 
Female, % 54.8 46.8 0.268 
Yrs of Education 13.8 (2.9) 12.5 (3.3) 0.004 
APOE4 positive, % (n) 22.2 (34) 65.0 (13) 0.003 
CDR global,  
0, 0.5, ≥1, % (n) 
84.9,15.1, 0.0  
(107, 19,0) 
5.2, 72.7, 20.8 
(4, 56, 16) 
<.001 
CDR SOB 0.1 (0.3) 3.1 (3.1) <.001 
MMSE 28.5 (1.4) 24.3 (4.6) <.001 
Memory function composite 0.0 (0.9) -2.7 (1.2) <.001 
Non-memory function 
composite 
-0.2 (0.7) -1.9 (1.3) <.001 
Beta-amyloid positive, % (n) 18.4 (23) 63.6 (49) <.001 
Visual Rating,  
Neg, LP, HCsp, Typical, % (n) 
87.3, 10.3, 0.0, 2.4 
(110,13,0,3) 
36.4, 19.5, 10.4, 33.8 
(28,15,8,26) 
<.001 
Quantitative Rating,  
Neg, LP, HCsp, Typical, % (n) 
86.5, 7., 1.6, 4.8  
(109, 9, 2, 6) 
40.8, 7.9, 6.6, 44.7  
(31, 6, 5, 34) 
<.001 
 
Mean (SD) for each group are presented, unless otherwise noted. P-values from t-tests or chi-
square tests, as appropriate, to evaluate group differences between cognitively normal and 
MCI/AD groups. Beta-amyloid positivity is based on a cut-off of 25 CL. APOE ε4 status 
reported in a subset of 128 individuals. Beta-Amyloid positivity is reported for a subset of 202 
individuals.  One individual was excluded from quantitative rating analyses due to issues with 
spatial normalization. Two individuals were excluded from analyses with MMSE.  
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Key: MCI= Mild Cognitive Impairment; AD= Alzheimer’s disease; Yrs=years; CDR= Clinical 
dementia Rating; SOB= Sum of Boxes; MMSE=Mini Mental State Exam; Neg=Negative; 



















Table 3.2.  Visual Rating NFT subtype classification is associated with decrements on cognitive 
and memory domains. 
 
F-statistic, ƞ2, and p-value from an ANCOVA where the IV of interest (fit as fixed factor) was 
the Visual Rating and DV of interest was a cognitive test; adjusting for age, sex, and years of 
education. Analyses were run, for each cognitive test, within the Cognitively Normal Group and 




Cognitively Normal MCI or AD Diagnosis 
F, ƞ2 P-value F, ƞ2 P-value 
MMSE 4.21, 0.066 0.017 6.24, 0.242 0.004 
Memory composite 0.68, 0.011 0.472 11.03, 0.331 <0.001 




Figure 3.1. NFT Subtype Visual Rating Representative Images.18F-MK-6240 tau-PET scans 
were visually inspected and rated on a 4-point scale for classification of NFT pattern, where 0 
represented no MTL or cortical NFT uptake (Negative; A); 1 represented MTL uptake with no or 
minimal cortical uptake (Limbic Predominant; B); 2 represented cortical uptake with no or 
minimal MTL uptake (Hippocampal Sparing; C); and 3 represented MTL and cortical uptake 
(Typical; D). The grey scale was set to the same intensity for all images.  









Figure 3.2. Association between visual NFT classification and quantitative values. Plots 
depicting the relationship between visual rating NFT subtypes and MTL SUVR (A), Cortical 
SUVR (B), and a ratio of MTL SUVR to Cortical SUVR (C).  
Key: NFT= Neurofibrillary tangle; Negative= Negative NFT group; LP= Limbic Predominant 
NFT group; HCsp= Hippocampal Sparing NFT group; Typical = Typical NFT group. 
Cognitively normal=circle; MCI=triangle; AD=square. Dashed lines represent positivity cut-offs 












Figure 3.3. Association between NFT classification and memory and cognitive functioning. 
Plots depicting the relationship between visual rating NFT subtypes and MMSE (A and D), 
Memory Function (B and E), and Non-Memory Function (C and F) for CN and MCI/AD group, 
respectively.  
Key: NFT= Neurofibrillary tangle; MMSE= Mini Mental State Examination; Negative= 
Negative NFT group; LP= Limbic Predominant NFT group; HCsp= Hippocampal Sparing NFT 






Figure 3.4. Association between NFT subtypes and age and Centiloid levels. Plots depicting the 
relationship between visual rating NFT subtypes and Age (A and B) and Centiloid levels (C and 
D) for CN and MCI/AD groups, respectively.  
Key: NFT= Neurofibrillary tangle; MMSE= Mini Mental State Examination; Negative= 
Negative NFT group; LP= Limbic Predominant NFT group; HCsp= Hippocampal Sparing NFT 






Serum neurofilament dynamics predicts 
neurodegeneration and clinical progression 
in presymptomatic Alzheimer disease. 
 
This chapter is adapted from a manuscript published in Nature Medicine. 
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M. N., Graff-Radford, N. R., Salloway, S., Ghetti, B., Ringman, J. M., Noble, J. M., Chhatwal, J., Goate, 
A. M., Benzinger, T. L. S., Morris, J. C., Bateman, R. J., Wang, G., Fagan, A. M., McDade, E. M., 
Gordon, B. A., Jucker, M. and Dominantly Inherited Alzheimer, N. [* denotes equal contributions]. 
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Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for 
various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly 
Inherited Alzheimer Network and ultrasensitive immunoassay technology to demonstrate that 
NfL levels in the cerebrospinal fluid (n = 187) and serum (n = 405) are correlated with one 
another and are elevated at the presymptomatic stages of familial Alzheimer's disease. 
Longitudinal, within-person analysis of serum NfL dynamics (n = 196) confirmed this elevation 
and further revealed that the rate of change of serum NfL could discriminate mutation carriers 
from non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels (that 
is, 16.2 versus 6.8 years before the estimated symptom onset). Serum NfL rate of change peaked 
in participants converting from the presymptomatic to the symptomatic stage and was associated 
with cortical thinning assessed by magnetic resonance imaging, but less so with amyloid-β 
deposition or glucose metabolism (assessed by positron emission tomography). Serum NfL was 
predictive for both the rate of cortical thinning and cognitive changes assessed by the Mini-
Mental State Examination and Logical Memory test. Thus, NfL dynamics in serum predict 
disease progression and brain neurodegeneration at the early presymptomatic stages of familial 
Alzheimer's disease, which supports its potential utility as a clinically useful biomarker. 
 
4.2 Introduction 
In most neurodegenerative diseases, brain changes manifest many years before clinical 
symptoms become apparent. In Alzheimer’s disease, presymptomatic changes in the brain 
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include cortical thinning and neuropathological depositions containing amyloid-β and tau. These 
pathological changes can be assessed by magnetic resonance imaging (MRI), positron-emission 
tomography (PET), and measurement of amyloid-β and tau protein levels in the cerebrospinal 
fluid (CSF)(R. J. Bateman et al., 2012; Brian A Gordon et al., 2018; Jack, Bennett, et al., 2018; 
Reisa A Sperling, Karlawish, & Johnson, 2013). However, CSF collection is invasive and 
imaging modalities are expensive; therefore, they are not well suited to routine clinical practice. 
Blood biomarkers for the presymptomatic phase of Alzheimer’s disease are largely lacking, 
although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain (NfL) in 
the blood have been reported (Noelia Fandos et al., 2017; Niklas Mattsson, Ulf Andreasson, 
Henrik Zetterberg, & Kaj Blennow, 2017; Mielke et al., 2018; Akinori Nakamura et al., 2018; 
Vitaliy Ovod et al., 2017; P. S. Weston et al., 2017). 
NfL is a component of the axonal cytoskeleton and is primarily expressed in large-caliber 
myelinated axons (Axel Petzold, 2005; W. Schlaepfer & R. Lynch, 1977). Changes of NfL in 
bodily fluids have been linked to brain damage and brain atrophy in mouse models and multiple 
neurological disorders including proteopathic neurodegenerative diseases (Mehtap Bacioglu et 
al., 2016; Christian Barro et al., 2018; Anthony Brureau et al., 2017; Jens Kuhle et al., 2016; 
Axel Petzold, 2005). Advancements in NfL measurements have revealed tight correlations 
between NfL in the CSF and blood and have sparked interest in an NfL blood-based biomarker 
that monitors neurodegeneration and disease progression. However, longitudinal analyses are 
largely missing and the importance of NfL as a molecular biomarker for the presymptomatic 
phase of neurodegenerative diseases remains unclear (Niklas Mattsson et al., 2017; P. S. Weston 





Participants at 50% risk of carrying an autosomal-dominant Alzheimer’s disease mutation 
in one of three genes (APP, PSEN1, PSEN2) were enrolled in the DIAN observational study 
(National Institute on Aging grant no. U19 AG032438; dian.wustl.edu; clinical trial no. 
NCT00869817)(John C Morris et al., 2012). DIAN participants are assessed at baseline and 
subsequent follow-up visits (annually to every third year). Assessment included collection of 
body fluids (CSF, blood), clinical testing (CDR), neuropsychological testing (including MMSE 
(raw scores) and the Logical Memory subtest of the Wechsler Memory Scale-Revised (story A), 
raw scores for immediate and delayed recall), and imaging modalities (MRI, PET with 
Pittsburgh Compound B (PiB-PET), and 18F-FDG) as described in earlier publications (R. J. 
Bateman et al., 2012; J. C. Morris, 1997; Wechsler, 1997). The institutional review board at 
Washington University in St. Louis provided supervisory review and human studies approval. 
Participants or their caregivers provided informed consent in accordance with their local 
institutional review boards. NfL analysis in the DIAN cohort was approved by the ethics 
committee at the medical faculty of the University of Tübingen, Germany (project number 
718/2014BO2). The detailed number of participants (mutation carriers, non-carriers) for baseline 
and longitudinal measurements are given in Tables 4.1 and 4.2 and the legends of Figures 4.2, 
4.3, and 4.4. 
 
4.3.2 Clinical assessment and EYO 
The presence of dementia (symptoms) was assessed using the CDR (J. C. Morris, 1997). 
Clinical evaluators were blinded to each participant’s mutation status. For every visit a 
participant’s EYO was calculated based on the participant’s age at the visit relative to their 
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‘mutation-specific’ expected age at dementia onset. The mutation-specific expected age of 
dementia onset was computed by averaging the reported age of dementia onset across individuals 
with the same specific mutation(Ryman et al., 2014). If the mutation-specific expected age at 
dementia onset was unknown, the EYO was calculated from the age at which parental cognitive 
decline began. The parental age of clinical symptom onset was determined by a semi-structured 
interview with the use of all available historical data. The EYO was calculated identically for 
both mutation carriers and non-carriers. Mutation status was determined using PCR-based 
amplification of the appropriate exon followed by Sanger sequencing (R. J. Bateman et al., 
2012). 
 
4.3.3 NfL measurements in the CSF and blood 
Fluids were collected in the morning under fasting conditions by venipuncture using a 21 
gauge (G) butterfly needle and red top plain Vacutainer tubes (Becton, Dickinson and 
Company). After blood collection the tubes were left upside at room temperature for 30 min to 
allow clotting. After clotting, tubes were centrifuged at 2,000g for 15 min at room temperature. 
Serum was taken with a disposable, non-sterile transfer pipette into a single transfer tube 
(SARSTEDT AG & Co. KG) and immediately frozen on dry ice. After venipuncture, CSF was 
collected by gravity drip into two 13 ml polypropylene tubes using standard lumbar puncture 
procedures (L4-L5) with an atraumatic Sprotte spinal needle (22 G). As with serum, CSF was 
flash-frozen upright on dry ice. Samples collected in the United States were shipped overnight on 
dry ice to the DIAN biomarker core laboratory at Washington University, whereas samples 
collected at non-United States sites were stored at −80 °C and shipped quarterly on dry ice to 
Washington University. At the core laboratory the frozen samples were subsequently thawed, 
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combined into a single polypropylene tube of serum or CSF, and aliquoted (300 or 500 μl) into 
polypropylene Corning microcentrifuge tubes (Thermo Fisher Scientific), after which they were 
again flash-frozen on dry ice and stored at −80 °C. For the current study, all available DIAN 
serum samples (data freeze 11) were shipped to the DIAN site in Tübingen. CSF samples (data 
freeze 9) were shipped to the DIAN site in Munich first and used for another analysis before 
being shipped to the DIAN site in Tübingen. Thus, CSF samples had one additional freeze–thaw 
cycle in Munich; however, prior work has indicated no significant effect of up to four freeze–
thaw cycles on NfL in CSF (Jens Kuhle et al., 2013). 
CSF and serum NfL measurements were performed using a highly sensitive single-
molecule array assay using the capture monoclonal antibody 47:3 and the biotinylated detection 
antibody 2:1 (UmanDiagnostics AB) (Disanto et al., 2017). The samples were measured in 
duplicate on a Simoa HD-1 platform (Quanterix) using a two-step neat assay. Serum samples 
were measured at 1:4 and CSF at 1:10 dilution (Tris-buffered saline, 0.1% Tween 20, 1% non-fat 
milk powder, HeteroBlock (300 ug ml−1; Omega Biologicals)). Batch-prepared calibrators 
(bovine lyophilized NfL) ranging from 0 to 10,000 pg ml−1 were stored at −80 °C (Uman 
Diagnostics AB). All samples were measured blinded. For serum, the mean intra-assay 
coefficient of variation of duplicate determinations for concentration was 4.2%. In the CSF, the 
mean intra-assay coefficient of variation was 3.7%. Inter-assay variability was evaluated with 
three native serum samples and three native CSF samples. The inter-assay coefficients of 
variation for serum were 7.7% (mean concentration 13.3 pg ml−1), 2.9% (30.9 pg ml−1), and 
3.7% (269.9 pg ml−1). In the CSF, the interassay coefficients of variation were 2.4% (445.4 pg 
ml−1), 12.2% (1486.3 pg ml−1), and 13.3% (14,049.0 pg ml−1). Note that the concentrations (pg 
ml−1) are calculated from the full-length NfL calibrator and thus may overestimate the 
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concentration of an NfL fragment in the blood. 
 
4.3.4 Imaging 
MRI was performed at the different DIAN sites on 3T scanners using the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) protocol. T1-weighted images (1.1 × 1.1 × 1.2 mm3 
voxels) were acquired for all participants. The ADNI Imaging Core screened images for artifacts 
and protocol compliance. FreeSurfer version 5.3 was used to perform volumetric segmentation 
and cortical surface reconstruction to define subcortical and cortical regions of interest (ROIs). 
Members of the DIAN Imaging Core examined each segmentation and edited them as needed. 
Cortical thickness measures were averaged across hemispheres. Since the precuneus region has 
been shown to be most sensitive to Alzheimer’s disease pathophysiology in autosomal-dominant 
Alzheimer’s disease (Benzinger et al., 2013; Brian A Gordon et al., 2018), we focused our 
analyses on this region a priori. 
Amyloid-β-PET imaging was done using a bolus injection of ¹¹C-PiB. Acquisition 
consisted of a 70-min scan starting at injection or a 30-min scan beginning 40 min after injection. 
Data in the common 40–70 min time frame were converted to regional standardized uptake value 
ratios (SUVRs) relative to the cerebellar gray matter using FreeSurfer-derived ROIs (PET 
Unified Pipeline, https://github.com/ysu001/PUP). Metabolic imaging was done with 18F-FDG 
PET with a 30 min dynamic acquisition beginning 30 min after injection. Data from the 40–60 
min time frame were converted to SUVRs relative to cerebellar gray matter. The ADNI Imaging 
Core verified that the PET images were acquired using the established protocol and free of 
substantial artifacts. All PET data were partial volume-corrected using a regional spread function 
technique. Scanner-specific spatial filters were applied to achieve a common resolution (8 mm) 
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across PET scanners. MRI and PET data acquisition and processing has been described in detail 
in previous studies (R. J. Bateman et al., 2012; Benzinger et al., 2013). Again, for the present 
analyses, we averaged SUVR values from the bilateral precuneus ROIs defined on the MRI. 
 
4.3.5 Statistical analysis 
Relating baseline CSF and serum NfL 
The relationship between baseline CSF and serum NfL was determined by using LMEMs 
implemented in R version 3.4.2 and RStudio version 1.1.453 using the package lme4, including a 
random intercept term for family and fixed effect for baseline age, sex, and baseline CSF NfL, 
with baseline serum NfL as the dependent variable. Separate models were fitted for non-carriers 
and mutation carriers. Baseline CSF and serum NfL values were log-transformed (due to non-
normal distribution) before being entered into the model. See also the supplementary statistical 
analysis section. 
 
Baseline CSF and serum NfL as a function of EYO 
The relationship between EYO and baseline CSF and serum NfL values was estimated 
using LMEMs. As previously done, to account for potential non-linear effects, EYO was 
modeled as a restricted cubic spline with knots at the 0.10, 0.50, and 0.90 quantiles (Brian A 
Gordon et al., 2018). The LMEMs for the baseline NfL values (CSF or serum) included: fixed 
effects for mutation status; the linear EYO component; the cubic EYO component; the linear 
EYO by mutation status interaction; the cubic EYO by mutation status interaction; and a random 
intercept for family. Model parameters were estimated using an open source package for 
Hamiltonian Markov chain Monte Carlo analyses, Stan (http://mc-stan.org/)45,46, implemented 
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using R. This resampling approach leads to a distribution of parameter estimates across 
iterations. From this distribution it is possible to estimate the 99% credible intervals of the model 
fits at every EYO for non-carriers, mutation carriers, and the distribution of the difference 
between non-carriers and mutation carriers. The first EYO where groups (non-carriers and 
mutation carriers) differed was determined to be the first point where the 99% credible intervals 
around the differences distribution between non-carriers and mutation carriers did not overlap 0. 
See also the supplementary statistical analysis section. 
 
Calculating the rate of change in biomarkers. 
 Longitudinal data was modeled using LMEMs. LMEMs are a powerful approach to 
account for the covariance structure introduced by serial measurements and are ideal to deal with 
imperfect timing or an unbalanced number of data points. The rate of change in log-transformed 
serum NfL for each individual was modeled using an LMEM with fixed effects of time from 
baseline (in years), mutation status, a time from baseline by mutation status interaction, and a 
random intercept for family, as well as random slope and intercept terms for each participant. 
The rate of NfL change for each individual was extracted from the model estimates for 
subsequent analyses. This model was also used for generating the rate of change for cortical 
thickness,18F-FDG PET, and PiB-PET, for each individual (for plotting purposes). See also the 
supplementary statistical analysis section. 
 
Longitudinal serum NfL as a function of EYO and cognitive status. 
As with the cross-sectional estimates, the relationship between EYO and rate of change in 
serum NfL was estimated using an LMEM in Stan. The EYO was modeled as a restricted cubic 
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spline with knots at the 0.10, 0.50, and 0.90 quantiles. The LMEM model for the rate of change 
in serum NfL included: fixed effects for mutation status; the linear EYO component; the cubic 
EYO component; the linear EYO by mutation status interaction; the cubic EYO by mutation 
status interaction; and a random intercept for family. Model parameters were estimated using 
Stan. Again, this resampling approach leads to a distribution of parameters estimates across 
iterations, resulting in 99% credible intervals of the model fits at every EYO for non-carriers, 
mutation carriers, and the distribution of the difference between non-carriers and mutation 
carriers. The first EYO where groups (non-carriers and mutation carriers) differed was 
determined to be the first point where the 99% credible intervals around the differences 
distribution between non-carriers and mutation carriers did not overlap 0. 
To determine whether the extracted rate of change in serum NfL was significantly 
different across mutation status and cognitive status we categorized mutation carriers based on 
cognitive status, where presymptomatic mutation carriers were individuals who scored as CDR = 
0 across all visits (n = 65), converters were mutation carriers who scored as CDR = 0 at baseline 
and CDR > 0 at subsequent visits (n = 13), and symptomatic mutation carriers were individuals 
who scored as CDR > 0 across all visits (n = 55). We used LMEMs, including a random 
intercept for family and fixed effects for baseline age, sex, and group (that is, non-carriers, 
presymptomatic mutation carriers, converters, or symptomatic mutation carriers), where group 
was the term of interest, and the extracted rate of change in serum NfL was the dependent 
variable. Models were computed using lme4 in R. See also the supplementary statistical analysis 
section. 
 
Association between expected age of onset and deviation from the EYO-adjusted median 
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rate of change in NfL 
We tested the hypothesis of whether individuals who have an earlier expected age of 
onset (for example, age of onset of 30 years old versus 55 years old) have an accelerated NfL 
rate of change. First, to determine if a participant deviated from its expected NfL rate of change, 
given its baseline EYO, we calculated the median rate of change in NfL at each EYO, generated 
from model estimates (for the calculation, see ‘Baseline CSF and serum NfL and longitudinal 
NfL as a function of EYO’ in the supplementary statistical analysis section; for the depiction of 
median values, see the red line in Figure 2b). We then took each participant’s extracted NfL rate 
of change and subtracted the median value corresponding to its baseline EYO. This resulting 
value represented the deviation from the expected value, whereby a positive value on this 
deviation measure indicates that an individual has a higher rate of change in serum NfL (that is, 
worse) than would be expected given their EYO. Conversely, a negative value on this deviation 
measure indicates that an individual has a lower rate of change in serum NfL (that is, better) than 
would be expected given their EYO. Next, to investigate if there was a relationship between 
individuals with the higher deviation measure and earlier expected age of onset, we grouped 
individuals by their expected age of onset (determined by their specific mutation type, grouped 
as age of onset 20–39, 40–49, 50–59, and 60+). See also the supplementary statistical analysis 
section. 
 
Relating NfL rate of change to imaging rate of change. 
The longitudinal relationship between the rate of change in serum NfL and concurrent 
rate of change in cortical thickness, metabolism, or amyloid-β accumulation was determined 
within each group of interest (that is, non-carriers, presymptomatic mutation carriers, and 
86 
 
symptomatic mutation carriers). Therefore, separate models were run for each non-carrier, 
presymptomatic mutation carrier, and symptomatic mutation carrier groups. The dependent term 
for each model was an imaging biomarker with fixed effect terms for baseline age, sex, time 
from baseline, extracted rate of change in serum NfL, and interaction between time from baseline 
and rate of change in serum NfL. Models contained random slope and intercept terms for 
participants and random intercepts for family. The primary term of interest was the interaction 
between the rate of change in serum NfL and the time from baseline term. Models were fitted 
using lme4 in R. 
To determine whether the relationship between groups was different, a model for each 
imaging modality containing all groups was run. Each model was fitted containing fixed effect 
terms for baseline age, sex, time from baseline, extracted rate of change in serum NfL, group 
(non-carriers, presymptomatic mutation carriers, or symptomatic mutation carriers), and two- 
and three-way interaction between time from baseline, rate of change in serum NfL, and group. 
Converters were included as part of the symptomatic mutation carrier group. The models also 
included random slope and intercept terms for the participants and random intercepts for family. 
The dependent variables were the longitudinal measures for cortical thickness, glucose 
metabolism, or amyloid-β deposition in the precuneus ROI. See also the supplementary 
statistical analysis section. 
 
Serum NfL at baseline predicts annual changes in cortical thickness and cognition 
To examine whether baseline serum NfL could predict subsequent changes in cortical 
thickness and cognition in mutation carriers we fitted LMEMs with random slope and intercept 
terms for participants, random intercepts for family, and fixed effect terms for baseline age, sex, 
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time, log-transformed baseline serum NfL, and an interaction between time and baseline serum 
NfL. The interaction term was the term of interest. The dependent terms entered into the models 
were longitudinal precuneus cortical thickness measurements, MMSE scores, and Logical 
Memory test scores. If significant, an association of baseline serum NfL with rate of change in 
cortical thickness or cognition was assumed. See also the supplementary statistical analysis 
section. 
 
Prospective prediction of cortical thickness and cognition by serum NfL rate of change. 
To determine whether the rate of change in serum NfL could predict subsequent changes 
in cortical thickness or cognition, we conducted a truly prospective study, whereby after 
longitudinal serum collection for NfL, we collected additional imaging and neuropsychological 
data on 39 mutation carriers. Twenty-eight individuals completed additional imaging and 
neuropsychological testing, 9 completed only additional neuropsychological testing but no MRI, 
and 2 who completed an additional MRI but not neuropsychological testing. To determine the 
rate of change in cortical thickness and cognition (MMSE, Logical Memory test) between the 
imaging and cognitive assessment concurrent to the participant’s last blood draw and follow-up 
session, we fitted an LMEM for each participant, where the dependent variable was the imaging 
or cognitive variable of interest at last serum visit and follow-up visit and the independent 
variable was the time between visits. Models were run in R. We then used this rate of change for 
cortical thickness or cognition as the dependent variable in an LMEM, which included fixed 
effects for age, sex, and the rate of change in serum NfL, and a random intercept term for family. 
The term of interest was the serum NfL rate of change. Models were fitted using lme4 in R. See 




Further statistical analyses and models. 
The unstandardized regression coefficients (B), standard error of the mean (s.e.m.), and P 
values from the LMEMs and linear regression models are reported in the figure legends. The 
statistical analyses mentioned in the figure legends of  Figures 4.7-4.9 and Tables 4.1 and 4.2 
were conducted using the JMP software, version 13.0 (SAS Institute Inc.). For the analysis of 
Figure 4.8 a regression model was created, which approximates the changes of non-carriers and 
mutation carriers. The model uses the rate of change of log serum NfL over EYO. For non-
carriers a slightly increasing line over the entire time period was created representing the NfL 
increase over age. For mutation carriers the same development was taken for the very early years 
until a bifurcation point indicating the divergence of non-carriers and mutation carriers. From 
this point on, mutation carriers were shown with a rising slope up to a break of slope, when the 
line came to a parallel increase as non-carriers. This model uses one common slope at the very 
beginning, one bifurcation point, and one shift leading to two parallel slopes after symptom 
onset. See also the supplementary statistical analysis section. 
 
Supplementary statistical analysis.  
Baseline CSF and serum NfL and longitudinal NfL as a function of EYO  
For these analyses we represented eyo using a cubic spline. The knot positions and spline 
values were calculated using the rcspline.eval function to produce a linear term and a cubic term 
for eyo as follows:  
splinefit=rcspline.eval(data$eyo, nk=3, norm=2, pc=FALSE, inclx=TRUE)  
89 
 
Model fitting was performed using a Hamilton Markov chain Monte Carlo implemented in 
version 2.17.4 of the probabilistic programming environment Stan (Carpenter et al., 2017). We 
implemented the STAN software using the wrapper stan_glmer (Muth, Oravecz, & Gabry, 
2018). Our R code is included below. A model was run using eight independent chains 
consisting of 5,000 iterations after 5,000 warm-up samples. In order to account for 
autocorrelation within a chain, we thinned he chains by limiting our analysis to every 10th 
sample. As a result, all inference was performed should equal 1.0. In all of our models R was 
found to be acceptably close to 1.0.  
As previously done (Brian A Gordon et al., 2018; Mishra et al., 2017), this resampling approach 
was taken in order to estimate credible intervals around the model fits which could in turn could 
be used accurately determine when mutation carriers and non-carriers first diverged.  
stan_glmer(analyte_value ~ (1|fam_id) + eyo_spline_linear + eyo_spline_cubic +mutation + 
eyo*mutation + eyo_cubic*mutation,  
data = data, family = gaussian(), 
prior = cauchy(), prior_intercept = cauchy(), chains = 8, cores = 1, iter = 10000, thin = 10)  
Relating baseline CSF and serum NfL  
All subsequent analyses were performed using linear mixed-effects models implemented in R 
using the lmer (https://cran.r-project.org/web/packages/lme4/lme4.pdf) package.  
lmer (Serum.NfL.log ~ sex + age + CSF_NfL_log +(1|fam_id), data)  
Calculating the rate of change in biomarkers  
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lmer (biomarker_value ~ 1 + time + mutation + mutation*time + (time | id) + (1 | fam_id) , data)  
 
Longitudinal serum NfL and cognitive status  
lmer (change_in_nfl_value ~ baseline_age + sex + cog_group + (1 | fam_id), data))  
Association between expected age of onset and deviation from the EYO-adjusted median rate 
of change in NfL  
lmer (deviation_from_change_in_nfl_value ~ baseline_age + sex + AO_group + (1 | fam_id), 
data))  
Relating Extracted NfL rate of change with imaging rate of change  
Within-group assessment: 
lmer(biomarker_value ~ (time | id)+ (1 | fam_id) + baseline_age + change_in_nfl_value + sex + 
time + time*change_in_nfl_value, data)  
Between-group assessment: 
lmer (biomarker_value ~ (tim) + (1 | fam_id) + cog_group + baseline_age + 
change_in_nfl_value + sex + time + time* change_in_nfl_value + time*cog_group + 
change_in_nfl_value *cog_group + time* change_in_nfl_value *cog_group, data  
Where cog_group is the associated mutation status and cognitive status group each individual is 
categorized to: NC are coded as “0”, presymptomatic MC (individuals who scored “zero” on the 
Clinical Dementia Rating (CDR) across all visits) are coded as “1”, and converters (CDR=0 at 
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baseline and CDR>0 at subsequent visits) and symptomatic MC (CDR>0 across all visits) are 
coded as “2”.  
Serum NfL at baseline predicting of the annual changes in cortical thickness and cognition  
lmer (biomarker_value ~ time + baseline_age + sex + baseline_serum_nfl_log_value*time + 
(time | id) + (1 | fam_id), data)  
Prospective prediction of cortical thickness and cognition by serum NfL rate of change  
lmer (prospective_change_biomarker_value ~ (1 | fam_id) + baseline_age + sex + 
change_in_nfl_value, data))  
Abbreviations  
eyo= estimated years to/from clinical symptom onset 
eyo_spline_linear= eyo linear component 
eyo_spline_cubic= eyo cubic spline component 
analyte_value= analyte of interest (e.g., baseline CSF NfL, baseline serum NfL) fam_id= family 
ID  
mutation= mutation status; non-carriers= 0, mutation carriers= 1 Serum.NfL.log= log-transform 
baseline serum NfL value CSF_NfL_log= log-transformed baseline CSF NfL value 
Sex= male= 0, female= 1  
Age= age at visit (years) 
Data= data matrix 
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ID= subject-specific identification number 
Biomarker_value= values of biomarkers (e.g., serum NfL, cortical thickness, FDG-PET SUVR, 
PiB SUVR, etc.) for each visit for every individual 
Time= time from baseline blood draw or imaging session, as appropriate, for each visit for every 
individual (years) 
Cog_group= the associated mutation status and cognitive status group each individual is 
categorized to: NC are coded as “0”, presymptomatic MC (individuals who scored “zero” on the 
Clinical Dementia Rating (CDR) across all visits) are coded as “1”, converters (CDR=0 at 
baseline and CDR>0 at subsequent visits) are coded as “2”, and symptomatic MC (CDR>0 
across all visits) are coded as “3” 
Change_in_”x”_value= extracted change slope with annual rate of change for biomarker 
Baseline_age= age at baseline visit (years) 
Prospective_change_biomarker_value= extracted change slope for biomarkers of interest 
(cortical thickness, MMSE, or Logical Memory), between the visit associated with last blood 
draw (i.e., last serum NfL measure),  
4.4 Results 
We made use of the Dominantly Inherited Alzheimer Network (DIAN)18 data and 
biospecimens to study NfL changes in the CSF and blood of presymptomatic and symptomatic 
Alzheimer’s disease. DIAN participants are members of families carrying highly penetrant 
autosomal-dominant mutations in the genes encoding the amyloid beta precursor protein (APP) 
or presenilin 1 (PSEN1) or 2 (PSEN2) (Moulder et al., 2013). Family members who do not carry 
the mutations serve as controls. Since the age of symptom onset tends to be consistent for a given 
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mutation, it is possible to calculate for participants an estimated years to symptom onset (EYO) 
from the known onset of individuals with the same mutation (Ryman et al., 2014). 
 We used the single-molecule array immunoassay technology to measure NfL in the CSF 
and blood serum of DIAN participants at their baseline (initial) visit (mutation carriers, n = 243; 
non-carriers, n = 162) (see Table 4.1 for participant characteristics). Multivariate linear mixed 
effects models (LMEMs) served to assess the earliest point in the disease when NfL starts to 
increase in mutation carriers in relation to non-carriers (Figures 4.1a and 4.1b). Results revealed 
that NfL in the CSF was significantly increased between mutation carriers and non-carriers at 
−6.8 EYO (Figure 4.1a, Figure 4.5a). Almost identically, serum NfL was also increased at −6.8 
EYO (Figure 4.1b; Figure 4.5b). Consistent with our earlier work13 CSF and serum NfL levels 
were tightly associated (Figures 4.1c and 4.1d). No differences in CSF or serum NfL levels 
between the three familial Alzheimer’s disease mutations were found (Figure 4.6). 
Given the strong association between serum and CSF NfL, and the obvious advantage of 
a non-invasive disease blood biomarker, we chose to focus on serum NfL for subsequent 
longitudinal analyses. From the 405 participants with baseline serum, 196 returned for at least 1 
and maximally 5 follow-up visits, with a mean number of 2.5 visits and a median observation 
time of 3 years from the baseline visit (see Table 4.2 for the longitudinal characteristics of 
participants). 
 Overall, the longitudinal analysis of serum NfL confirmed the cross-sectional findings 
(Figure 4.2a). Using LMEMs we calculated the slope of NfL change per year for each 
participant. As with cross-sectional values, the NfL rates of change were significantly elevated in 
mutation carriers relative to non-carriers. Strikingly, however, the first EYO point where this 
increase became significant was at − 16.2 years (Figure 4.2b; see also Figure 4.7), which is 
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almost a decade earlier than the cross-sectional baseline estimates (−6.8 EYO, see earlier). 
Consistent with this earlier separation of mutation carriers and non-carriers using longitudinal 
measurements, the rate of change could distinguish presymptomatic mutation carriers from non-
carriers more accurately compared to base-line serum NfL using receiver operating 
characteristics analysis (Figure 4.8). 
Next, we subdivided mutation carriers into three groups: presymptomatic mutation 
carriers (individuals who scored 0 on the Clinical Dementia Rating (CDR) scale across all visits); 
converters (CDR = 0 at baseline and CDR > 0 at subsequent visits); and symptomatic mutation 
carriers (CDR > 0 across all visits). Then we compared the rate of change in serum NfL across 
these groups. Analyses revealed that the rate of change in serum NfL peaked in the converter 
group with no further increase in the symptomatic carriers (Figure 4.2c). Interestingly, flattening 
or even U-shaped curves have also been observed in longitudinal studies for CSF biomarkers in 
dominant and sporadic AD (McDade et al., 2018; Sutphen et al., 2018). 
No differences in NfL rate of change were found between mutations in APP, PSEN1, and 
PSEN2 (Figure 4.9). To analyze whether the NfL rate of change was associated with the 
aggressiveness of individual mutations or EYO, we analyzed how far away the NfL rate of 
change of each mutation carrier was from the median value from the model estimates at that 
individual’s EYO (Figure 4.9b). Although we did not find any significant differences, it is 
possible that differences become apparent when the number of individuals and longitudinal data 
points increase. 
 To study if brain changes are coupled with changes in serum NfL, regression analysis 
between NfL rates of change and rates of change in brain imaging modalities were performed. 
We focused on the precuneus since previous analyses have shown this area to be most sensitive 
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to Alzheimer’s disease progression (Benzinger et al., 2013). NfL rates of change in serum and 
rates of precuneus cortical thinning were significantly associated in symptomatic mutation 
carriers with a trend toward significance in presymptomatic mutation carriers (Figure 4.3a). The 
rate of change in serum NfL and the rate of change in precuneus glucose metabolism (18F-
fluorodeoxyglucose (18F-FDG) PET) were significantly associated in symptomatic mutation 
carriers but not in presymptomatic mutation carriers (Figure 4.3b). Although there was a 
positive relationship between NfL rate of change and the rate of change in precuneus amyloid-β 
deposition (amyloid-β-PET), the association did not reach significance (Figure 4.3c). These 
results indicate that NfL changes in the blood most closely reflect cortical thinning and support 
the view that serum NfL is primarily a marker of neurodegeneration. 
 To examine the utility of serum NfL for predicting subsequent neurodegeneration and 
clinical symptoms, we performed a (retrospective) pseudo-predictive analysis to ask whether 
baseline serum NfL levels were predictive of subsequent cortical thinning (Figure 4.4a). In 
addition, we assessed the predictability of baseline serum NfL for detecting change in two 
cognitive parameters, namely the Mini–Mental State Examination (MMSE) and the Logical 
Memory test (Figures 4.4b-c). Indeed, baseline NfL was highly predictive of future annualized 
cortical thinning, for both presymptomatic and symptomatic mutation carriers, at subsequent 
visits (Figure 4.4a) and was also predicative for a decrease in MMSE and Logical Memory 
scores (Figures 4.4b-c). 
 To examine whether serum NfL is also predictive in a truly prospective design, the first 
39 mutation carriers returning for follow-up visits after the last serum collection were included in 
the analysis. (The median time between last serum collection and subsequent visit was 2.1 
years.) This prospective analysis allowed us to use the serum NfL rate of change for the 
96 
 
prediction of further cortical thinning and cognitive changes (from the last visit with serum 
collection to the follow-up visit). Despite the small sample size, significant (predictive) 
associations were found between serum NfL rate of change and cortical thinning as well as 
MMSE and Logical Memory test (Figure 4.4d–f). 
4.5 Discussion 
Cross-sectional and longitudinal data analyses of DIAN and other large Alzheimer’s 
disease cohorts have demonstrated that the pathological processes in Alzheimer’s disease begin 
more than two decades before the onset of clinical symptoms. The accumulation of amyloid-β in 
the brain (estimated 15–20 years before clinical onset) is followed by declines in cortical 
metabolism (estimated 10–15 years before clinical onset) and brain atrophy (5–10 years before 
clinical onset) (R. J. Bateman et al., 2012; Burnham et al., 2016; Brian A Gordon et al., 2018; 
McDade et al., 2018). Thus, it is generally agreed that therapeutic interventions should start as 
early as possible making disease bio-markers of the presymptomatic phase of utmost importance 
(Jack Jr & Holtzman, 2013; Reisa A Sperling et al., 2013). The present results suggest that NfL 
levels in the blood may serve as such a biomarker to monitor neurodegeneration and disease 
progression already in presymptomatic Alzheimer’s disease. 
The strong association between NfL levels in the CSF and blood indicates that NfL 
changes in the blood reflect changes in the brain, a finding also reported for other 
neurodegenerative diseases including sporadic Alzheimer’s disease (Mehtap Bacioglu et al., 
2016; Lu et al., 2015; Niklas Mattsson et al., 2017; Julio C Rojas et al., 2016). In the present 
study serum was analyzed but similar levels and tight correlations have also been reported for 
NfL in the plasma (Mehtap Bacioglu et al., 2016; Lu et al., 2015). The antigen detected with the 
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(ultrasensitive) immunoassay used in this study is presumably a short and stable fragment (~10 
kD) of the core domain of NfL (Anthony Brureau et al., 2017; Norgren, Karlsson, Rosengren, & 
Stigbrand, 2002). Such a stable fragment appears well suited as a blood biomarker for 
monitoring a slow neurodegenerative process in the brain. 
Using serial NfL measurements we found that the NfL annual rate of change can 
distinguish non-carriers and mutation carriers as early as 16 years before the estimated symptom 
onset. This is almost a decade earlier than when using absolute NfL levels measured at a single 
time point. Consistently, previous studies reported only non-significant or barely significant 
increases in absolute NfL in the blood in presymptomatic or even mildly cognitive impaired 
Alzheimer’s disease patients (Mehtap Bacioglu et al., 2016; Niklas Mattsson et al., 2017; P. S. 
Weston et al., 2017). In symptomatic Alzheimer’s disease, our results suggest that the NfL rate 
of change reaches a plateau, whereas absolute NfL levels continue to increase. Increased 
absolute NfL levels in the blood in the symptomatic disease phase is consistent with similar 
observations in progressive supranuclear palsy (Julio C Rojas et al., 2016), Huntington’s disease 
(Byrne et al., 2017), and multiple sclerosis (Christian Barro et al., 2018). 
The very early changes of NfL in the blood may appear surprising in light of the reported 
overall brain atrophy only 5–10 years before symptom onset. However, atrophy of individual 
cortical regions occurs earlier (R. J. Bateman et al., 2012; Burnham et al., 2016; Brian A Gordon 
et al., 2018; McDade et al., 2018). In fact, precuneus thinning was also detected around 16 years 
before symptom onset (Brian A Gordon et al., 2018), suggesting that NfL changes are sensitive 
enough to pick up such early regional brain atrophy. The association between NfL and cortical 
thinning, rather than amyloid-β deposition, is in line with cerebral amyloid-β aggregation being a 
trigger of subsequent neurodegeneration that, however, become independent of each other at 
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later disease stages (Karran, Mercken, & De Strooper, 2011). The relationship of NfL to tau in 
bodily fluids needs further work. In the DIAN cohort, the increase of tau in the CSF (absolute 
levels, cross-sectional) occurs as early as 15 years before the estimated age of symptom onset 
(Fagan et al., 2014), which is much earlier than the increase of baseline NfL in the CSF. 
While an increase of NfL levels is not specific for Alzheimer’s disease, the present 
findings are relevant for understanding Alzheimer’s disease progression and highlight their 
utility as a marker in clinical trials. In presymptomatic Alzheimer’s disease, the greater the NfL 
rate of change, the closer an individual is to converting to symptomatic Alzheimer’s disease, a 
finding also reported for cortical atrophy (Kinnunen et al., 2018). This suggests that longitudinal 
measures of NfL in the serum are a reliable, relatively cheap, and fast readout of 
neurodegeneration in the brain with comparable diagnostic value to neuroimaging but without 
the regional resolution. 
Although our prospective predication analysis was not adequately powered to 
demonstrate that NfL rate of change is indeed a better predictor of disease progression 
(neurodegeneration and cognitive decline) than absolute NfL values, our observations suggest 
that this is the case in presymptomatic Alzheimer’s disease, while absolute NfL levels are better 
predictors in the symptomatic phase. Absolute NfL levels have been successfully used to predict 
brain volume changes in (symptomatic) multiple sclerosis (Christian Barro et al., 2018) and 
clinical outcome in traumatic brain injury (Shahim et al., 2016). In a recent study with 
Huntington’s disease patients, NfL blood levels were predictive of disease onset within three 
years (Byrne et al., 2017), but NfL rate of change was not assessed. 
 The current study design with the 2–3 years interval between participant assessments did 
not allow us to determine the relationship between the time over which the NfL rate of change 
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was calculated and its clinical predictability. However, the latter appears important to advance 
the NfL rate of change as a biomarker. Future analyses should also assess more accurately the 
disease period at which the NfL rate of change is a better predictor of neurodegeneration and 
cognitive decline than absolute NfL. Finally, it is important to translate our findings to sporadic 
Alzheimer’s disease and other cerebral proteopathies (Mehtap Bacioglu et al., 2016; Jucker & 
Walker, 2018). Studies have indicated that the pathogenesis of familial and sporadic Alzheimer’s 
disease are very similar and share similar pathophysiology and progression (Randall J Bateman 
et al., 2011; Cairns et al., 2015; Tang et al., 2016; Thomas et al., 2014). However, sporadic 
Alzheimer’s disease patients are typically older and have more comorbidities, which in turn may 
influence NfL levels in the blood. The latter is however a further argument that absolute NfL 
levels may be less useful for prediction in early disease stages compared to the NfL rate of 
change. 
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Table 4.1. Baseline characteristics of DIAN participants 
 
Baseline value of all participants. Estimated year to symptom onset (EYO), was analyzed by 
two-sided t-test. Mini-Mental State Examination (MMSE) and biomarkers data were analyzed by 
two-sided Wilcoxon rank sum test. CDR= Clinical Dementia Rating. 
 
* Note that from 5 participants MMSE was not available. Moreover, CSF was only available 
from 80 and 107 for NC and MC, respectively. (CSF was not collected from all participants and 
the CSF samples were obtained from Data Freeze 9 while serum was obtained from Data Freeze 
11. Moreover, from the originally 221 CSF samples obtained, 3 were excluded by empty tubes, 3 
were excluded as no corresponding ID in Data Freeze 11 was found, 3 were excluded because 
sample date did not match to data of Data Freeze 11, and 25 were excluded because CSF samples 








Table 4.2. Characteristics of DIAN participants with longitudinal visit 
 







Figure 4.1. CSF and serum NfL levels are highly correlated and divert between mutation carriers 
and non-carriers already in the presymptomatic phase. a, CSF NfL values of non-carriers (blue, n 
= 80) and mutation carriers (red, n = 107) as a function of EYO. Shown is −27.5 until +15 years 
before or after EYO, respectively. b, Serum NfL for non-carriers (n = 162) and mutation carriers 
(n = 243) as a function of EYO. For a and b, the shaded areas represent the 99% credible 
intervals around the model estimates. The curves and credible intervals are drawn from the actual 
distributions of model fits derived by the Hamiltonian Markov chain Monte Carlo analyses (see 
Methods). The first EYO where non-carriers and mutation carriers differed was determined to be 
the first point where the 99% credible intervals around the difference distribution between non-
carriers and mutation carriers did not overlap 0 (−6.8 years before EYO for both CSF and serum, 
see Figure 4.5). Our analysis is influenced by the available number of participants. Thus, results 
do not represent absolute measures, but rather relative EYO points where we could detect effects 
given the limitations of sample size. c,d, Significant associations from LMEMs between CSF 
NfL and serum NfL in non-carriers (n = 80; B(s.e.m.) = 0.350(0.14), P = 0.014) and mutation 








Figure 4.2. Longitudinal serum NfL distinguishes mutation carriers from non-carriers very early 
in the presymptomatic disease process, with the NfL rate of change peaking in individuals 
converting from the presymptomatic to the symptomatic phase. a, Spaghetti plot showing 
longitudinal serum NfL for non-carriers (blue, n = 63) and mutation carriers (red, n = 133) as a 
function of EYO. The displayed x axis range is limited to −27.5 until +12.5 years before or after 
EYO, respectively, to maintain blinding of some individuals contributing to this dataset. In 
addition, again to maintain blinding, the EYO of two participants (one mutation carrier and one 
non-carrier) was set to the mean of both EYO values. A logarithmic version of the spaghetti plot 
is shown in Figure 4.8a to better appreciate that changes between mutation carriers and non-
carriers already occur at presymptomatic levels. b, Estimated rate of change per year in serum 
NfL (see Methods for calculation) plotted against baseline EYO for mutation carriers and non-
carriers (shown is −27.5 until +12.5 years). Individual random effect slope estimates are plotted 
as colored symbols. The shaded areas represent the 99% credible intervals around the model 
estimates. The curves and credible intervals are drawn from the actual distributions of model fits 
derived with the Hamiltonian Markov chain Monte Carlo analyses. The first EYO where groups 
(non-carriers and mutation carriers) differed was determined to be the first point where the 99% 
credible intervals around the difference distribution between non-carriers and mutation carriers 
did not overlap 0 (−16.2 years before EYO; see Figure 4.8b). An even earlier deviation of the 
two curves was calculated when linear regression analyses were performed (Figure 4.7c). c, Rate 
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of change per year in serum NfL across four groups differing by mutation and cognitive status: 
non-carriers (blue, n = 63); presymptomatic (Presym) mutation carriers (yellow, n = 65) are 
individuals who scored as CDR= 0 across all visits; converters (orange, n = 13) are mutation 
carriers who scored as CDR= 0 at baseline and CDR> 0 at subsequent visits; symptomatic (Sym) 
mutation carriers (red, n = 55) are individuals who scored as CDR> 0 across all visits. The boxes 
map to the median, 25th and 75th quintiles, and the whiskers extend to 1.5 × interquartile range 
(IQR). Comparisons were done with LMEMs. Presymptomatic mutation carriers had a 
significantly higher annual rate of change compared to non-carriers (B(s.e.m.) = 0.009(0.003), P 
= 6.71 × 10−4). Converters had significantly higher rate of change compared to both non-carriers 
(B(s.e.m.) = 0.024(0.004), P = 3.05 × 10−7) and presymptomatic mutation carriers (B(s.e.m.) = 
0.015(0.005), P = 1.19 × 10−3). Symptomatic mutation carriers had significantly higher rates of 
change compared to both non-carriers (B(s.e.m.) = 0.020(0.003), P = 8.78 × 10−12) and 
presymptomatic mutation carriers (B(s.e.m.) = 0.011(0.003), P = 1.51 × 10−4). There was no 













Figure 4.3. Rate of change per year in serum NfL in mutation carriers mirrors rate of change in 
cortical thinning. a, Relationship between estimated annual rate of change in serum NfL and 
estimated annual rate of change in precuneus cortical thickness for non-carriers, presymptomatic 
(Presym) mutation carriers, and symptomatic (Sym) mutation carriers (including converters to 
the symptomatic phase, see Figure 4.2c). Results from LMEMs revealed a significant association 
in symptomatic mutation carriers (n = 60; B(s.e.m.) = −0.914(0.367), P = 0.018) and a close to 
significant association in presymptomatic mutation carriers (n = 65; B(s.e.m.) = −0.325(0.166), 
P = 0.054) but not in non-carriers (n = 59; B(s.e.m.) = −0.210(0.149), P = 0.886). Between-group 
comparison indicated that the rate of change in serum NfL was slightly more associated in 
symptomatic than in asymptomatic mutation carriers (B(s.e.m.) = −0.573(0.305), P = 0.063). b, 
Relationship between rate of change in serum NfL and rate of change in precuneus 18F-FDG 
PET. Using LMEMs, a positive association was only found in symptomatic mutation carriers 
(n = 55; B(s.e.m.) = −1.149(0.501), P = 0.031) but not in presymptomatic mutation carriers 
(n = 64; B(s.e.m.) = −0.227(0.456), P = 0.620) or non-carriers (n = 55; B(s.e.m.) = 0.161(0.347), 
P = 0.465). c, Relationship between rate of change in serum NfL and rate of change in precuneus 
amyloid-β-PET. Using LMEMs, no significant association in any of the three groups was found 
(non-carriers: n = 57; B(s.e.m.) = −0.468(0.547), P = 0.403; presymptomatic mutation carriers: 
n = 64; B(s.e.m.) = 1.248(1.000), P = 0.216; symptomatic mutation carriers: n = 51; 
B(s.e.m.) = 1.805(1.556), P = 0.266). The shaded area around each linear fit line represents 
one s.e.m. Note that not all participants with longitudinal NfL measurements had imaging 







Figure 4.4. Prediction of changes in cortical thinning and cognition by baseline serum NfL 
(retrospective prediction) and serum NfL rate of change (prospective prediction). a–c, Higher 
baseline serum NfL levels were significantly associated with an increased rate of change in 
cortical thickness (n = 125; B(s.e.m.) = −0.105(0.013), P = 4.47 × 10−13) (a), MMSE (n = 132; 
B(s.e.m.) = −3.980(0.537), P = 2.38 × 10−11) (b), and Logical Memory test (immediate recall, 
n = 133; B(s.e.m.) = −1.478(0.502), P = 0.004) (c). A similar significance (P = 0.015) was 
obtained for the Logical Memory test delayed recall. LMEMs (see Methods) were run with all 
mutation carriers together (n = 125) because of the high degree of overlap in cognitive and 
biomarker levels between presymptomatic (Presym) and symptomatic (Sym) mutation carriers. 
However, at least for cortical thickness, separate analyses for presymptomatic and symptomatic 
mutation carriers were also significant (n = 65, presymptomatic mutation carriers (yellow): 
B(s.e.m.) = −0.03(0.01), P = 0.047; n = 60, symptomatic mutation carriers (red): 
B(s.e.m.) = −0.10(0.03), P = 0.002). d–f, In a true prospective design, mutation carriers returning 
for follow-up visits after the last serum collection were included in the analysis. Individuals’ 
rates of change in serum NfL levels predicted subsequent cortical thinning (d; n = 30; 
B(s.e.m.) = −1.867(0.769), P = 0.024). The same predictive associations were also significant for 
the MMSE (e; n = 37; B(s.e.m.) = −52.23(20.19), P = 0.015) and Logical Memory test scores (f; 
immediate recall, n = 37; B(s.e.m.) = −75.91(18.07), P = 0.0002). For descriptive purposes, 
presymptomatic and symptomatic mutation carriers are plotted in yellow and red, respectively. 
Note that not all participants with baseline NfL measurements had longitudinal MRI imaging and 
longitudinal cognitive parameters available; thus, sample sizes (n) in a–c are slightly lower than 
those in Supplementary Table 2. This was also true for the mutation carriers returning for follow-
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up visits after the last serum collection (d–f). The shaded area around each linear fit line 

















Figure 4.5. Difference distribution curve for baseline (cross-sectional) CSF and serum NfL 
levels in mutation carriers and non-carriers. a,b, Difference of posterior distribution for baseline 
CSF NfL (n = 187) (a) and baseline serum NfL (n = 405) (b) as a function of EYO. The solid red 
lines depict the median of the difference distribution; the shaded area represents the 99% equal-
tailed credible intervals. EYO was considered statistically significant if the 99% equal-tailed 
credible intervals of the posterior distribution did not overlap 0 (6.8 years before EYO for both 
baseline CSF and serum NfL). For the absolute values of baseline CSF and serum NfL, See 












Figure 4.6. No difference in baseline CSF and serum NfL levels among APP, PSEN1, and 
PSEN2 mutation carriers. a, Two-tailed pairwise Student’s t-test comparisons of CSF NfL levels 
of carriers of a mutation in APP (n = 14), PSEN1 (n = 82), or PSEN2 (n = 11). b, Same analysis, 
using a two-tailed pairwise Student’s t-test for the serum NfL of carriers of a mutation in APP 
(n = 39), PSEN1 (n = 185), or PSEN2 (n = 19). No differences in log(CSF NfL) or log(serum 
NfL) were found between the groups (F(2, 104) = 1.8108, P = 0.1686 and F(2, 240) = 1.9205, 
P = 0.1488, respectively). Similarly, no differences were found by two-tailed pairwise Student’s 
t-test when age and disease status (presymptomatic, symptomatic) were treated as covariates. 





Figure 4.7. Longitudinal serum NfL and bifurcation of mutation carriers from non-carriers. a, 
Spaghetti plot showing longitudinal serum NfL for non-carriers (NC, n = 63, blue) and mutation 
carriers (MC, n = 133, red) as a function of EYO. These are the same data as in Figure 2a but 
with a logarithmic scale on the y axis to better appreciate the changes during the presymptomatic 
stage (for details, see Figure 2a). b, Difference of posterior distribution for serum NfL rate of 
change between mutation carriers and non-carriers, as a function of EYO (n = 196). The solid red 
line depicts the median of the difference distribution, and the shaded area represents the 99% 
equal-tailed credible intervals. EYO was considered statistically significant if the 99% equal-
tailed credible intervals of the posterior distribution did not overlap 0 (16.2 years before EYO). c, 
Individual estimated rate of change in serum NfL (same data as in Figure 2b, n = 63 for non-
carriers and n = 133 for mutation carriers). A regression analysis was performed with two breaks 
of slope (see Methods for calculation). With this model the first bifurcation point was found at 





Figure 4.8. Rate of change per year of serum NfL is a better parameter to distinguish 
presymptomatic and symptomatic mutation carriers from non-carriers compared to single cross-
sectional serum NfL. Receiver operating characteristic analysis for non-carriers (NC) versus 
presymptomatic mutation carriers (MC) and non-carriers versus symptomatic mutation carriers 
with cross-sectional (baseline serum NfL) and longitudinal (serum NfL rate of change per year) 
data. The true positive fraction (sensitivity) is on the y axis and the false positive fraction (1-
specificity) on the x axis. The area under the curve (AUC, accuracy), as well as the cutoff value 
and χ2 P value from the logistic regression are shown. The chance level of the area under the 









Figure 4.9. No difference in serum NfL rate of change among APP, PSEN1, and PSEN2 
mutation carriers and no association with estimated age of onset. a, Using two-tailed pairwise 
Student’s t-tests, no differences in the rate of change of log(serum NfL) (year−1) levels among 
APP (n = 24), PSEN1 (n = 104), and PSEN2 (n = 5) mutation carriers (F(2, 130) = 0.4678, 
P = 0.6274) was found. Similarly, no differences were found when age and disease status 
(presymptomatic, symptomatic) were treated as covariates in a two-tailed pairwise Student’s t-
test. b, No difference between an individual’s deviation from the EYO-adjusted median rate of 
change in NfL and their expected age of symptom onset using LMEMs. Individuals were 
grouped in 4 categories with expected symptom onset at 20–39 (n = 17), 40–49 (n = 54), 50–59 
(n = 56), and over 60 years of age (n = 6); group comparisons, P > 0.146. See Methods for the 
calculations. The boxes map to the median, 25th and 75th quintiles, and the whiskers extend to 













Serum neurofilament light chain predicts 
white matter integrity in autosomal dominant 
Alzheimer disease. 
 










5.1 Summary  
Neurofilament light chain (NfL) is a protein that is selectively expressed in neurons. Increased 
levels of NfL measured in either cerebrospinal fluid or blood is thought to be a biomarker of 
neuronal damage in neurodegenerative diseases. However, there have been limited investigations 
relating NfL to concurrent measures of white matter (WM) decline that it should reflect. White 
matter damage is a common feature of Alzheimer disease. We hypothesized that serum levels of 
NfL would associate with WM lesion volume and diffusion tensor imaging (DTI) metrics cross-
sectionally in 117 autosomal dominant mutation carriers (MC) compared to 84 non-carrier (NC) 
familial controls as well as in a subset (N=41) of MC with longitudinal NfL and MRI data.  
In MC, elevated cross-sectional NfL was positively associated with WM hyperintensity 
lesion volume, mean diffusivity, radial diffusivity, and axial diffusivity and negatively with 
fractional anisotropy. Greater change in NfL levels in MC was associated with larger changes in 
fractional anisotropy, mean diffusivity, and radial diffusivity, all indicative of reduced WM 
integrity. There were no relationships with NfL in NC. Our results demonstrate that blood-based 
NfL levels reflect WM integrity and supports the view that blood levels of NfL are predictive of 
WM damage in the brain. This is a critical result in improving the interpretability of NfL as a 
marker of brain integrity, and for validating this emerging biomarker for future use in clinical 







Neurodegenerative disease biomarkers have important roles in defining disease presence and 
severity, predicting progression, and monitoring disease-modifying therapies. For clinical and 
research settings such in vivo measures include magnetic resonance imaging (MRI), positron 
emission tomography (PET), cerebrospinal fluid (CSF) assays, and blood-based tests. Blood-
based biomarkers (Lewczuk et al., 2018; Zetterberg & Blennow, 2018) have the advantages of 
minimal invasiveness, subject acceptability, low cost, as well as accessibility in diverse clinical 
settings, including lesser developed countries.  
Neurofilaments are a component of the cytoskeleton in the neuronal axons and are critical 
for the radial growth and stability of axons (Barry et al., 2012; Rao et al., 2003). Mutations in the 
genes that encode neurofilament proteins lead to axonal dysfunction and degeneration 
(Jordanova et al., 2003). When axonal membranes are damaged or disrupted, neurofilaments are 
thought to be released into the interstitial fluid, and from there move subsequently into the CSF 
and blood (Khalil et al., 2018). Neurofilament proteins measured in biofluids have one of three 
basic structures with light, medium, or heavy molecular weights, with the majority of work in 
neurodegenerative conditions focusing on the light subunit. Concentrations of neurofilament 
light chain (NfL) are high enough in the CSF to be reliably measured with either enzyme-linked 
immunosorbent assays (ELISA) or electro-chemiluminescence (ECL)-based assays (Khalil et al., 
2018; Jens Kuhle et al., 2016). The introduction of the single-molecule array (SIMOA) (D. H. 
Wilson et al., 2016) platform has provided the sensitivity to reliably detect the lower 
concentrations of NfL present in blood samples (Khalil et al., 2018; Jens Kuhle et al., 2016).  
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Any pathological process that leads to axonal damage or neuronal death should release 
neurofilament proteins into the surrounding extracellular fluid. Thus, elevations in neurofilament 
protein biofluid concentrations are not specific to one disease but are a general indicator of 
axonal damage. Indeed, CSF NfL has been evaluated as a potential fluid biomarker in a wide 
range of neurodegenerative disorders including frontotemporal dementia (FTD), progressive 
supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), Parkinson disease (PD), multiple 
sclerosis (MS), vascular dementia (VAD), dementia with Lewy bodies (DLB) as well as sporadic 
and autosomal dominant Alzheimer disease (AD) (see (Bridel et al., 2019) for meta-analysis). 
Comparison between NfL levels in CSF and either plasma (J. C. Rojas et al., 2018; Julio C Rojas 
et al., 2016) or serum (Bergman et al., 2016; Meeter et al., 2016; Preische et al., 2019; Steinacker 
et al., 2018) has shown high correlations, suggesting that blood levels reflect ongoing biological 
processes in the brain (Mehtap Bacioglu et al., 2016). As with the CSF studies, blood levels of 
NfL have been examined across a range of neurodegenerative conditions including PSP, ALS, 
PD, MS, head trauma, and stroke as well as AD (Chitnis et al., 2018; De Marchis et al., 2018; 
Disanto et al., 2017; Gaiottino et al., 2013; Hansson et al., 2017; J. Kuhle et al., 2019; Lin, Lee, 
Wang, & Fuh, 2018; Niklas Mattsson et al., 2017; Meeter et al., 2016; Oliver et al., 2016; Rohrer 
et al., 2016; Sanchez-Valle et al., 2018; Tiedt et al., 2018; P. S. Weston et al., 2017). 
Despite the growing usage of NfL as a biomarker, only a modest number of studies have 
related NfL levels to the markers of white matter (WM) health to which it should be intimately 
related and mechanistically linked. Most of these studies have been performed on clinical MS 
populations. Results have shown that increased levels of NfL in the CSF or blood were related to 
greater WM hyperintensity (WMH) volumes and gadolinium enhancing lesions(Chitnis et al., 
2018; Dalla Costa et al., 2019; Siller et al., 2019). A similar pattern was found in patients with 
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ischemic stroke (Tiedt et al., 2018) and cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) (Gravesteijn et al., 2019). Diffusion 
tensor imaging (DTI) is a particular form of diffusion-weighted imaging that characterizes the 
movement of water molecules in the brain and provides a way to examine microstructural 
changes of WM integrity. Prior studies found that higher levels of NfL are related to worse WM 
health as captured by higher levels of mean diffusivity (MD) and lower fractional anisotropy 
(FA) (Menke et al., 2015; Mielke et al., 2018; E. E. Moore et al., 2018) although this is not 
always the case (Mielke et al., 2018; Racine et al., 2019).  
Autosomal dominant AD (ADAD) is a form of AD caused by heritable mutations in 
genes that are involved in the production of beta-amyloid (Aβ). The young age at onset (30-60 
years) of ADAD means individuals are largely free of age-related comorbidities (i.e. vascular 
health) that can contribute to WM disease. The relatively predictable age of dementia onset in 
ADAD also means that one can align asymptomatic individuals relative to their estimated 
disease onset. This makes it possible to investigate decades’ worth of the disease course from 
large cross-sectional samples. Such studies of ADAD have shown that CSF and blood NfL levels 
are elevated in symptomatic individuals and begin to increase 10 to 20 years before symptom 
onset (Preische et al., 2019; Sanchez-Valle et al., 2018; P. S. Weston et al., 2017), consistent 
with the notion that WM damage is an early event in AD. There is an emerging recognition that 
frank WM lesions as well as changes observed with DTI are a core feature of ADAD (Araque 
Caballero et al., 2018; Lee et al., 2016). As a result, ADAD can serve as a model to test whether 
elevated levels of NfL are related to changes in WM over the course of the disease. In the current 
work we test the sensitivity of NfL as a measure of white matter decline in neurodegenerative 
disorders. We hypothesize that serum levels of NfL are associated with WM hyperintensity 
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lesion volume and diffusion metrics in both cross-sectional and longitudinal cohorts with 
ADAD.  
5.3 Methods 
5.3.1 Participants  
Participants were from the Dominantly Inherited Alzheimer Network (DIAN) observational 
study recruited from 14 study sites in the USA, UK, Germany, and Australia. DIAN participants 
are from families with known mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and 
amyloid precursor protein (APP) genes and have a 50% risk of inheriting the mutation from their 
affected parent at a relatively similar, and therefore predicable, age at onset within families. 
Participants who completed genetic, clinical, neuroimaging, and blood draw assessments, and 
whose data passed quality control as part of the 11th DIAN data release were considered for this 
study. The sample was restricted to those who had at least one serum NfL measurement and one 
DTI scan within one year of serum NfL measurement. The average number of days between 
blood draw for NfL and DTI scan was 0.92 ± 0.66 (mean ± SE) days. This sample included a 
subset of DIAN participants previously described (Preische et al., 2019). 
The final cross-sectional sample consisted of data from 117 mutation carriers (MC; 87 
PSEN1, 12 PSEN2, and 18 APP) and 84 familial non-carrier (NC) controls. Of the 117 MC with 
baseline data, 41 had two or more visits with serum NfL measurement, DTI scan, and FLAIR 




The institutional review board at Washington University in St. Louis provided 
supervisory review and human studies approval. Participants or their caregivers provided written 
informed consent in accordance with their local institutional review board. Participants’ relevant 
background characteristics are listed in Table 5.1.  
 
5.3.2 Clinical 
Cognitive and functional status was assessed using the Clinical Dementia Rating (CDR). 
‘Presymptomatic’ was defined as CDR = 0, and ‘symptomatic’ as CDR > 0. For each visit, a 
participant's estimated years from expected symptom onset (EYO) was calculated based upon the 
participant's current age relative to either the family mutation-specific expected age at onset of 
cognitive symptoms or parental age at first progressive cognitive decline if onset for the mutation 
was unknown. EYO was established identically for both MC and NC family members. The 
presence or absence of an autosomal dominant AD mutation was determined using PCR-based 
amplification of the appropriate exon followed by Sanger sequencing (R. J. Bateman et al., 
2012). Clinical evaluators were blind to the mutation status of participants.  
 
5.3.3 Imaging 
DIAN Imaging data was screened for protocol compliance and artifacts. All sites used a 3T 
scanner, which was qualified for use at study initiation and was required to pass regular quality 
control assessments. Volumetric T1-weighted images (repetition time = 2300 ms, echo time = 
2.95 ms, flip angle = 9°, 1.1 x 1.1 x 1.2 mm3 resolution) were acquired for all participants and 
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were processed using FreeSurfer 5.3 (http://surfer.nmr.mgh.harvard.edu/)(Fischl, 2012) and the 
Desikan atlas to produce regional estimates of grey matter for use in PET processing.  
To characterize diffusion, whole brain DTI data were acquired using T2*-echo planar 
imaging with one reference volume (b0, b = 1000 mm2) and 64 diffusion directions (repetition 
time = 6000/7800/11000 ms, echo time = 87/85 ms, flip angle = 90°, b-value=1000/s mm2 
2.5mm isotropic voxels). Only DTI data collected on a Siemens scanner was included in the 
current study.  
 
5.3.4 DTI preprocessing 
Preprocessing included correction for motion and eddy-current distortions followed by skull 
stripping with FMRIB software library (FSL) 5.0.9. Rigorous motion inspection was applied 
after eddy-current correction. Participants who moved >3.5 mm in more than 10% of the 
diffusion directions were removed (n=35).  
The diffusion tensor model was fit using dtifit within the FMRIB’s Diffusion Toolbox 
included in FSL. Fractional anisotropy (FA) measures how much water movement is restricted to 
one primary direction. FA ranges from zero to one, with zero being complete isotropic diffusion 
and one being anisotropic diffusion. Axial diffusivity (DA) and radial diffusivity (DR) 
respectively reflect the movement of water parallel and perpendicular to (axis of) the fiber 
bundle. Mean diffusivity (MD) reflects the total amount of diffusion present in all directions. FA 
images from all subjects were nonlinearly aligned to the FMRIB58 atlas, which is a diffusion 
specific template in MNI space, and averaged to create a mean FA image. A skeletonized atlas 
was generated from this mean image using a threshold of 0.2, which excluded any voxels not 
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overlapping in at least 80% of participants. Each diffusion metric (FA, DA, DR, and MD) was 
smoothed with a 2-mm kernel and projected onto the skeletonized atlas using the nonlinear 
registration. Voxel-wise analyses were performed on the skeletonized maps using tract based 
spatial statistics (TBSS) in FSL (Smith et al., 2006). 
 
5.3.5 DTI regions of interest creation 
Well-studied, anatomically derived tracts provide an alternative approach to voxel-wise analyses. 
For this approach, all DTI metrics were also analyzed using previously defined regions of 
interest (ROIs) (Strain et al., 2018) from a group of younger adults from a separate cohort (Van 
Essen et al., 2013). Briefly, deterministic tractography was performed with the MedINRIA 
software in native space, and each participant’s tracts were then transformed to MNI space. 
Tracts were combined across individuals and limited to only those voxels present in a majority of 
individuals. This resulted in the creation of 20 tracts including cingulum (left and right), superior 
and inferior longitudinal fasciculus (left and right), corticospinal (left and right), frontal aslant 
tract (left and right), perforant pathway (left and right), uncinate fasciculus (left and right), 
fronto-occipital fasciculus (left and right), forceps major, forceps minor, anterior corpus 
callosum, and posterior corpus callosum. These WM ROIs were overlaid to the TBSS derived 
skeletonized atlas and the averaged WM metrics (FA, MD, DA, and DR) were calculated in each 
ROI. We averaged values from the left and right for each ROI, as applicable, resulting in a total 
of 12 final ROIs. MD, DA, and DR values were re-scaled by a factor of 1000 before being 




5.3.6 WM hyperintensities 
WMH were quantified on T2-weighted fluid-attenuated inversion recovery (FLAIR) scans 
(repetition time = 9000 ms, echo time = 90 ms, TI = 2500 ms, flip angle = 150°, 0.9 x 0.9 x 5.0 
mm3 resolution) using maps generated with the open-source lesion segmentation tool for SPM 
that includes a lesion growth algorithm (Schmidt et al., 2012). This algorithm identifies voxels 
likely to be WMH. For the current analyses, we used the global volume of identified WMH. 
WMH volumes were not normally distributed, thus a log-transformation was applied. 
 
5.3.7 Aβ-Amyloid PET 
Aβ-amyloid (Aβ) PET imaging was performed after a bolus injection of [11C]Pittsburgh 
Compound B (PiB). Acquisition consisted of a 70-minute scan starting at injection or a 30-
minute scan beginning 40 minutes post-injection. Data in the 40–70 minutes post-injection 
window were converted to regional standardized uptake value ratios (SUVRs) relative to the 
cerebellar grey matter using FreeSurfer-derived ROIs, (Su et al., 2013) and were partial volume 
corrected using a regional spread function technique (Rousset et al., 1998; Su et al., 2015). A 
global measure of mean cortical uptake of Aβ burden was derived from cortical regions 
previously shown to have elevated signal in AD (Su et al., 2013). Global Aβ positivity was 
defined as a mean cortical SUVR ≥1.42. 
5.3.8 Serum NfL measurements  
All available DIAN serum samples through the 11th annual data release were shipped to the 
University of Tübingen for analysis. These processed data were originally published by Preische 
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and colleagues (2019), and a subset was used in the current study. As previously described 
(Preische et al., 2019), fluids were collected in the morning under fasting conditions. After blood 
collection, the tubes were left at room temperature for 30 minutes to allow clotting, and then 
centrifuged at 2,000 g for 15 min. Serum was placed into a single transfer tube (#60.541, Sarstedt 
AG&CO.KG, Nümbrecht, Germany) and immediately frozen on dry ice. NfL measurements 
were performed using a highly sensitive Single Molecule Array (SIMOA) assay using the 
capture monoclonal antibody (mAB) 47:3 and the biotinylated detector antibody mAB 2:1 
(Uman Diagnostics, Umeå, Sweden). The samples were measured in duplicate on a Simoa HD-1 
platform (Quanterix) using a 2-step neat assay. All samples were measured blinded. As NfL 




To compare background characteristics between mutation MC and NC, we performed t-tests and 
chi-square tests, as appropriate.  
White matter hyperintensities within MC 
As done in prior analyses examining NfL and WM(Chitnis et al., 2018; Dalla Costa et al., 2019; 
Gravesteijn et al., 2019; J. Kuhle et al., 2019), we examined WMH volumes. All linear mixed 
effect (LME) models were constructed and evaluated using the lme4 and lmerTest packages in 
the R statistical environment. Log transformed WMH volume was entered as the dependent 
variable; age, sex, and NfL as fixed effects; a separate term for family was included as a random 
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intercept. This family term represents the specific family a participant comes from. NfL was the 
predictor of interest. Analyses were performed only in MC since, due to their young age, NC are 
unlikely to have any WMH; whereas WMH have been shown to be a common feature in ADAD 
(Lee et al., 2016). We wanted to determine if the relationship between WMH and NfL levels 
were simply driven by WM microstructural changes as measured by DTI. Therefore, we repeated 
our original analysis after including a global MD metric as a covariate.  
 
 Voxel-wise analyses of DTI 
To examine whether the associations between baseline WM metrics of interest and NfL levels 
varied by mutation status at the voxel level, we implemented linear regression models with 
skeletonized maps of either MD, FA, DA, or DR as the dependent variable and age at visit, sex, 
NfL, mutation status, and a NfL x mutation status interaction as predictor terms. The initial focus 
was on the interaction between NfL and mutation status. Statistical modeling was performed 
with the Randomise toolbox in FSL (Winkler et al., 2014), a nonparametric statistical approach 
using permutation testing implemented with 5000 permutations. Significant clusters were 
identified using threshold-free cluster enhancement (TFCE) with a family-wise error corrected 
significance level of p = 0.05 (Smith and Nichols, 2009). 
Prior work indicates that NfL levels are most informative within MC (Preische et al., 
2019), suggesting a priori that the interaction term will be highly significant. Therefore, as a 
follow-up analysis, we examined the relationship between baseline DTI metrics and NfL within 
each mutation status group to better interpret the interaction and to understand the relationship 
between NfL and voxel-wise measures of WM within MC and NC, separately. We restricted 
126 
 
these analyses to voxels that were significant in the interaction analyses described above. We ran 
separate models predicting MD, FA, DA, or DR, as a function of age, sex, and NfL.  
 
ROI analyses of DTI within MC 
An alternate approach to voxel-wise analyses is to use ROIs representing specific WM tracts. To 
determine if the relationship between WM integrity and NfL is tract specific, we ran a series of 
LME models in each ROI treating age, sex, and NfL as fixed effects and including a random 
intercept for family. Dependent variables were the average WM metrics (FA, MD, DA, and DR) 
from each ROI. As we primarily expected the effects to be in MCs (Preische et al., 2019), we 
restricted the analyses to this group.  
To correct for multiple comparisons, we implemented a Benjamin-Hochberg procedure 
with a false discovery rate of 5%. Although analyses were performed for each tract, we focused 
on the posterior corpus callosum, superior longitudinal fasciculus, and corticospinal tracts for 
visualization. These regions were selected as exemplar ROIs as: 1) posterior corpus callosum is a 
region with early WM disruption in ADAD and shows the most robust association between NfL 
and WM metrics in our primary analyses; 2) superior longitudinal fasciculus is associated with 
default mode network and executive functioning; and 3) corticospinal tract, as a control, is 
relatively spared in AD until very late stages. 
Prior work has shown dramatic changes in Aβ PET, structural MRI, and WMH(R. J. 
Bateman et al., 2012; Benzinger et al., 2013; Lee et al., 2016; McDade et al., 2018) in the DIAN 
cohort as the disease progresses. In a cohort such as DIAN where there are dramatic changes 
occurring as the disease progresses there is always a concern that statistical relationships can be 
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observed due to the parallel timing of biomarker changes rather than true biological 
relationships. To rule out if the association between NfL and DTI was simply driven by other, 
more overt changes in the disease we additionally include global Aβ-amyloid, total WMH load 
and precuneus cortical thickness measures. These covariates account for the general disease 
stage of an individual (Aβ-amyloid), overt white matter lesions (WMH), or atrophy that could 
drive Wallerian degeneration (structural MRI). Of the 117 MC included in primary analyses, 97 
had completed a baseline Aβ PET scan. We repeated our original ROI models, with particular 
focus on the posterior corpus callosum, superior longitudinal fasciculus, and corticospinal tracts, 
after adding a global Aβ PET, precuneus cortical thickness, and total WMH volume measures as 
covariates to examine whether they altered the relationship between NfL and DTI metrics. We 
additionally provide scatter plots of serum NfL, global Aβ PET, precuneus cortical thickness, 
and total WMH volume to DR in posterior corpus callosum and correlation matrix in the 
supplemental material to better interpret the relationship amongst these biomarkers. 
 
White matter integrity markers and NfL across the course of the disease 
ADAD has a long preclinical phase evolving over decades (Bateman et al., 2012). To evaluate 
the relationship of NfL and DTI metrics as a function of disease progression, our MC sample 
was categorized by baseline CDR score into presymptomatic (CDR=0, n= 76) and symptomatic 
(CDR>0, n= 28) groups. The presymptomatic group was further subdivided by Aβ positivity into 
early (summary Aβ SUVR <1.42; Aβ-, n= 35) and late (summary Aβ SUVR ≥1.22; Aβ+, n=34) 
groups. These analyses were restricted to the investigation of FA and MD DTI metrics as these 
are the most common DTI metrics presented in the literature. We predicted FA and MD values in 
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the posterior corpus callosum using LME models that included sex, NfL, group (presymptomatic 
Aβ-, presymptomatic Aβ+, and symptomatic), and a NfL x group interaction as the fixed effects 
and family as the random effect. If a significant interaction was present, we compared the 
relationship between NfL and the corresponding diffusion metric between each group. 
 
Longitudinal relationship between white matter integrity markers and NfL 
Longitudinal data were analyzed using LME models as these models can account for covariance 
introduced by serial measurements within the model and are more ideally suited for dealing with 
variability in timing or an unbalanced number of data points. The rate of change in NfL (NfL) 
for each individual was modeled using an LME with fixed effects of time from baseline in years, 
and a random intercept for family, as well as random slope and intercept terms for each 
participant. The NfL for each individual was extracted from the model estimates for subsequent 
analyses. The NfL was then used for a second LME model where the dependent term for each 
model was a WM measure of interest (MD, FA, DA, and DR DTI measures in posterior corpus 
callosum ROI and WMH volume) with fixed effect terms for baseline age, sex, time from 
baseline, extracted NfL, and a time from baseline x NfL interaction. Models contained 
random slope and intercept terms for participants and random intercepts for family. The primary 
term of interest was the interaction between the NfL and the time from baseline term. Models 
were fitted using lme4 in R. For plotting purposes, LMEs were also used to generate individual 






5.4.1 Participant characteristics 
 Demographics are presented in Table 5.1.  
5.4.2 Relationship between NfL and WMH in MCs 
Within the MC cohort there was an association between NfL and total WMH volume (B[SE]= 
2.54 [0.56], p= 1.44e-05). Figure 5.1. When evaluating whether the relationship between NfL 
and WMH remained after accounting for a global DTI MD measure (as a proxy for overall WM 
changes measured with DTI) we found the relationship between WMH and NfL was reduced to a 
trend (B[SE]= 1.15 [0.58], p= 0.05). This suggests that at least a proportion of the association 
between NfL and WMH is captured by DTI metrics. 
Voxel-wise relationship between NfL and baseline DTI metrics 
There were interactions between NfL and mutation status on all four DTI metrics (FA, 
MD, axial diffusivity [DA], and radial diffusivity [DR]; see Figure 5.2). As there was a 
significant interaction between NfL and mutation status, we next looked within each mutation 
status group for a main effect of NfL on DTI metrics. Within MCs, a strong association between 
higher NfL levels and low FA was observed throughout the skeletonized atlas (Figure 5.3A). 
Similarly, there was a strong association between higher NfL levels and higher MD, DA and DR 
levels across all WM tracts (Figure 5.3B, C, and D, respectively). The threshold free cluster 
enhancement (TFCE) method (see Methods) within our voxel-wise analyses resulted in an 
inclusive cluster of much of the WM voxels, emphasizing a robust and widespread association 
130 
 
between NfL and WM metrics. To better understand subtle tract-specific variations, we 
subsequently generated a mask containing all significant voxels surviving multiple comparisons 
correction and applied this mask to our voxel-wise uncorrected statistical map (Figure 5.4). 
Within NCs there was no association between NfL levels and FA, MD, DA, or DR across 
the entire cortex (data not shown).  
5.4.3 Regional association between NfL and baseline DTI metrics in MC 
As an alternative to voxel-wise analyses we utilized 12 ROIs that summarized important white 
matter tracts. There were significant associations between higher NfL levels and lower FA levels 
across all 12 ROIs examined. There were consistent associations between higher NfL and higher 
MD, DA, and DR levels in all tracts examined, with the exception of the corticospinal tract. 
Regression coefficients and p-values from statistical models are presented in Table 5.2. 
Representative plots are shown depicting the relationship between NfL and FA, MD, DA, and 
DR in the posterior corpus callosum (Figure 5.5A, 5.5D, 5.5G, and 5.5J), superior longitudinal 
fasciculus (Figure 5.5B, 5.5E, 5.5H, and 5.5K), and corticospinal (Figure 5.5C, 5.5F, 5.5I, and 
5.5L) tracts. For exploratory purposes, to better understand whether there were unique 
relationships within specific mutation types (i.e., PSEN1, PSEN2, and APP), we evaluated the 
association between NfL and a singular region and DTI metric of RD in the posterior corpus 
callosum within each mutation type. (Figure 5.6).  
Including Aβ PET, cortical thickness, and WMH as additional covariates in ROI models 
for posterior corpus callosum, superior longitudinal fasciculus, and corticospinal tracts in a 
subset of 97 individuals with Aβ PET available, the relationship between NfL and DTI metrics 
persisted (p values = 5.78e-04, 4.21e-04, 0.020, 4.68e-04 for FA, MD, DA, and DR in posterior 
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corpus callosum, and p’s= 0.029, 0.002, 0.038, 0.003 for FA, MD, DA, and DR in superior 
longitudinal fasciculus). The relationship between FA, MD and DR in corticospinal tract and 
NfL remained significant (p’s= 0.028, 0.046, 0.015, respectively) and relationship between DA 
in the corticospinal tract and NfL remained nonsignificant in the revised models with Aβ PET 
and WMH as additional covariates. (Full models in Table 5.3). These results suggest that the 
association between NfL and FA or MD is not driven solely by Aβ pathology, thinning grey 
matter, or WMH load.  
 5.4.4 White matter integrity markers and NfL across the course of the disease  
We stratified MC into Symptomatic individuals and Presymptomatic Late (Aβ +), and Early 
(Aβ-) groups. There was a group x NfL effect on MD (F=4.3, p=0.017), DA (F=4.49, p=0.014), 
and a trend for DR (F=2.52, p=0.087), but not for FA (F=0.89, p=0.415) in the posterior corpus 
callosum.  
Between-group comparisons revealed that the relationship between NfL and MD in the 
posterior corpus callosum in the Symptomatic group was stronger than that of the 
Presymptomatic Early group (B [SE]= 0.285 [.10], p=0.004), and similar to that of the 
Presymptomatic Late group (B [SE]= .169 [.10], p=0.095) (Figure 5.7). Similarly, the 
relationship between NfL and DA or DR in the posterior corpus callosum in the Symptomatic 
group was stronger than that of the Presymptomatic Early group (B [SE]= .448 [.15], p=0.004 
and B [SE]= .239 [.11], p=0.029, respectively), and not different from that of the 
Presymptomatic Late group on DA (B [SE]= .288 [.16], p=0.068) or DR (B [SE]= .164 [.14], 
p=0.143) (Figure 5.7C-D). There were no differences between Presymptomatic Early and 
Presymptomatic Late groups across any of the DTI metrics examined (p’s > 0.278). These results 
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suggest that the relationship between NfL and WM is most robust in those with cognitive 
symptoms but may begin in cognitively normal MCs with significant Aβ pathology and continue 
or even intensify with the onset of cognitive symptoms. 
 
5.4.5 Longitudinal relationship between white matter integrity markers and 
NfL 
Rate of change in NfL (NfL) was associated with rate of change in FA, MD, and DR in 
posterior corpus callosum (B[SE]= -0.238 [.05], p=1.74e-05; B[SE]=.0004 [9.0e-05], p=3.02e-
04; and B[SE]=.0005 [8.64e-05], p=1.42e-06, respectively), but not with rate of change in DA 
(B[SE]= .0002[1.58e-04], p=0.287) or rate of change in WMH (B[SE]= 1.04[.65], p=0.121) 
(Figure 5.8 and Figure 5.9a-d) consistent with the view that changes in NfL reflect increasing 
white matter changes in this cohort as measured with DTI. 
 
5.5 Discussion 
NfL is a promising fluid biomarker to study neurodegeneration across multiple neurological 
diseases. Although NfL is thought to reflect damage to large myelinated axons there is a paucity 
of work systematically examining how NfL levels relate to established markers of 
macrostructural and microstructural WM damage. In the current work we examined how levels 
of serum NfL predict WM lesion volumes and DTI metrics of WM integrity. Across all 
measures, we found that elevated levels of serum NfL were significantly associated with 
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increased levels of WM pathology. This indicates that a blood-based measure of NfL does 
indeed track WM damage in the brain.  
Due to its predictable age of dementia onset and low comorbidities, ADAD serves as a 
useful model to understand the evolution of AD pathology (R. J. Bateman et al., 2012). Prior 
work established increases in WMH volumes (Lee et al., 2016) as well as alterations in DTI 
metrics (Araque Caballero et al., 2018) as core features of ADAD. Across multiple neurological 
conditions, increased NfL levels in CSF and blood have been tied to greater WMH volumes 
(Chitnis et al., 2018; Dalla Costa et al., 2019; Gravesteijn et al., 2019; Kuhle et al., 2019, 2013; 
Siller et al., 2019; Tiedt et al., 2018). Consistent with this work, we found that in MC, higher 
serum NfL levels at baseline predicted greater WMH lesion volumes. However, when we 
included a global MD DTI measure for microstructural WM integrity as a covariate, the 
relationship between NfL and WMH was no longer present. This suggests that at least some of 
the information contained by global WMH volumes is also reflected in DTI metrics. For 
exploratory purposes, a correlation matrix depicting the relationship between biomarkers 
examined is presented in Figure 5.10. In the subset with longitudinal data, there was a trend that 
a greater increase in serum NfL was related to increases in WMH volume, but this did not 
approach significance (B[SE]= 1.04[.65], p=0.121). 
WMH represent macrostructural WM insults in the brain. In addition to such overt 
damage, microstructural changes in WM can be assayed using DTI. There have been inconsistent 
results establishing whether CSF and blood levels of NfL are sensitive to such microstructural 
changes in WM detectable using DTI (Menke et al., 2015; Mielke et al., 2019; Moore et al., 
2018; Racine et al., 2019; Tiedt et al., 2018). When examining baseline DTI data using voxel-
wise- and ROI-based approaches we found that higher levels of serum NfL were negatively 
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associated with FA, and positively associated with MD, RD, and DA throughout the entire 
cortex, although effects were strongest in posterior regions (Table 5.2 and Figure 5.4). Lower 
FA and higher MD, RD, and DA are indicative of a less constrained flow of water molecules and 
are generally viewed as markers of WM damage. This widespread pattern of WM decline is 
consistent with prior work in ADAD (Araque Caballero et al., 2018; Gordon et al., 2018). The 
strong observed relationship suggests that NfL is a robust marker of active microstructural WM 
damage beyond overt lesions.  
As the mutations in ADAD lead to such a dramatic disease phenotype, there is always a 
concern that significant relationships between biomarkers may be due simply to a common time 
course rather than measures being truly interrelated. Even when including Aβ PET and cortical 
thickness as a markers of general disease progression and WMH volume to account for 
macrostructural WM damage, we still found highly significant associations between serum NfL 
levels and DTI metrics. The relationship between NfL and DTI was present not only at baseline 
but was consistent over time. In the subsample of MC with longitudinal data, a greater rate of 
serum NfL change predicted greater WM declines in FA, and increases in MD, and RD. 
Establishing such a longitudinal relationship is critical to be able to use CSF and blood-based 
measures of NfL to monitor disease progression and to potentially use NfL as a marker of 
response to disease intervention in clinical trials for AD as well as other neurodegenerative 
disorders.  
The heritability in the onset of dementia in ADAD families provides the unique ability to 
stage individuals relative to their expected time of cognitive decline. Stratifying by CDR and Aβ 
positivity status, we were able to examine the relationship between NfL and WM integrity across 
the course of the disease. In asymptomatic MC without advanced disease progression (Aβ-), 
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levels of NfL were low and WM, assessed with DTI, was healthy. As the disease progressed 
(Aβ+), levels of NfL increased and WM health declined in individuals who were still classified 
as asymptomatic but Aβ+. Finally, there were even further increases in NfL and declines in DTI 
metrics in symptomatic individuals. The distribution of the groups overlapped and within the 
entire cohort NfL and DTI measures were tightly coupled. This suggests that continuous levels 
of the biomarkers add to the assessment of the health of the brain over and above Aβ positivity 
status and staging by CDR alone.  
The current work is a critical step towards establishing NfL as a marker of 
neurodegeneration that reflects likely WM damage and decline. Still, there are limitations to the 
current analyses. ADAD is a continually progressive neurodegenerative condition with relatively 
stereotyped phenotypes and rates of progression, and manifests during a younger age range, 
during which, secondary comorbidities are uncommon. These features make ADAD a very 
useful model of AD pathobiology and a model to test the relationship between NfL and WM 
damage. However, these features may affect the generalizability of the current findings to late 
onset AD. For example the degree of pathology seen in ADAD is also higher than that seen in 
late onset AD (B. A. Gordon et al., 2019), and as a result NfL may not be as useful a predictor in 
the sporadic form of the disease.  
Although longitudinal relationships between NfL and WM are rarely examined, our 
longitudinal sample is modest. CSF and blood-based biomarkers reflect properties of the brain 
and body at the time of collection. Prior work suggested that CSF biomarkers of neuronal injury 
decline at symptomatic stages of AD (Sutphen et al., 2018), which could lead to a mismatch 
between biofluid and imaging markers in later stages of disease. Further work is needed to test 
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whether the relationship between imaging and NfL measures changes at more advanced stages of 
neurodegenerative conditions. 
Finally, further examinations relating neuroimaging and biofluid measures across 
multiple neurological disorders are needed. In ADAD we showed that neuroimaging and biofluid 
measure are highly related. Although elevated in most neurodegenerative conditions (Bridel et 
al., 2019), the degree that NfL becomes abnormal varies widely between disorders. In other 
diseases the strength of the relationship between neuroimaging and biofluid measures may be 
more or less robust.  
 Biomarkers provide the ability to measure the health of the central nervous system in vivo 
to aid disease diagnosis and prognosis. Blood-based markers are minimally invasive and 
relatively low cost but few have been validated against neuroimaging biomarkers (Lewczuk et 
al., 2018). NfL in the blood is highly correlated with measures in the CSF and is becoming 
widely adopted in diagnosing and monitoring multiple diseases. Our current work supports the 
view that blood levels of NfL are predictive of WM damage in the brain at least as measured 
with neuroimaging. This is a critical result in improving the interpretability of NfL as a marker 
of brain integrity, and for validating this novel biomarker for future use in clinical and research 
settings.  
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Table 5.1. Baseline sample characteristics. 
 
Key: NfL= Neurofilament light chain; EYO = estimated years from expected symptom onset; 















Age (yrs), mean (SD) 40.5 (10.7) 38.6 (10.8) .230 
Sex, female (%) 58.3 50.8 .293 
Serum NfL (pg/mL), mean (SD) 23.7 (12.5) 33.4 (23.1) .001 
EYO (yrs), mean (SD) - -8.5 (11.0) - 
MMSE, mean (SD) 29.2 (1.2) 27.2 (4.1) <.001 
Clinical Dementia Rating, 0, 0.5, ≥ 1, 
n (%) 
81 (96.4), 3 (3.6), 0 
(0) 






Table 5.2. Main effect of serum NfL on DTI metrics in MC. 
 
WM Tract Fractional Anisotropy Mean Diffusivity Axial Diffusivity Radial Diffusivity 
  B (SE) p B (SE) p B (SE) p B (SE) p 
Inferior Longitudinal 
Fasciculus 




-.048 (.01) 0.00025 .091 (.02) 2.8E-06 .090 (.02) 4.07E-05 .094 (.02) 7.65E-
06 
Frontal Occipital Fasciculus -.071 (.01) 1.06E-08 .108 (.02) 2.96E-08 .084 (.02) 3.59E-05 .124 (.02) 5.3E-09 
Perforant Pathway -.106 (.02) 1.15E-06 .150 (.02) 6.78E-08 .084 (.04) 0.020267 .162 (.03) 2.79E-
08 
Uncinate Fasciculus -.048 (.01) 6.49E-05 .060 (.02) 0.00024 .037 (.02) 0.041739 .071 (.02) 4.86E-
05 
Cingulum -.088 (.02) 2.08E-07 .133 (.02) 1.97E-08 .091 (.03) 0.0012 .153 (.02) 3.09E-
09 
Frontal Aslant  -.060 (.01) 2.48E-07 .089 (.02) 6.37E-05 .088 (.03) 0.002341 .101 (.02) 1.04E-
05 
Corticospinal -.027(.01) 0.012 .032 (.02) 0.070468 .007 (.03) 0.785 .042 (.02) 0.00893 
Anterior Corpus Callosum -.119 (.02) 5.72E-06 .284 (.04) 4.14E-09 .301 (.06) 1.03E-06 .279 (.04) 2.88E-
08 
Posterior Corpus Callosum -.155 (.02) 4.14E-09 .321 (.04) 8.78E-11 .276 (.06) 6.68E-06 .344 (.04) 1.94E-
10 
Forceps Minor -.074 (.01) 3.77E-08 .099 (.02) 3.84E-07 .086 (.02) 0.000448 .114 (.02) 3.97E-
08 
Forceps Major -.087 (.01) 2.29E-08 .122 (.02) 6.72E-08 .082 (.02) 0.000145 .146 (.02) 1.88E-
08 
Unstandardized regression coefficient B and adjusted p-values for serum NfL from a series of 
linear mixed effect models in each ROI, which included random intercepts for family, and fixed 
effects for age, sex, and NfL. Dependent variables were the average WM metrics (FA, MD, DA, 
and DR) from each ROI. N=117.  











Unstandardized regression coefficient and adjusted p-values for fixed effects from a series of 
linear mixed effect models in PCC, SLF, and CST, which included random intercepts for family, 
and fixed effects for age, sex, precuneus cortical thickness, global Aβ-amyloid, total WMH 
volume, and serum NfL. Dependent variables were the average WM metrics (FA, AD, DA, and 
DR) from each ROI. N=97. 
 
Key: WMH = White matter hyperintensity; NfL = Neurofilament light chain; FA = fractional 
anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial diffusivity; PCC = 











Figure 5.1. Relationship between serum NfL and total white matter hyperintensity volume in 
mutation carriers. Scatterplot showing the relationship between total WMH volume and serum 
NfL in MC (n=117). The shaded area around the linear fit line represents one standard error of 







Figure 5.2. Interaction between serum NfL and mutation status on DTI metrics. P-value map 
(red-yellow) of statistically significant voxel-wise interactions of NfL x mutation status and (A) 
lower fractional anisotropy, (B) higher mean diffusivity, (C) higher axial diffusivity, and (D) 
higher radial diffusivity superimposed on the white matter skeleton (blue). N=201. Family-wise 





Figure 5.3. Main Effect of serum NfL on DTI metrics in MC. P-value map (red-yellow) of 
statistically significant voxel-wise associations of higher NfL and (A) lower fractional 
anisotropy, (B) higher mean diffusivity, (C) higher axial diffusivity, and (D) higher radial 
diffusivity superimposed on the white matter skeleton (blue), within mutation carriers (n=117). 




Figure 5.4. Uncorrected voxel-wise associations of NfL and DTI metrics. Uncorrected T-value 
map (red-yellow) of voxel-wise associations of higher NfL and (A) lower fractional anisotropy, 
(B) higher mean diffusivity, (C) higher axial diffusivity, and (D) higher radial diffusivity 
superimposed on the white matter skeleton (blue), within mutation carriers (n=117). Uncorrected 
maps were restricted to significant clusters identified using threshold-free cluster enhancement 






Figure 5.5. Tract-specific white matter measures are associated with serum NfL in MC. 
Scatterplots depicting the relationship between serum NfL and DTI metrics from FA, MD, DA, 
and DR within three representative ROIs (PCC, SLF, and CST) in MC (n=117). The shaded area 
around each linear fit line represents one SE from LME models.  
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Key: FA = fractional anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial 
diffusivity; PCC = posterior corpus callosum; SLF = superior longitudinal fasciculus; CST = 
corticospinal tract; NfL = neurofilament light chain; DTI = diffusion tensor imaging; ROIs= 


















Figure 5.6. Relationship between serum NfL and radial diffusivity within posterior corpus 
callosum by mutation type. Graphical depiction, for exploratory purposes, of the relationship 
between serum NfL and radial diffusivity in the posterior corpus callosum within each mutation 
type. Those with mutations in PSEN1 (N= 87) are blue, PSEN2 are yellow (N=12), and APP are 
purple (N=18). Individuals who are Presymptomatic (CDR=0) are coded as squares and 
Symptomatic (CDR>0) as triangles. The shaded area around each linear fit line represents one 
SE.  
Key: DR = radial diffusivity; PCC = posterior corpus callosum; NfL = neurofilament light chain; 






Figure 5.7. Interaction between serum NfL and disease progression on DTI metrics. Scatterplots 
depicting the relationship between serum NfL and DTI metrics from FA, MD, DA, and DR 
within PCC for Presymptomatic MC early (gray circles), Presymptomatic MC late (yellow 
triangles), and Symptomatic MC (red diamonds). 
The shaded area around each linear fit line represents one SE from LME models. 
Key: FA = fractional anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial 
diffusivity; PCC = posterior corpus callosum; NfL = neurofilament light chain; DTI = diffusion 






Figure 5.8. Longitudinal relationship between serum NfL and WMH in MC. Scatterplot showing 
the relationship between the estimated annual rate of change in total WMH volume and the 
estimated annual rate of change in NfL in MC (n=41). The shaded area around the linear fit line 
represents one SE from the LME model.  
Key: NfL = neurofilament light chain; WMH= white matter hyperintensity; ROIs= regions of 





Figure 5.9. Longitudinal relationship between NfL and DTI metrics in PCC. Scatterplot showing 
the relationship between the estimated annual rate of change in serum NfL and the estimated 
annual rate of change in (A) FA in PCC, (B) MD in PCC, (C) DA in PCC, and (D) DR in PCC in 
MC (n=41). The shaded area around each linear fit line represents one SE from LME models.  
Key: FA = fractional anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial 
diffusivity; PCC = posterior corpus callosum; NfL = neurofilament light chain; DTI = diffusion 







Figure 5.10. Relationship between biomarkers and radial diffusivity within posterior corpus 
callosum in MC.  Depiction of the relationship between radial diffusivity within posterior corpus 
callosum in MC and serum NfL (A), total WMH volume (B), global beta-amyloid (C), and 




coefficients amongst all biomarkers considered is presented to better understand these 
relationships.  
Key: DR = radial diffusivity; PCC = posterior corpus callosum; NfL = neurofilament light chain; 














Relationship between physical activity and 














6.1. Summary  
The objective of this study was to examine the relationship between engagement in 
physical activity (PA) and the loss or preservation of brain metabolism in older adults.  
Ninety cognitively healthy individuals (age 25 – 85 years old) participated in this cross-
sectional study. They wore an accelerometer (ActiGraph GT3+) for seven consecutive days to 
measure free-living PA and underwent multi-tracer positron emission tomography to evaluate 
total glucose use (CMRglc), oxygen metabolism (CMRO2), and AG which were normalized to 
literature-based whole brain metabolism estimates. Participants were categorized as either having 
met physical activity recommendations (PAR) or not based on the US Department of Health and 
Human Services recommendations of 150 minutes of moderate-to-vigorous physical activity per 
week. We focused our initial analysis on the rostral middle frontal gyrus, based on previously 
published results on the association between physical activity and CMRglc in this region. 
Older age is associated with lower levels of total PA (r = -0.339) and lower normalized 
CMRglc in rostral middle frontal gyrus (r = -0.594). Hierarchical testing first aimed to examine 
the relationship between rostral middle frontal CMRglc and PA in older individuals (60+ years 
old, N = 64). Using analyses of covariance (ANCOVA) adjusted for age and gender, we confirm 
that individuals who meet PAR had higher rostral middle frontal CMRglc compared to those 
who do not meet PAR (F = 9.18, p = 0.004). Further analyses show a similar association of 
meeting PAR on AG (F = 6.35, p = 0.014), but not CMRO2 (F = 0.04, p = 0.836).  
In this cross-sectional study we confirm that meeting PAR is associated with maintained 
CMRglc in the rostral middle frontal cortex, which is more likely due to a difference in AG than 
CMRO2. These results suggest that maintaining PA might be specifically associated with better 
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preservation of glycolytic metabolism in the aging brain, and further analysis of other brain 
regions is now ongoing. 
 
6.2 Introduction 
There are robust brain changes, including the brain’s use of glucose, that occur 
throughout adulthood. Specifically, brain aerobic glycolysis (AG)—which represents the use of 
glucose beyond that required for oxidative phosphorylation—is higher in young adults and 
decreased in many older individuals. Maintaining a physically active lifestyle is at the forefront 
of recommended areas of focus to promote healthy brain aging, including preserving AG 
pathways, but the relationship between the two remain to be determined. 
Engagement in physical activity increases peripheral metabolic fitness (Laye, Nielsen, 
Hansen, Knudsen, & Pedersen, 2015), decreases risk for metabolic disorders (Lavie et al., 2014; 
Tuomilehto et al., 2001), and is associated with beneficial cerebral glucose metabolism 
(Dougherty, Schultz, Kirby, et al., 2017), suggesting potential link between physical activity and 
metabolic pathways. 
Research on the relationship between physical activity levels and cerebral metabolism 
functioning has focused on examining total cerebral glucose use (CMRGlc) as measured 
by fluorodeoxyglucose (18F-FDG) positron emission tomography (PET). For example, a recent 
study found middle-aged individuals who engaged in free-living physical activity had higher 
CMRGlc levels in the rostral middle frontal regions. However, advances in PET studies now 
allow multiple tracers to measure of AG, CMRGlc, and oxygen (CMRO2) metabolism in the 
same individual. Investigating these three measures concurrently may provide insight into 
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specific metabolic dysregulation pathways. For example, AG may support specific metabolic 
functions of biosynthesis of glycogen, proteins, and lipids; neuroprotection by managing reactive 
oxygen species and apoptosis; production of lactate, a potential fuel and signaling molecule 
(Suzuki et al., 2011); and supports synaptic formation and turnover (Goyal, Hawrylycz, Miller, 
Snyder, & Raichle, 2014; Goyal et al., 2017). Taking an integrative approach to the study of 
brain metabolism may elucidate pathways by which physical activity protect brain metabolism 
mechanisms.  
Accordingly, the objective of this study was to examine the relationship between 
engagement in physical activity (PA) and the loss or preservation of brain metabolism, using a 




The Washington University in St. Louis Institutional Review Board approved all study 
procedures, and informed consent was obtained from all individual participants. Ninety 
cognitively healthy individuals (age 25 – 85 years old) participated in this cross-sectional study. 
All 90 individuals wore an accelerometer (ActiGraph GT3+) for seven consecutive days to 
measure free-living PA and underwent multitracer positron emission tomography to evaluate 
total glucose use (CMRglc), oxygen metabolism (CMRO2), and AG. 
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6.2.2 Physical activity assessment 
A triaxial accelerometer (Actigraph GT3X+, Actigraph LLC, Pensacola, FL) measured PA over 
7 consecutive days. Participants were instructed to place the accelerometer on their hip, affixed 
to an elastic belt, and to wear the device during all waking hours, with the exception of when 
showering, swimming, or bathing. Standard accelerometry inclusion criteria consisted of at least 
10 hours of valid wear time per day for a minimum of 3 weekdays and 1 weekend day (Troiano 
et al., 2008). Accelerometer data (in 1-s epochs) were processed using the sojourn-3 axis method 
(Staudenmayer, Pober, Crouter, Bassett, & Freedson, 2009) to calculate time spent in 3 well-
established intensity categories of PA, that is LPA, MPA, VPA, and time spent sedentary. This 
method utilizes information from all three axes (vertical, anterior-posterior, and medial-lateral) 
to identify independent bout intervals— the time between starting one activity (e.g., sitting, 
standing, walking, running, jumping, etc.) and transitioning to another— by instances of rapid 
acceleration or deceleration. 
Within the sojourn-3 axis method (Lyden, Keadle, Staudenmayer, & Freedson, 2014), 
estimated metabolic equivalents (METs) are determined for each bout interval using a validated 
neural network approach (Staudenmayer et al., 2009), as opposed to the traditional counts-per-
minute approach. The MET values were classified into PA intensity categories thus: <1.5 
METs = sedentary, 1.5-2.99 METs = LPA, 3–6 METs = MPA, and >6 METs = vigorous VPA 
(Troiano et al., 2008). Average total minutes/day of activity were calculated for each participant 
by coming average total minutes/day spent engaging in LPA, MPA, and VPA. Participants were 
categorized as either having met physical activity recommendations (PAR) or not based on the 
US Department of Health and Human Services recommendations of 150 minutes of moderate-to-
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vigorous physical activity per week. An example day of actigraphy data from an Active and 
Sedentary individual is displayed in Figure 6.1 
6.3.3 MRI 
MRI scans were obtained on a 3T PRISMA scanner using a high resolution (0.8 mm isotropic) 
T1-weighted magnetization-prepared rapid gradient-echo sequence. 
FreeSurfer 5.3 (http://freesurfer.net) HCP structural Pipeline was used to segment the MRI into 
cortical and subcortical regions of interest (ROIs). These ROIs were used for regional estimation 
of all PET measures.  
 
6.3.4 PET 
 All participants underwent one FDG scan and 2 sets of 15O-CO, 15O-H2O, and 15O-
O2 scans.
 18F-FDG and 15O PET scans were performed on a Siemens ECAT Exact HR+ PET 
scanner as described previously (Vlassenko et al., 2010). 
FDG scans were performed after injection of ∼5 mCi of FDG. Cerebral blood volume 
was measured with a 5-minute emission scan beginning 2 minutes after brief inhalation of 
∼75 mCi of [15O]CO in room air. Dynamic scans of 3 minutes were acquired after injection of 
∼50 mCi [15O]H2O in saline or inhalation of 60 mCi of [15O]O2 in room air. The 
CMRO2 parametric image was derived from these 
15O scans and corrected for cerebral blood 
volume.  
The local-to-global images obtained as described previously for CMRGlc, CMRO2 were 
summarized to the FreeSurfer ROIs. These were then multiplied by age-specific literature-based 
whole-brain estimates for each of the metabolic parameters (Goyal et al., 2014; Goyal et al., 
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2017; Vlassenko et al., 2018). AG was calculated by dividing the CMRO2 values by six, and then 
subtracting this resultant value from the CMRGlc values. 
We focused our initial analysis on the rostral middle frontal gyrus, based on previously 
published results on the association between physical activity and CMRglc in this region. 
 
6.3.5 Statistics 
Pearson correlation coefficients were calculated between age and average daily total activity and 
brain metabolism measures in the rostral middle frontal gyrus.  
 Hierarchical testing first aimed to examine the relationship between rostral middle frontal 
CMRglc and PA in older individuals (60+ years old, N = 64). Analyses of covariance 
(ANCOVA) adjusted for age and gender, were performed to examine whether individuals who 
meet PAR had higher rostral middle frontal CMRglc compared to those who do not meet PAR. If 
a relationship was observed, we further examined associations between meeting PAR and both 
AG as well as CMRO2.  
6.4 Results 
Participant demographic, physical functioning, and biometric characteristics are reported in 
Tables 6.1-6.3. 
Older age is associated with lower levels of total PA (r = -0.339; Figure 6.2A) and lower 
normalized CMRGlc (r = -0.594, p = 6.6e-10; Figure 6.2B) and AG ( r = -0.523, p = 1.2e-07; 






We confirm that individuals who meet PAR had higher rostral middle frontal CMRglc 
compared to those who do not meet PAR (F = 9.18, p = 0.004; Figure 6.3A). Further analyses 
show a similar association of meeting PAR on AG (F = 6.35, p = 0.014; Figure 6.3B), but not 




In this cross-sectional study found that brain metabolism measures, and to a lesser extent 
physical activity, decrease across adulthood. Additionally, we report that individuals who met 
PAR had maintained CMRGlc in the rostral middle frontal cortex, compared to inactive 
individuals. 
 Furthermore, this maintenance of CMRGlc is more likely due to a difference in AG than 
CMRO2. These results, performed in a independent cohort of similar age, cognitive status, and 
physical activity levels, confirm the findings by Dougherty and colleagues (2017) suggesting that 
engagement in physical activity is associated with higher CMRGlc in the rostral medial frontal 
gyrus. 
Importantly, we extend these prior findings by showing a novel relationship between 
physical activity and AG in the rostral middle frontal gyrus, suggesting a mechanism by which 
physical activity may provide resilience aging brain aging and dysfunction.   
Overall, these results suggest that maintaining PA might be specifically associated with 
better preservation of glycolytic metabolism in the aging brain, and further analysis of other 
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Table 6.1. Background characteristics. 
 Variable Range 
Full Sample 
Mean (SD) or % 
Full Sample 
Mean (SD) or % 
60 years + 
Age, years 25.1-85.3 64.6 (14.7) 72.3 (5.9) 
Met National PA Rec, % - 32.2 28.1 
Female, % - 60.0 59.4 
Prefrail or Frail, % - 41.0 44.5 
Caucasian, % - 84.5 78.4 
Diabetes, % - 6.1 7.0 
*MoCA 15-30 25.4 (3.1) 24.8 (2.8) 
*MMSE 28-30 29.4 (0.6) 29.5 (0.6) 
 
*N= 64 for MoCA and N = 26 for MMSE in Full Sample. N = 41 for MoCA and N = 24 for 












Table 6.2. Physical functioning characteristics. 
 Variable Range 
Full Sample 
Mean (SD) or % 
Full Sample 
Mean (SD) or % 
60 years + 
Avg total daily minutes of 
activity 
682-1,318 907 (96) 896 (103) 
Avg daily steps 822-24,610 6,372 (4,426) 5,173 (2,854) 
Avg daily sedentary minutes 408-1,133 707 (113) 709 (123) 
Avg daily light minutes 33-304 133 (51) 129 (52) 
Avg daily moderate minutes 6-156 53 (30) 51 (29) 
Avg daily vigorous minutes 0-132 12 (21) 7 (8) 
BMI 17.4-44.2 27.4 (5.6) 27.9 (5.5) 
Grip Strength, kg 11.3-50.3 29.3 (9.0) 29.1 (8.6) 
Gait Test, sec. 2.1-5.6 3.3 (0.7) 3.5 (0.7) 
Systolic BP, 
 Diastolic BP 
92-198, 
 56-108 
135 (19),  
79 (9) 









Table 6.3.  Lab values. 
 Variable Range 
Full 
Sample 
Mean (SD) or % 
Full Sample 
Mean (SD) or % 
60 years + 
HBA1C, % 4-7 5.4 (0.5) 5.4 (0.5) 
Glucose, mg/dL 67-177 96.3 (14.3) 97.4 (14.4) 
Lactate, mmol/L 0-5 1.2 (0.6) 1.2 (0.6) 
Triglycerides, mg/dL 40-328  104.2 (50.9) 109.5 (51.8) 
Total Cholesterol, mg/dL 111-283 179.2 (34.6) 179.1 (36.1) 
HDL, mg/dL 26-124 63.7 (19.6) 62.1 (19.5) 








Figure 6.1. Example actigraphy data. An example of vector magnitude values, binned into 60 








Figure 6.2. Activity and brain metabolism measures across adulthood. Relationship between 
age and (A) average active minutes per day, (B) mean rostral middle frontal CMRGlc, (C) mean 








Figure 6.3. Association between meeting PAR and brain metabolism. Values of mean rostral 
middle frontal (A) CMRGlc, (B) AG, and (C) CMRO2 in those who are Active compared to 


















Feasibility and validation of the Ekblom-Bak 













7.1 Summary  
Cardiorespiratory fitness (CRF) is routinely investigated in diverse populations, including in 
older adults of varying physical activity levels; however, the most appropriate testing method for 
evaluating CRF in this population and more diverse populations is not well 
understood. Commonly performed maximal exercise testing protocols are often inadequate for 
older individuals who may have physical or cognitive impairment, underestimating CRF due to 
early test termination. The goal of the current study was to determine feasibility of performing 
the Ekblom-Bak (EB) submaximal exercise test and validity of this method to determine CRF in 
a diverse, Midwestern United States population. Fifteen individuals were included in this study 
who were either “Young” (25-34 years old) or “Older” (55-75 years old) as well as either 
sedentary or highly active. Participants completed the EB submaximal exercise test, followed 
immediately by a maximal exercise test. We found that all fifteen individuals were able to 
successfully perform the EB submaximal testing method, showing feasibility of this protocol in a 
diverse population.  Importantly, we observed strong correlations between the EB method 
estimated volume of maximal oxygen consumption (VO2max) values and the observed VO2max 
values (rrange = 0.97 - 0.98), without significant bias, as observed with Bland-Altman Plot 
analyses. Our findings thus suggest that the EB method likely retains similar validity in a diverse 
US cohort as has been found in Scandinavian cohorts. Future studies further assessing validity in 
cognitively impaired populations will be useful for assessing utility of exercise interventions 





Cardiorespiratory fitness (CRF) and physical activity are important physiological and behavioral 
measures that predict health outcomes throughout the lifespan. In adulthood, poor CRF and 
sedentary lifestyle are associated with risk for cardiovascular disease (Kodama et al., 2009), type 
2 diabetes (Lavie et al., 2014), and Alzheimer disease (Silva et al., 2019). Improvement of CRF, 
through engagement in regular physical activity, leads to a significant improvement in health 
outcomes including lowering risk of all-cause mortality (Harber et al., 2017), cardiovascular 
disease (Safdar & Mangi, 2020), and diabetes (Tuomilehto et al., 2001). There is now growing 
interest to consider the predictive value and effects of improved CRF on brain aging and 
dementia. 
Assessment of maximal oxygen consumption (VO2max) during a graded exercise test is 
considered the gold standard measure for evaluating CRF (Lea & Febiger, 1995). Obtaining a 
true measure of VO2max, where a plateau in oxygen consumption is observed despite further 
increases in intensity of exercise, is often challenging in certain populations, including older 
adults, individuals with physical limitations, and with cognitive impairment. In at-risk 
individuals, maximal exercise testing requires immediate oversight by a trained physician and in 
some cases may not be feasible due to the increased risk of adverse events. Peak exercise testing 
also requires the tested individuals to give a high level of effort and understanding of the test in 
order to exercise to volitional exhaustion.  Furthermore, measurement of VO2max testing 
requires expensive equipment for gas analyses, which is burdensome on the clinical and research 
teams to acquire and maintain. Importantly, all of these challenges might restrict cohorts that can 
participate in important studies relating CRF to health and cognitive outcomes. 
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Submaximal exercise testing is therefore commonly used to predict VO2max, as a proxy 
measure of CRF, particularly when laboratory equipment or physician supervision is unavailable 
or when the target population is unlikely to go to volitional exhaustion. Interest in the role of 
maintaining CRF throughout life to help protect against age-related diseases, such as Alzheimer 
disease, is rapidly increasing (Hamer & Chida, 2009; Pentikainen et al., 2019). The need to 
develop and validate submaximal exercise tests that will be more reliable given a mixed 
population across a wide range of age, physical functioning, and cognitive functioning thus 
cannot be overstated. 
Submaximal tests are typically based on heart rate response at one or more submaximal 
work rates and often utilize a regression-equation method to predict VO2max. A range of 
submaximal exercise testing protocols exist, which each have optimal testing populations that are 
validated to have only moderate reliability and predictability (correlation coefficients of 0.52-
0.93) of VO2max (Noonan & Dean, 2000). Furthermore, some studies suggest that submaximal 
test based estimates of VO2max might be less accurate in ethnic populations (Vehrs & 
Fellingham, 2006). 
A recently developed Ekblom-Bak (EB) cycle ergometer test (Bjorkman et al., 2016; 
Ekblom-Bak et al., 2014) for prediction of VO2max is low-risk, easy to administer, and shown to 
be valid for a wide range of aerobic capacities and ages (Vaisanen et al., 2020). The initially 
reported (Ekblom-Bak et al., 2014) association between estimated and observed VO2max using 
the EB method was r = 0.91, and showed significant improvements on corresponding coefficient 
of variation (9.3%) compared to the Åstrand-Rhyming method (18.0%). The EB test has been 
further recently tested in an older population showing good agreement with maximal test 
VO2max estimates, which further improved when applying the EB equation designed for women 
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to both sexes. While these results are highly promising for use of the EB method in aging 
studies, they were performed in a Scandinavian population and may or may not be replicable in 
other ethnic populations. 
The goal of the current study was to determine feasibility and validity of the EB method 
in a Midwestern United States population of diverse races,  ages, including  “Young” (25-34 
years old) and “Older” (55-75 years old) individuals, and physical active levels. 
7.3 Methods 
7.3.1 Participants 
The Washington University in St. Louis Institutional Review Board approved all study 
procedures, and informed consent was obtained from all individual participants. Fifteen 
individuals recruited from a larger pilot study focused on cardiorespiratory fitness and brain 
metabolism were included in this small validation study based on completion of both 
submaximal EB and maximal exercise tests. Participants were screened and deemed eligible 
based on age (either 25-34 years old or 55 years or older) and current self-reported physical 
activity levels on the International Physical Activity Questionnaire (IPAQ; either Sedentary 
[MET minutes/week <1000] or Active [MET minutes/week > 3000]) (Booth, 2000).  Individuals 
were excluded from maximal exercise testing for any of the following: documented 
cardiovascular disease, type 1 or 2 diabetes mellitus, self-reported body mass index > 35, and 
severe untreated hypertension (>200/100mmHg). Further, a study physician reviewed a 




7.3.2 Submaximal exercise test 
Participants were instructed not to perform any heavy or prolonged physical activity the day 
before or on the day of the test.  Participant body mass and height were obtained upon arrival to 
the testing center. The participants were informed of test procedures and equipped with 12-lead 
continuous ECG. 
Tests were conducted on a recumbent cycle ergometer (Lode, The Netherlands) with 
continuous 12-lead ECG monitoring (General Electric, Case, V6.73). Participants were 
instructed to pedal at a cadence of 60 RPM for the duration of the test. The test consisted of an 
initial stage at a fixed work rate of 30 W for four minutes, directly followed by a higher 
individualized work rate that varied between 60-200 W. The individualized work rate was 
subjectively chosen by the test leader (SAS) with regards to gender, age, training background 
and current engagement in physical activity. Mean HR was recorded during the last minute of 
each work rate calculated as the average of the heart rate recorded at 3:15, 3:30, 3:45, and 4:00 
minutes. Participants reported a Borg rating of perceived exertion (RPE) during both stages of 
the test, with the goal of reaching 13-15 during the second stage of testing. 
VO2max was predicted using the EB prediction equation (Bjorkman et al., 2016) for 
women and men separately. For women, the equation used was ln VO2max = 1.84390 – 0.00673 
x age – 0.62578 (∆HR/∆PO) + 0.00175 x (∆PO) – 0.00471 x HR at initial work rate. Where the 
difference in HR between the high and initial work rate is denoted as ΔHR and the difference in 
work rate between the high and initial work rate ∆PO. For men the equation used was ln 
VO2max = 2.04900 − 0.00858 x age − 0.90742 x (∆HR/∆PO) + 0.00178 x ∆PO − 0.00290 x HR 
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at initial work rate. After entering the corresponding values into the equation, VO2max (in L min
-
1) was estimated by putting in the obtained value as an exponent in the natural logarithm. 
7.3.3 Maximal exercise test 
Maximal exercise testing was performed on the same recumbent cycle ergometer (Lode, The 
Netherlands) with continuous 12-lead ECG monitoring following the submaximal test. 
Participants were allowed a short break of 5 minutes after the end of the submaximal exercise 
test. Participants were instructed to pedal at a cadence of 60 RPM for the duration of the test. The 
work rate started between 20 and 30 W and increased by 20 W every minute until an RPE of 15 
was reached, after which work rate was increased by 10 W every minute until volitional 
exhaustion. Continuous measurements of oxygen uptake (VO2), carbon dioxide production, and 
minute ventilation were obtained using a metabolic cart and two-way non-rebreathing valve 
(ParvoMedics TrueOne, Sandy, UT). The system was calibrated prior to each test using standard 
gases with known concentrations and with a calibrated three-liter syringe. Maximum effort was 
determined based on the American College of Sports Medicine criteria (ACSM, 2014) that 
require meeting at least two of the following: (1) respiratory exchange ratio ≥ 1.1, (2) change in 
VO2 < 200 ml with an increase in work, (3) rating of perceived exertion of 17 or greater, and (4) 
achieving at least 90% of age predicted maximal heart rate. 
7.3.4 Statistics 
Pearson correlation coefficients were calculated between the estimated and measured VO2max L 
min-1and mL kg-1 min-1.To determine whether validity was different for different demographics, 
Pearson correlation coefficient for continuous demographic variables (VO2max and maximal 
HR) or t-test and Cohen’s d effect sizes for categorical demographic variables (age 
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dichotomized, self-rated physical activity dichotomized, and gender) were used to compare the 
difference of estimated and measured VO2max mL kg
-1 min-1 and demographic variables of 
interest. Age and self-rated physical activity were considered as dichotomous variables due to the 
bimodal distribution introduced by our recruitment criteria.  
Lastly, while correlations test the relationship between estimated VO2max and measured 
VO2max, we additionally performed a Bland-Altman plot analysis to evaluate bias between the 
mean differences, and to estimate an agreement interval, within which 95% of the differences of 
the estimated VO2max, compared to the measured VO2max, fall. Limits of Agreement (LoA) 
were calculated using the equation: mean of the difference between estimated and measured 
VO2max ± 1.96 multiplied by the SD of difference between the measured and estimated 
VO2max. R software version 3.5.0 was used for the statistical analyses.  
7.4 Results 
Participant characteristics are presented in Table 7.1. The age and self-reported physical activity 
ranges for the participants were 25-73 years and 198 - 25,992 MET minutes per week, 
respectively. All 15 individuals were able to fully tolerate and complete both the submaximal 
and maximal exercise tests and met ACSM criteria for maximal effort on the latter test. 
In our diverse sample, there was good agreement between the estimated VO2max by the 
EB test equation with respect to measured VO2max (r = 0.97, p = 3.80 x 10
-9 and r  = 0.98, p = 




The absolute difference between measured and estimated VO2max L min
-1 were not 
associated with maximal HR (r = - 0.30, p = 0.271), age (d [95% CI] = -0.03 [-1.3 to 1.2], p = 
0.968), gender (d [95% CI] = -0.23 [-0.91 to 1.37], p = 0.705), nor VO2max L min
-1 (r = -0.48, p 
= 0.07). Self-reported physical activity (d [95% CI] = 1.40 [-2.67 to – 0.14], p = 0.019) was, 
however, associated with a difference between measured and estimated VO2max L min
-1 levels.  
 As shown in Figure 7.2, the upper and lower LoA for L min-1 was -0.06 and -0.91, 
respectively, and for ml kg-1 min-1 was -1.06 and -11.29, respectively. The mean bias between the 
estimated and measured VO2max was -0.48 for L min
-1 and -6.17 for ml kg-1 min-1. 
 
7.5. Discussion 
The current study was aimed at examining the feasibility and validity of the Ekblom-Bak 
submaximal exercise test in a small diverse cohort typical of a Midwestern United States 
community. We found that all fifteen individuals were able to perform the EB submaximal 
testing method without issue, showing feasibility of this protocol in a diverse population.  
Importantly, we observed strong correlations between the EB method estimated VO2max values 
and the observed VO2max values (rrange = 0.97 - 0.98), without significant bias, as observed with 
Bland-Altman Plot analyses. Our findings thus suggest that the EB method is a valid method to 
estimate VO2max in a representative US cohort. 
Prior submaximal testing protocols have only moderate validity in predicting VO2max, 
including a 12-minute walk test (McGavin, Gupta, & McHardy, 1976), 1-mile Rockport Fitness 
Test (Kline et al., 1987), and Åstrand and Ryhming Cycle Ergometer Test (P. O. Astrand & 
Ryhming, 1954), with reported correlations between measured and estimated VO2max of 0.52, 
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0.93, 0.71, respectively (I. Astrand, 1960; Kline et al., 1987; McGavin et al., 1976). The Åstrand 
test is one of the most commonly used submaximal cycle ergometer tests and utilizes the heart 
rate response to one submaximal work rate. This test has been validated for a population up to 
only 65 years old. In comparison, the EB showed to have the highest prediction validity in the 
current study population, highlighting the EB method as potentially a superior method versus 
other submaximal methods. 
However, similar to our findings that self-reported physical activity was associated with 
difference between measured and estimated VO2max L min
-1 levels, prior studies (Bjorkman et 
al., 2016; Vaisanen et al., 2020) have found that individuals with lower CRF levels are more 
likely to have overestimated VO2max values on EB method. One possible explanation of the 
increased frequency of the EB method overestimating the observed VO2max in low CRF and 
sedentary individuals could reflect the order of the submaximal and maximal testing procedures. 
For consistency and safety reasons, the submaximal testing was always performed immediately 
before the maximal exercise testing. It may be that individuals who have lower CRF and are less 
active are challenged more by performing two exercise tests in a row, compared to the high CRF 
and highly active individuals. This discrepancy could lead to a biased underestimation of the 
observed VO2max in this sedentary population. However, we investigated this in our sample and 
found neither physical activity level nor CRF level (observed VO2max) was associated with 
percent of age-predicted HR (220-age) or respiratory exchange ratio (RER) at peak effort during 
maximal exercise test, suggesting all participants performed similarly valid maximal exercise 
tests. Nonetheless, future validation studies might consider performing multiple submaximal and 
maximal tests, in varying order, in individuals with a range of age and fitness levels. 
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These findings advance the existing body of literature suggesting submaximal exercise 
tests, including the EB method, are a feasible and valid method for estimation of VO2max and 
assessment of CRF across adulthood, genders, and physical activity levels. A limitation of this 
study is its small sample size, which precludes precise estimates of validity for subgroups within 
this cohort. Future studies validating the EB method in the US would be strengthened by a larger 
testing sample, testing on clinical populations, longitudinal assessment, and an experimental 
structure where submaximal and maximal testing procedure order is performed both ways across 
age, gender, and physical activity level groupings. 
The current study supports the notion that the EB method should be considered when 
designing research studies and clinical interventions aimed at evaluating CRF levels, especially 
in populations where maximal exercise testing is not accessible, due to equipment, physician 
supervision, or physical functioning constraints or populations that are not willing or able to 
perform maximal effort. Importantly, submaximal tests such as the EB method might be critical 
to avoid cohort effects in studies of aging. 
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Table 7.1. Background characteristics. 
Characteristic Range Mean value (SD) or %(n) 
Age, years   
Total 25 - 73 51.9 (16.5) 
Young (n=4) 25-28 26.5 (1.7) 
Older (n=11) 56-73 61.1 (5.5) 
Body Mass Index 20-42 27.8 (5.9) 
Female - 60.0 (9) 
Caucasian - 86.7 (13) 
Self-report PA, MET-min/week   
Total 198 - 25,992 7471 (8779) 
Sedentary (n=6) 198 - 900 499 (293) 
Active (n=9) 4,236 - 25, 992 12,120 (8,605) 
Resting Sys/Dia BP 113-183 / 72-106 135.8 (21.0) / 83.5 (10.0)  
Submaximal Exercise Test   
Peak HR, BPM  103 - 179 137.0 (24.1) 
Peak RPE 13 - 16 14.3 (0.9) 
Estimated VO2max, L min
-1 1.7 - 4.1 2.8 (0.8) 
Estimated VO2max, mL kg
-1 min-1 17.3 - 58.7 36.9 (12.8) 
Maximal Exercise Test    
Peak HR, BPM  129 - 206 166.5 (24.1) 
Peak RPE 16-19 17.7 (1.0) 
VO2max, L min
-1 0.91 - 3.94 2.3 (0.8) 
VO2max, mL kg




Key: PA = Physical Activity; Sys = Systolic; Dia = Diastolic; BP = Blood pressure; HR = Heart 
















Figure 7.1. Correlation between estimated and measured VO2max. The submaximal Ekblom-
Bak method estimate of VO2max compared to the measured maximal VO2max L min
-1 (A) and 
mL kg-1 min-1 (B). Linear regression equation for interpretation of intercept and slope are 
presented where measured VO2max is the dependent variable and estimated VO2max is the 
independent variable. Pearson correlation coefficient and p-value are reported for each 
association examined. Shading represents 95% confidence interval. Individuals are coded by 
gender, age (Young = 25-28 years old; Older = 56-73 years old), and current physical activity 
level (Sedentary = 198 – 900 MET-minutes/week; Active = 4,236 - 25, 992 MET-
minutes/week). 









Figure 7.2.  Bland-Altman Plot. Bland-Altman Analyses Plot between differences in estimated 
and measured VO2max compared to mean VO2max in L min
-1 (A) and mL kg-1 min-1 (B). 
Horizontal lines represent mean bias (black line), upper Limit of Agreement (blue line), lower 
Limit of Agreement (red line). Shaded areas represent 95% confidence intervals around mean 
bias (grey), upper Limit of Agreement (blue), and lower Limit of Agreement (red). Individuals 
are coded by gender, age (Young = 25-28 years old; Older = 56-73 years old), and current 
physical activity level (Sedentary = 198 – 900 MET-minutes/week; Active = 4,236 - 25, 992 
MET-minutes/week). 
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Personality traits such as Neuroticism and Conscientiousness are associated with Alzheimer 
disease (AD) pathophysiology in cognitively normal (CN) and impaired individuals, and may 
represent potential risk or resilience factors, respectively. This study examined the cross-
sectional relationship between personality traits and regional tau deposition using positron 
emission tomography (PET) in cognitively normal older adults. A cohort of CN (Clinical 
Dementia Rating (CDR) 0, n=128) older adults completed the NEO Five-Factor Inventory to 
assess traits of Neuroticism, Extroversion, Openness, Agreeableness, and Conscientiousness and 
underwent tau-PET and β-amyloid (Aβ)-PET imaging. We utilized linear regression models, 
adjusting for age, sex, geriatric depression score, and Aβ to evaluate the association between 
each of the personality traits and regional tau-PET accumulation. Elevated Neuroticism scores 
were associated with higher tau-PET accumulation in the amygdala (p=.002), entorhinal cortex 
(p=.012), and inferior temporal cortex (p=.016), as well as with a composite tau-PET measure 
(p=.002). In contrast, Extroversion, Openness, Agreeableness, and Conscientiousness were not 
associated with tau deposition in any of these regions (p’s >0.160).  Our results indicate that 
increased Neuroticism is associated with higher tau pathophysiology in regions known to be 
vulnerable to AD pathophysiology in CN participants. High Neuroticism scores may therefore 
serve as a potential risk factor for tau accumulation. Alternatively, personality has been shown to 
change with the onset of AD, thus increased tau levels may affect Neuroticism scores. While 
future longitudinal studies are needed to determine directionality, our findings suggest early 






Personality represents a stable organization of character and temperament of a person. It 
can be quantified for study using personality inventories such as the Neuroticism, Extroversion, 
and Openness to experience Five-Factor Inventory (NEO; Costa & McCrae, 1985). The NEO 
provides estimates of Neuroticism, Extraversion, Conscientiousness, Agreeableness, and 
Openness. Prior work has demonstrated ties between personality, measured by the NEO, and 
physical activity (Rhodes & Smith, 2006), longevity (Friedman et al., 1993), obesity (Brummett 
et al., 2006), depression (Chioqueta & Stiles, 2005), and Alzheimer disease (Duchek, Balota, 
Storandt, & Larsen, 2007; Tautvydaite, Antonietti, Henry, von Gunten, & Popp, 2017). Thus, it 
appears that certain personality traits are associated with both diverse health habits and health 
outcomes, including AD.  
For example, previous work has noted personality changes in demented individuals 
(Dawson, Welsh-Bohmer, & Siegler, 2000; Petry, Cummings, Hill, & Shapira, 1988) and that 
these changes may precede the clinical diagnosis of dementia (Balsis, Carpenter, & Storandt, 
2005). Work by Duchek and colleagues (2007) has indicated that self-reported neurotic traits are 
higher in individuals with very mild AD dementia compared with cognitively normal (CN) 
adults. Similarly, in this study, they also found lower self-reported Openness to experience 
scores in individuals in the very mild and mild AD dementia cohorts compared to CN controls.  
Rather than being altered with the onset of impairment, a resilient personality profile may 
be associated with a lower risk of developing symptomatic dementia. Specifically, Wilson and 
colleagues (2007) found that individuals with a high Conscientiousness score had an 89% 
reduction in their risk for AD. Another study, utilizing a meta-analytic approach (Antonio 
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Terracciano et al., 2014), reported higher Neuroticism and lower Conscientiousness associated 
with a threefold increased risk of AD. 
 Furthermore, qualities of anxiety, depression, impulsiveness, and vulnerability to stress 
are often used to describe Neuroticism (John & Srivastava, 1999). These qualities may confer 
risk for psychological illness and AD dementia, suggesting a possible common mechanism 
linking stress, neuroticism and AD pathology. However, there remains a dearth of studies 
investigating the role of personality traits as risk and resilience factors for AD within CN 
cohorts. 
AD is the most common form of dementia, and currently there are no successful 
pharmacological interventions for preventing or combating AD pathophysiology. In turn, there 
has been a new focus on non-pharmacological interventions to prevent or delay the onset of 
cognitive decline. Modifiable lifestyle habits, such as engagement in cognitively-stimulating 
activities (S. A. Schultz, Larson, et al., 2015) and physical activity (Barnes & Yaffe, 2011; Boots 
et al., 2015; S. A. Schultz, Boots, et al., 2015), are potential approaches. These lifestyle habits 
may be driven by personality traits. With the established relationship between personality and 
health habits and disease (Brummett et al., 2006; Chioqueta & Stiles, 2005; Friedman et al., 
1993; Rhodes & Smith, 2006), personality may represent an identifier of those who may benefit 
most from lifestyle interventions aimed at altering the trajectory of pathological aging in 
individuals.  
Neuroimaging techniques have been implemented in prior studies to investigate the 
relationship between personality traits and AD-related neuropathology. A prior study (Jackson, 
Balota, & Head, 2011) has shown that there are associations between Neuroticism and 
Conscientiousness and cortical volumes in CN individuals, such that higher Neuroticism and 
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lower Conscientiousness scores corresponded to lower cortical volumes.  Additionally, recent 
work (Tautvydaite, Antonietti, et al., 2017; Tautvydaite, Kukreja, et al., 2017) has evaluated the 
relationship between personality and in vivo cerebrospinal fluid levels of amyloid-beta (A) and 
tau in a heterogeneous sample of older adults with and without dementia. Others have reported 
that CSF AD biomarkers are associated with increases in Neuroticism and decreases in 
Conscientiousness, further bolstering the link between personality traits and AD (Tautvydaite, 
Antonietti, et al., 2017). 
Prior work using in vivo imaging has also demonstrated that tau, rather than Aβ, is more 
strongly tied to proximal measures of cognition and symptomatic AD (Matthew R. Brier et al., 
2016). Importantly, pathologic tau begins to accumulate in asymptomatic individuals (A. J. 
Aschenbrenner, B. A. Gordon, T. L. S. Benzinger, J. C. Morris, & J. J. Hassenstab, 2018; S. A. 
Schultz et al., 2018). The introduction of tau-PET ligands that bind to neurofibrillary tangles 
(NFT)(Johnson et al., 2016) provide a new in vivo biomarker of tau pathology. The association 
between personality and PET measures of tau pathophysiology in cognitively normal (CN) 
individuals remains unexamined. Therefore, this study examined the cross-sectional relationship 
between personality traits, focusing on Neuroticism and Conscientiousness, and regional tau-




Data from 128 participants from local studies at the Knight Alzheimer Disease Research Center, 
Washington University in St Louis (including the Adult Children Study and the Healthy Aging 
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and Senile Dementia Study) were used. Inclusion criteria included: having undergone Aβ- and 
tau-PET scans, completion of a personality assessment, and Geriatric Depression Scale (GDS), 
and normal cognition (defined by having a Clinical Dementia Rating (CDR) score of 0 at the 
visit closest to the personality assessment)(J. C. Morris, 1997). The Washington University in St. 
Louis Institutional Review Board approved all procedures and each participant provided signed 
informed consent for the study.  
8.3.2 Personality measure 
A shortened version of the Revised NEO Personality Inventory (NEO-PI-R) called the NEO Five 
Factor Inventory Test (NEO-FFI) was administered to each participant (P. T. Costa & McCrae, 
1992b). This 60-item questionnaire measures the personality traits within five factors: 
Neuroticism, Extraversion, Openness, Agreeableness and Conscientiousness. Every item is rated 
on a 1-5 scale from ‘strongly agree’ to ‘strongly disagree’. The NEO-FFI is a commonly used 
personality trait questionnaire, which is highly correlated with the full-length Revised NEO 
Personality Inventory and has strong internal consistency (P. T. Costa & McCrae, 1992b). The 
descriptive statistics for the NEO-FFI factors are presented in Table 8.1. The mean scores on the 
NEO-FFI for the present sample are consistent with mean scores obtained from a similar adult 
sample (Duchek et al., 2007). Neuroticism and Conscientiousness are our personality factors of 
primary interest; Extraversion, Openness, and Agreeableness are included for completeness. 
Additionally, a subset of our cohort had two or more total NEO-FFI assessments (N=113), 






8.3.3. MRI  
Imaging data were acquired on a Siemens Biograph mMR (n=125) or Trio 3T scanner (n=3). T1-
weighted images were acquired using a magnetization prepared rapid acquisition gradient echo 
(MPRAGE) sequence with repetition time = 2300 ms, echo time = 2.95 ms, flip angle = 9°, 176 
slices, in plane resolution 240 x 256, and slice thickness = 1.2 mm acquired in sagittal 
orientation. Images underwent volumetric segmentation using FreeSurfer 5.3 
(http://freesurfer.net) (Fischl et al., 2004) and Desikan Killany atlas to identify regions of interest 
(ROIs) used in the PET analyses. 
8.3.4 PET imaging 
Tau-PET 
Tau-PET imaging was performed using 18F-AV-1451 (flortaucipir), a radioligand that 
preferentially binds to neurofibrillary tau. Scans were acquired on a PET/CT scanner. Data were 
processed using a Freesurfer ROI approach as done in prior work using flortaucipir (M. R. Brier 
et al., 2016; B. A. Gordon et al., 2016; S. A. Schultz et al., 2018; L. Wang et al., 2016). In each 
ROI, data from the 80–100 minute post-injection window were converted to standardized uptake 
value ratio (SUVRs) using the cerebellar grey matter as the reference region and partial volume 
corrected using a regional spread function approach (Su et al., 2015).  We focused on bilateral 
SUVR averages from FreeSurfer ROIs including the entorhinal cortex, amygdala, inferior 
temporal cortex, and lateral occipital regions (Figure 8.1a), which have previously been 
identified as the regions that best discriminate CN participants from those with preclinical AD 
(Mishra et al., 2017). For our main analyses, a summary composite measure was created using 
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the average across these four regions. The average time between NEO-FFI assessment and tau-
PET imaging was a mean (SD) of 3.44 (3.31) months.  
Aβ-PET 
Participants underwent Aβ-PET imaging with 18F-AV-45 (florbetapir). Scans were acquired on a 
PET/MR scanner and attenuation corrected with corresponding PET/CT. FreeSurfer ROI data 
between the 50–70 minute post-injection window were converted to SUVRs using the cerebellar 
grey matter as the reference region and partial volume corrected using a regional spread function 
approach (Su et al., 2013). As previously described, a summary Aβ deposition measure which 
represents regions with earliest Aβ burden was created using the average across the left and right 
ROIs from FreeSurfer areas corresponding to the lateral orbitofrontal, medial orbitofrontal, 
rostral middle frontal, superior frontal, superior temporal, middle temporal, and precuneus 
regions (Figure 8.1b) (Su et al., 2016; Su et al., 2013). The summary Aβ deposition measure 
was treated as a continuous measure.  For descriptive purposes only we split our sample based on 
a partial volume corrected florbetapir SUVR cutoff of 1.22 (S. A. Schultz et al., 2018). The 
average time between NEO-FFI assessment and Aβ-PET imaging was a mean (SD) of 4.12 
(5.91) months. 
8.3.5 Statistical analyses 
Association between tau-PET and personality 
First, to determine whether there were global associations between tau-PET and each of the 
personality traits (Neuroticism, Extraversion, Openness, Agreeableness and Conscientiousness), 
we fitted a linear regression model for the composite tau-PET measure with each of the five 
personality factors as the independent variable of interest. Additionally, all models included 
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covariates for age, sex, and GDS. We included GDS as a covariate in order to ensure that people 
with high Neuroticism and low Conscientiousness don’t primarily have more tau deposition due 
to depressive symptoms. 
Next, to determine where there were region-specific effects of personality on NFT 
burden, we repeated our analyses for each of the four individual regions that comprise the 
composite tau-PET measure, including the entorhinal cortex, amygdala, inferior temporal cortex, 
and lateral occipital region, with each of the five personality factors as the independent variable 
of interest.  
Association between Aβ-PET and personality 
Since the relationship between Aβ and personality in AD as well as Aβ load and tau levels in AD 
have been reported in previous studies (S. A. Schultz et al., 2018; Tautvydaite, Antonietti, et al., 
2017) we evaluated the relationship between Aβ and personality. We fitted a linear regression 
model for the composite Aβ-PET SUVR, with the independent variable of interest being each of 
the five personality factors, adjusting for age, sex, and GDS. For analyses that showed an 
association between Aβ-PET SUVRs and personality factors, we repeated the original linear 
regression models evaluating the relationship between tau-PET and that personality factor, 
including Aβ-PET SUVRs as a covariate in order to ensure that people with high Neuroticism 
and low Conscientiousness don’t primarily have more tau deposition due to Aβ deposition. 
Stability of NEO factors 
Although we are unable to evaluate the longitudinal relationship between tau-PET SUVRs and 
personality traits in our current cohort, and therefore have limited ability to infer causation, we 
were able to investigate the stability of the NEO-FFI assessments in our CN study sample. To 
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determine the stability of the personality measures in a subset of our cohort who had two or more 
total NEO-FFI assessments (N=113) collected prior to flortaucipir imaging, we ran a linear 
mixed effects model for each of the five personality factors to determine if the factors 
significantly changed over time. Fixed effect terms included the time from the first NEO-FFI 
assessment (in years) and a random slope and intercept terms for each participant. We 
additionally examined the intraclass correlation coefficient (ICC) for each factor for the first two 
NEO-FFI assessments available.  
The demographics for the longitudinal cohort are reported in Table 8.1. The average 
number of NEO-FFI assessments was 2.23 visits and the time interval between first and last 
NEO-FFI assessment span between 2.74 and 13.53 years. 
Only findings with values of p ≤ 0.05 (2-tailed) were considered significant. Cross-
sectional analyses and longitudinal analyses were conducted with lme4 package in R. 
 
8.4 Results 
8.4.1 Participant characteristics 
Table 8.1 details the relevant characteristics of the participants. The average age of the cross-
sectional sample was 67.5 ± 8.7 years and 29.7% were APOE4 positive.  
8.4.2 Association between composite tau-PET measure and personality 
There was a significant positive association between Neuroticism and our composite measure of 
flortaucipir SUVR (B=0.007, p=0.002) (Figure 8.2). There were no associations between 
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Extroversion, Openness, Agreeableness, or Conscientiousness and our composite flortaucipir 
SUVR measure (p’s≥0.298) (Table 8.2).  
8.4.3 Association between tau-PET ROIs and personality 
There were significant positive associations between Neuroticism and flortaucipir SUVR in the 
entorhinal cortex (B=0.009, p=0.012), inferior temporal lobe (B=0.005, p=0.016), and amygdala 
(B=0.010, p=0.002), but not in the lateral occipital cortex (B= 0.004, p=0.154) (Figure 8.2). 
There were no associations between regional tau-PET SUVRS and Openness (p’s≥0.572), 
Agreeableness (p’s≥0.296), Extraversion (p’s≥0.160), or Conscientiousness (p’s≥0.236) factors 
(Table 8.2). 
8.4.4 Association between composite Aβ-PET measure and personality 
As expected, there was a strong relationship between tau-PET and Aβ-PET SUVRs, after 
adjusting for age and sex, in our sample (B[SE]=0.156[.027], p=6.73e-08). Additionally, there 
was a positive association between Neuroticism scores and the composite Aβ-PET SUVRs 
(B[SE]=0.014 [.007], p=0.038). There was no relationship between Extroversion, Openness, 
Agreeableness, or Conscientiousness and Aβ-PET SUVRs (p’s≥0.189, Table 8.2). 
Next, to determine whether Aβ deposition was driving the relationship between tau-PET 
SUVRs and Neuroticism scores, we repeated our analyses, with Aβ-PET SUVRs included in the 
models as a covariate. After adjusting for Aβ-PET SUVRs, results remained essentially the same 
for our composite measure of flortaucipir SUVR (B=0.005, p=0.018) and flortaucipir amygdala 
SUVRs (B=0.007, p=0.014), but were non-significant for the entorhinal cortex (B=0.006, 
p=0.104), and inferior temporal cortex (B=0.004, p=0.064).  
195 
 
8.4.5 Stability of NEO factors 
In a subset of our sample (N=113) with longitudinal NEO-FFI assessments, Neuroticism and 
Openness scores showed a decrease over time (B=-0.140, p=0.025 and B=-0.140, p=0.003, 
respectively), while Agreeableness (B=0.054, p=0.245), Extroversion (B=-0.004, p=0.927), and 
Conscientiousness (B=0.013, p=0.749) scores remained stable. These results are presented in 
Table 8.3 and Figure 8.3. ICC for Neuroticism, Openness, Agreeableness, Extroversion, and 
Conscientiousness scores were 0.832, 0.886, 0.780, 0.887, and 0.883, respectively.  
8.5 Discussion 
This study showed that, in a cohort of CN older adults, Neuroticism is associated with increased 
tau and Aβ levels, detected by tau- and Aβ-PET. Specifically, individuals with higher 
Neuroticism scores had higher flortaucipir SUVR in regions including the amygdala, entorhinal 
cortex, and inferior temporal cortex, as well as a composite measure of tauopathy. Similarly, 
higher Neuroticism scores were associated with higher Aβ deposition. These relationships were 
selective, as there were no associations between Agreeableness, Openness, Extroversion, or 
Conscientiousness, with tau-PET or Aβ-PET SUVRs. Importantly, the relationship between 
Neuroticism and tau was not driven by depressive symptoms.  
Furthermore, when we re-examined the relationship between neuroticism and tau-PET 
SUVRs, accounting for Aβ levels, results remained the same for select regions, including the 
amygdala, with a trend towards significant for the inferior temporal cortex tau-PET SUVRs. 
However, after adjusting for Aβ levels, there was no association between Neuroticism and 
entorhinal tau-PET. This could suggest that Aβ may be moderating the effect of tau on 
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personality traits in some regions, but not others. Larger cohort studies with sufficient ranges of 
Aβ levels are needed to test the interaction between personality traits and Aβ on flortaucipir PET 
SUVRs. 
Initial studies from our group and others report relationships between personality traits 
and cognitive functioning in older individuals with (Duchek et al., 2007) and without (Jackson et 
al., 2011) dementia. For example, Duchek and colleagues (2007) examined the differences in 
personality traits in the earliest stages of AD and found that informant ratings of Neuroticism, 
Extraversion, Openness, Agreeableness, and Conscientiousness were able to discriminate CN 
controls from individuals with very mild AD. Furthermore, informant ratings of Neuroticism and 
Conscientiousness discriminated these groups as well as was associated with a composite 
episodic memory measure. These results suggest that personality, including Neuroticism, may 
serve as an early marker for onset of AD. Interestingly, our sample had relatively low scores for 
Neuroticism, albeit within a normal range, suggesting the associations could be even more 
pronounced if the cohort had higher levels of Neuroticism.  
Additionally, in a more recent study, Jackson and colleagues (2011) have examined the 
relationship between personality traits and common pathophysiological features of cognitive 
dysfunction and dementia, including grey and white matter volumes. They found that higher 
Neuroticism was associated with smaller regional volumes and greater decreases in volume with 
advancing age, and conversely, higher Conscientiousness was associated with larger regional 
volumes and less decline in volumes with aging. While these results and others (Zufferey et al., 
2017) point to a potential detrimental effect of Neuroticism on age-related volume loss in CN 
individuals a major limitation of these past studies is that they did not screen for presence of AD-
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related pathology including Aβ or tau, which are known to accumulate in the brain decades 
proceeding any cognitive deficits in healthy control individuals.  
Animal models have shown that prolonged stress, a trait of individuals with high 
neuroticism, has negative effects on neural integrity, particularly in medial temporal lobe regions 
such as the hippocampus and amygdala. Specifically, chronic stress has been shown to lead to 
dendritic atrophy, synaptic loss, and suppression of neurogenesis in the hippocampus (Radley & 
Morrison, 2005) and alterations of limbic connectivity (Poeggel et al., 2003).  In human studies, 
results suggest that stress and anxiety may confer risk for psychological illness and dementia 
through interaction with the hypothalamus-pituitary-adrenal (HPA)-axis. The HPA axis is 
required for stress adaptations and mechanisms involved in regulating function of the HPA axis 
and sensitivity to stress include the amygdala and medial temporal regions such as hippocampus 
and entorhinal cortex (Herman et al., 2016). Similar to animal studies mentioned above these 
limbic and medial temporal regions have been shown to be vulnerable to negative effects of 
abnormal HPA axis functioning in humans (Valli et al., 2016). 
The results of our study highlight region-specific associations of higher Neuroticism with 
higher in vivo tau-PET SUVRs bilaterally in the amygdala, entorhinal cortex and inferior 
temporal cortex, which are HPA axis-associated brain regions. Since these regions are known to 
be the most sensitive to early accumulation of tau, it may be that chronic stress, expressed by a 
neurotic personality, creates region-specific vulnerability for future tauopathy. However, 
intricate molecular and behavioral animal and human translational studies are needed to explore 
this mechanism in further detail. Furthermore, PET tracer limitations, including non-specific off-
target binding, make it difficult to disentangle the associations between Neuroticism and tau 
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within subcortical structure of HPA-associated areas including hypothalamus and pituitary 
regions in vivo.  
A limitation of this study is the cross-sectional nature of the imaging data therefore we 
cannot determine causality. Prior work has shown that personality measures are stable over time 
(P. T. Costa & McCrae, 1992a, 1992b), but this may not be true in the case of pathological aging. 
However, a recent study in the Baltimore Longitudinal Study of Aging cohort (A. Terracciano, 
An, Sutin, Thambisetty, & Resnick, 2017) analyzed longitudinal personality trait data from over 
2,000 individuals and examined whether the trajectory of personality traits was dependent on 
conversion to MCI or dementia from baseline. They found that MCI and AD individuals had 
higher mean levels of Neuroticism and lower Conscientiousness, compared to non-impaired 
older adults. Importantly, personality traits remained stable even in those who converted to MCI 
or dementia; there were no differences in trajectory of personality traits in individuals who 
converted to MCI or dementia, compared to non-impaired older adults. These data suggest that 
personality changes do not occur as a function of underlying proteinopathy, and that personality 
changes may not be a useful tool in identifying individuals at risk for conversion. Instead, these 
data, and results from the current study suggest cross-sectional assessment of personality traits 
may provide indicators of individuals who may be at increased risk for developing dementia.  
We do not yet have enough longitudinal tau-PET data to directly compare change in tau 
pathophysiology to change in personality factors in our cohort. Therefore, we are unable to infer 
causality of the cross-sectional results we report. However, we do have longitudinal NEO-FFI 
assessments, collected prior to the tau-PET data, and examined whether the personality traits 
changed over time. Using a linear mixed effects model, Neuroticism and Openness decreased 
over time, while Extroversion, Agreeableness, and Conscientiousness remained stable, in our 
199 
 
subset of individuals with longitudinal data. However, with our small sample size, the change of 
over time may be partially due to noise. In contrast, when comparing our longitudinal 
assessments with an ICC, all of the NEO-FFI appeared relatively stable. Personality traits, 
including Neuroticism, have been reported to decrease with advancing age in some (Donnellan & 
Lucas, 2008; A. Terracciano, McCrae, Brant, & Costa, 2005), but not all (P. J. Costa & RR, 
1988) prior studies. Larger samples and samples with concurrent longitudinal tau measures are 
needed to better understand the implications of decreasing neuroticism on tau pathophysiology in 
CN adults.  
Overall, the present study provides evidence for a link between Neuroticism and tau 
deposition in CN individuals, independent of depressive symptoms or Aβ burden. While others 
have reported associations between Neuroticism and cognitive decline and dementia, our 
findings suggest that Neuroticism is associated with early pathophysiologic features of 
neurodegenerative diseases, including AD. While we cannot draw strong conclusions regarding 
causation in this study, our findings, in the context of the literature, suggest that Neuroticism is 
related to tau burden in the absence of cognitive impairment. This work makes a critical 
contribution to the efforts to determine the risk and resilience of AD-related pathophysiology 
that certain personality traits confer. 
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Table 8.1. Participant characteristics. 
Characteristic Value 
Cross-sectional cohort (N=128)  
Age, Years 66.7 (8.1) 
Female, % 60.9 
APOE4 positive, % 32.5 
Mini Mental State Exam§⌃ 29.4 (0.9) 
Geriatric Depression Scale* 0.98 (1.3) 
Summary tau-PET SUVR, 1.12 (0.2) 
Summary beta-amyloid-PET SUVR 1.15 (0.5) 
beta-amyloid- positive, % (n) 21.0 (27) 
NEO Factors, raw score (SD), T score   
Neuroticism† 13.6 (7.5), 42.9 
Extroversion† 30.2 (6.3), 54.3 
Agreeableness† 35.5 (5.2), 55.4 
Conscientiousness† 35.3 (6.1), 51.2 
Openness† 29.3 (5.9), 53.9 
  
  
Longitudinal Subset (N=113)  
Age, Years 67.6 (7.7) 
Female, % 61.9 
APOE4 positive, % 31.9 
Mini Mental State Exam§ 29.4 (0.9) 
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Geriatric Depression Scale* 0.89 (1.1) 
Summary tau-PET SUVR 1.19 (0.2) 
Summary beta-amyloid-PET SUVR 1.18 (0.6) 
NEO Factors, raw score (SD), T score  
Neuroticism† 13.6 (7.4), 42.9 
 Extroversion† 30.3 (6.4), 54.5 
Agreeableness† 35.5 (5.1), 55.4 
Conscientiousness† 35.3 (6.1), 51.2 
Openness† 29.1 (6.1), 53.9 
Number of NEO assessments, N (%), 
2/3/4/5/6/7 
40 (35)/ 28 (25)/ 25 (22)/ 18 (16)/ 1 (1)/ 1 
(1) 
 
Characteristics reported for cross-sectional sample are from study visit closest in time to the tau-
PET imaging date. Characteristics reported for the subset with longitudinal data are from the 
baseline study visit. Mean (SD) is presented unless otherwise noted.  
† Raw scores are on scale of 0-60; § Scored on a scale of 0-30; * Scored on a scale of 0-10; ⌃Note 














































































































































Association between each of the five personality traits and composite or regional tau-PET SUVR 
and composite Aβ-PET SUVR levels. Unstandardized regression coefficients (B) and p-values 
correspond to multivariate models, adjusted for age, sex, and geriatric depression scale score.  
 






















Table 8.3. Stability of NEO factors. 
 
NEO Factor B (SE) p 
Neuroticism -0.140 (.061) .025 
Conscientiousness 0.013 (.039) .749 
Openness -0.140 (.037) <.001 
Extroversion -0.004 (.046) .927 
Agreeableness 0.054 (.046) .245 
 
Change in personality traits over time. Unstandardized regression coefficients B values and p-
values from linear mixed effects model. Fixed effect terms included the time from the first NEO 










Figure 8.1. Regions of interest. Selected regions of interest included in the composite tau-PET 








Figure. 8.2. Association between Neuroticism and regional tau-PET. Covariate-adjusted 
residuals from linear regression models examining the relationship between Neuroticism and tau-
PET SUVR in the composite (a), amygdala (b), inferior temporal cortex (c), entorhinal cortex 
(d), and lateral occipital cortex (e).  









Figure 8.3. Neuroticism and Openness decrease over time. Spaghetti plot showing longitudinal 
Neuroticism (a), Conscientiousness (b), Openness (c), Extroversion (d), and Agreeableness (e) 


























9.1 Summary: Overall 
Pathophysiological brain changes that occur during normal aging and in neurodegenerative 
diseases, such as AD, can begin several decades prior to overt cognitive symptoms or the 
diagnosis of clinical dementia (J. C. Morris, 2005). The vast majority of adults will experience 
age- and disease-related alterations in cognition driven by pathological changes in the brain. 
Importantly, the advent of neuroimaging and fluid biomarkers to study structural, protein, and 
metabolic brain changes now permits in vivo identification and monitoring of these of complex 
process throughout adulthood. Investigating biomarkers throughout adulthood uniquely allows us 
to understand how proteins in specific pathways are temporally and spatially related to one 
another, and to the eventual manifestation of cognitive decline and disease symptoms. To this 
end, there has been an emergence of several novel biomarkers to study healthy aging and age-
related neurodegenerative diseases including in vivo assessments of tau/neurofibrillary tangle 
burden and brain metabolism via positron emission tomography (PET) imaging and neurofilament 
light chain (NfL), a marker of neurodegeneration, via fluid biomarkers.  
 Additionally, there is a need to develop interventions that delay or prevent age- and 
disease-related cognitive decline and pathological brain changes. Unfortunately, currently 
available drugs for AD only treat AD symptoms and do not alter the course of further 
pathophysiological changes. Furthermore, findings from clinical trials testing disease-modifying 
therapeutics have been unsuccessful. Physical activity is important physiological and behavioral 
measures that predict health outcomes throughout the lifespan. In adulthood, a sedentary lifestyle 
increases an individual’s risk for cardiovascular disease. There is now growing interest to 




The overall goal of my thesis research was to gain an understanding of emerging biomarkers in 
field of healthy aging and Alzheimer’s disease (AD) and apply this knowledge to evaluate the role 
of physical activity and personality traits in aging and AD. Therefore, my objectives were to 
evaluate (1) first- and second-generation PET tracers developed to measure neurofibrillary tangles 
in vivo, (2) cerebrospinal fluid (CSF) and blood-based measurements of NfL protein, and (3) multi-
tracer PET measurements for assessment of brain metabolism. Secondarily, I aimed to utilize gold-
standard techniques to examine effects of objectively-measured physical activity engagement and 
established personality trait assessments on brain pathophysiology related to aging and AD using 
these emerging biomarkers.  
9.2 Summary: Tau-PET 
 Results from my thesis work have demonstrated the importance of utilizing tau-PET tracers 
to identify early neurofibrillary tangle pathology in older adults, showing that there is widespread 
neurofibrillary tangle accumulation in cognitively normal individuals who have increased beta-
amyloid deposition, a hallmark feature of AD, compared to individuals void of beta-amyloid 
pathology. Additionally, I furthered the field’s understanding of an emerging second-generation 
tau-PET tracer, MK-6240. My work resulted in the discovery of visually-identified neurofibrillary 
tangle distribution patterns (subtypes) that relate to distinct cognitive performance deficits. Next 
steps include characterizing whether and to what extent these subtypes accumulate additional NFT 
pathology and cognitive symptoms over time. Additionally, further work is needed to complete a 




9.3 Summary: Blood-based NfL 
Next, NfL has emerged as a promising fluid biomarker of disease progression for various 
cerebral proteopathies. In collaboration with Dr. Mathias Jucker at the University of Tuebingen in 
Germany, I translated initial work performed in an APP/PSEN1 mouse model showing increases in 
blood-based measures of NfL are a reflection of AD-related neurodegeneration, into a human 
population with an autosomal dominant form of AD. I leveraged the unique characteristics of the 
Dominantly Inherited Alzheimer Network (DIAN) and ultrasensitive immunoassay technology 
to demonstrate that NfL levels in cerebrospinal fluid (CSF) (n=187) and serum (n=409) are 
strongly correlated and increase already at presymptomatic stages of AD. Longitudinal within-
person analysis of serum NfL (n=330) confirmed the increase at presymptomatic disease stages 
and, strikingly, revealed that rate of change of serum NfL could discriminate mutation carriers 
from the non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels 
(i.e. 16.2 vs. 6.8 years before estimated symptom onset). Serum NfL rate of change peaked in 
subjects converting from the presymptomatic to the symptomatic stage. The tight association of 
serum NfL rate of change with cortical (precuneus) thinning (MRI), but less so with Aβ 
deposition or glucose metabolism (assessed by PET) underlines serum NfL utility as a marker for 
brain neurodegeneration. Retrospectively, but also prospectively, serum NfL was predictive for 
the rate of cortical thinning and cognitive changes assessed by mini-mental state examination 
and logical memory assessment. In conclusion, I found that NfL changes in serum predict 
disease progression at a very early presymptomatic stage and will become important for subject 




In this initial study we showed NfL is likely reflecting neurodegeneration. However, 
there have been limited investigations relating NfL to concurrent measures of white matter 
(WM) decline that it should reflect. In a follow-up study I wanted to investigate the relationship 
between NfL and in vivo measures of WM health in same DIAN cohort.  
I hypothesized that serum levels of NfL would associate with WM lesion volume and 
diffusion tensor imaging (DTI) metrics cross-sectionally in 117 autosomal dominant mutation 
carriers (MC) compared to 84 non-carrier (NC) familial controls as well as in a subset (N=41) of 
MC with longitudinal NfL and MRI data.  
I found that in MC elevated cross-sectional NfL was positively associated with WM 
hyperintensity lesion volume, mean diffusivity, radial diffusivity, and axial diffusivity and 
negatively with fractional anisotropy. Greater change in NfL levels in MC was associated with 
larger changes in fractional anisotropy, mean diffusivity, and radial diffusivity, all indicative of 
reduced WM integrity. These results demonstrate that blood-based NfL levels reflect WM 
integrity and supports the view that blood levels of NfL are predictive of WM damage in the 
brain. This is a critical result in improving the interpretability of NfL as a marker of brain 
integrity, and for validating this emerging biomarker for future use in clinical and research 
settings across multiple neurodegenerative diseases.  
9.4 Summary: Multi-tracer PET for brain metabolism 
Lastly, AG is an emerging biomarker measured via multi-tracer PET, of a group of 
metabolic functions, which includes biosynthesis of glycogen, proteins, lipids, and nucleic acids; 
and neuroprotection. Metabolic dysfunction appears to be a prominent feature of AD and is 
known to occur early in the disease process. Recent studies suggest that a specific component of 
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brain glucose metabolism, that which is outside of oxidative phosphorylation (referred to as AG), 
not only plays an important role in brain function, but also carries with it a risk for AD. In an 
initial study, in collaboration with Dr. Manu Goyal and Dr. Andrei Vlassenko, we enrolled 90 
individuals between the ages of 25 and 85 years old. Individuals underwent intensive multi-tracer 
positron emission tomography to evaluate total glucose use (CMRglc), oxygen metabolism 
(CMRO2), and AG, which were normalized to literature-based whole brain metabolism 
estimates. We found that there was age-related decrease in CMRGlc and AG in a specific region 
of interest, the rostral middle frontal gyrus. In contrast, age was not related to CMRO2.  
Additional ongoing research is extending these results to a longitudinal design of cognitively 
normal and impaired individuals.  
9.5 Summary: Physical activity and brain metabolism 
The brain retains the potential for neuroplasticity throughout adulthood and it is possible 
that maintained utilization glycolytic metabolism is a proxy for measuring a component of this 
neuroplasticity. Prior research in mouse models and humans has suggested mechanisms by 
which physical activity may preserve neuroprotective pathways, including utilization of cerebral 
brain metabolism. Under faculty supervision of Dr. Manu Goyal, in the same cohort of 
individuals mentioned above who underwent multi-tracer brain metabolism PET imaging, we 
assessed participant’s free-living physical activity habits using accelerometry. I found that 
individuals who were physically active had maintained CMRGlc in the rostral middle frontal 
cortex, compared to inactive individuals. Furthermore, my results suggest that the maintenance 
of CMRGlc is more likely due to a difference in AG than CMRO2. Taken together, these 
findings suggests a mechanism by which physical activity may provide resilience aging brain 




9.6 Summary: Submaximal exercise testing 
An important next step is to translate these cross-sectional results to an exercise 
intervention aimed at maintaining or improving CMRGlc or AG. A limitation of current exercise 
interventions in older adults is the ability to accurately measure and monitor cardiorespiratory 
fitness (CRF), a measure of habitual exercise, in this population. Assessment of maximal oxygen 
consumption (VO2max) during a graded exercise test is considered the gold standard measure for 
evaluating CRF. However, there is concern regarding obtaining a true measure of VO2max in 
certain populations, including older adults, individuals with physical limitations, and with 
cognitive impairment. Submaximal exercise testing is therefore commonly used to predict 
VO2max, as a proxy measure of CRF, particularly when laboratory equipment or physician 
supervision is unavailable or when the target population is unlikely to go to volitional 
exhaustion. The need to develop and validate submaximal exercise tests that will be more 
reliable given a mixed population across a wide range of age, physical functioning, and cognitive 
functioning thus cannot be overstated.  
Therefore, I sought to validate and determine feasibility of a recently developed Ekblom-
Bak cycle ergometer submaximal exercise test for use in a diverse US population. I enrolled 15 
who were either “Young” (25-34 years old) or “Older” (55-75 years old) as well as either 
sedentary or highly active. Participants completed the submaximal exercise test, followed 
immediately by a maximal exercise test. I found that all fifteen individuals were able to 
successfully perform the EB submaximal testing method, showing feasibility of this protocol in a 
diverse population.  Importantly, we observed strong correlations between the Ekblom-bak 
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method estimated volume of maximal oxygen consumption (VO2max) values and the observed 
VO2max values without significant bias. My findings thus suggest that the EB method likely 
retains similar validity in a diverse US cohort as has been found in Scandinavian cohorts. Future 
studies further assessing validity in cognitively impaired populations will be useful for assessing 
utility of exercise interventions aimed at increase CRF in this population.  
9.7 Summary: Personality traits and tau-PET 
An additional environmental factor that has been linked to risk and resilience of cognitive decline 
and brain health is personality. Prior work by Duchek and colleagues (2007) has indicated that 
self-reported neurotic personality traits are higher in individuals with very mild AD dementia 
compared with cognitively normal adults. Similarly, in this study, they also found lower self-
reported Openness to experience scores in individuals in the very mild and mild AD dementia 
cohorts compared to cognitively normal controls. It is possible a resilient personality profile, 
such as decreased neurotic traits and increased Openness traits, may be associated with a lower 
risk of developing cognitive impairment. I therefore sought to better understand the relationship 
between personality traits and an age- and AD-related pathology. In vivo imaging has 
demonstrated that tau, rather than other know AD pathophysiology, such as Aβ, is more strongly 
tied to proximal measures of cognition and symptomatic AD (M. R. Brier et al., 2016). 
Therefore, I examined the cross-sectional relationship between personality traits, focusing on 
Neuroticism and Conscientiousness, and regional tau-PET deposition. In a cohort of 128 
cognitively normal older adults, Neuroticism was associated with increased tau levels. 
Specifically, individuals with higher Neuroticism scores had higher flortaucipir SUVR in regions 
including the amygdala, entorhinal cortex, and inferior temporal cortex, as well as a composite 
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measure of tauopathy. These relationships were selective, as there were no associations between 
Agreeableness, Openness, Extroversion, or Conscientiousness, with tau-PET.  
Importantly, there is an established relationship between personality and health habits and 
disease (Brummett et al., 2006; Chioqueta & Stiles, 2005; Friedman et al., 1993; Rhodes & 
Smith, 2006). There may be an intersection between lifestyle factors of personality and physical 
activity habits, whereby physical activity habits may be partially driven by personality traits and 
therefore personality may represent an identifier of those who may benefit most from exercise 
interventions aimed at altering the trajectory of pathological aging in individuals.  
9.8 Conclusions 
Overall, my thesis work advances our understanding of emerging biomarkers to study and monitor 
pathophysiology underlying brain aging and neurodegenerative diseases. Additionally, my thesis 
research has provided evidence for a potential mechanism between lifestyle factors and cerebral 
glycolytic metabolism, which will need to be extended to cognitive functioning. Ultimately, these 
findings may lead to novel approaches and nonpharmacological interventions, involving exercise, 
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